[{"id": 45001, "ingredient1": "Bisoprolol", "ingredient2": "Mexiletine", "severity": "Moderate", "effect": "The concomitant use of mexiletine with beta blockers may increase negative inotropic effects and potentiate effects on atrioventricular conduction time.", "source": "DDInter", "management_text": "Caution and monitoring for cardiac arrhythmias, bradycardia, and heart failure are recommended during concurrent therapy.", "mechanism_text": "Synergism", "recommendation": "Caution and monitoring for cardiac arrhythmias, bradycardia, and heart failure are recommended during concurrent therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45071/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Bystolic (nebivolol).\" Forest Pharmaceuticals, St. Louis, MO.[3] Leopold G, Pabst J, Ungethum W, Buhring KU \"Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.\" J Clin Pharmacol 26 (1986): 616-21[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Propafenone, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Felodipine, Atenolol, Ivabradine, Sotalol, Acebutolol, Labetalol, Nadolol, Sotalol, Timolol, Atenolol, Acebutolol, More", "updated_at": 1767369485}, {"id": 45002, "ingredient1": "Bisoprolol", "ingredient2": "Midodrine", "severity": "Moderate", "effect": "Midodrine, an alpha-1 adrenergic agent may lead to bradycardia if administered concomitantly with any agent that directly or indirectly reduces heart rate. This may be most important for beta blockers and tricyclic antidepressants.", "source": "DDInter", "management_text": "Patients should be advised to discontinue midodrine if they experience signs or symptoms of decreased heart rate (i.e., slow pulse, dizziness, syncope, cardiac awareness) and to contact their provider for reevaluation.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised to discontinue midodrine if they experience signs or symptoms of decreased heart rate (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45072/", "reference_text": "[1] \"Product Information. ProAmatine (midodrine).\" Roberts Pharmaceutical Corporation, Eatontown, NJ.", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Hydrochlorothiazide, More", "updated_at": 1767369485}, {"id": 45003, "ingredient1": "Bisoprolol", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45073/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45004, "ingredient1": "Bisoprolol", "ingredient2": "Mivacurium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45074/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45005, "ingredient1": "Bisoprolol", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45075/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 45006, "ingredient1": "Bisoprolol", "ingredient2": "Morphine (liposomal)", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45076/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Carteolol, Penbutolol, Felodipine, Enalapril, Amlodipine, More", "updated_at": 1767369485}, {"id": 45007, "ingredient1": "Bisoprolol", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45077/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Rolapitant, Aprepitant, Granisetron, Palonosetron", "alternatives_b": "Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 45008, "ingredient1": "Bisoprolol", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45078/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45009, "ingredient1": "Bisoprolol", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45079/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 45010, "ingredient1": "Bisoprolol", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45080/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine", "alternatives_b": "Bremelanotide, Black cohosh, Flibanserin, Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib", "updated_at": 1767369485}, {"id": 45011, "ingredient1": "Bisoprolol", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45081/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, More", "updated_at": 1767369485}, {"id": 45012, "ingredient1": "Bisoprolol", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.", "source": "DDInter", "management_text": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45082/", "reference_text": "[1] \"Product Information. Serzone (nefazodone).\" Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45013, "ingredient1": "Bisoprolol", "ingredient2": "Neostigmine", "severity": "Moderate", "effect": "Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.", "source": "DDInter", "management_text": "The patient's hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.", "mechanism_text": "Others", "recommendation": "The patient's hemodynamic status should be monitored during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45083/", "reference_text": "[1] Eldor J, Hoffman B, Davidson JT \"Prolonged bradycardia and hypotension after neostigmine administration in a patient receiving atenolol.\" Anaesthesia 42 (1987): 1294-7", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Hydrochlorothiazide, More", "alternatives_b": "Ambenonium, Bethanechol, Pyridostigmine, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 45014, "ingredient1": "Bisoprolol", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45084/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Felodipine, Felodipine, Indapamide, Verapamil", "alternatives_b": "Mibefradil", "updated_at": 1767369485}, {"id": 45015, "ingredient1": "Bisoprolol", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45085/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Mibefradil", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Perindopril, Benazepril, More", "updated_at": 1767369485}, {"id": 45016, "ingredient1": "Bisoprolol", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "mechanism_text": "Metabolism, Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45086/", "reference_text": "[1] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[2] Strauss WE, Egan T, McIntyre KM, Parisi AF \"Combination therapy with diltiazem and propranolol: precipitation of congestive heart failure.\" Clin Cardiol 8 (1985): 363-6[3] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[4] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[5] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[6] Bauer LA, Murray K, Horn JR, et al \"Influence of nifedipine therapy on indocyanine green and oral propranolol pharmacokinetics.\" Eur J Clin Pharmacol 37 (1989): 257-60[7] Yust I, Hoffman M, Aronson RJ \"Life-threatening bradycardic reactions due to beta blocker-diltiazem interactions.\" Isr J Med Sci 28 (1992): 292-4[8] Oesterle SN, Alderman EL, Beier-Scott L, Bain DS, Rothman MT, Schroder JS \"Diltiazem and propranolol in combination: hemodynamic effects following acute intravenous administration.\" Am Heart J 111 (1986): 489-97[9] Hartwell BL, Mark JB \"Combinations of beta blockers and calcium channel blockers: a cause of malignant perioperative conduction disturbances?\" Anesth Analg 65 (1986): 905-7[10] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[11] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[12] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[13] Tateishi T, Nakashima H, Shitou T, et al \"Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol.\" Eur J Clin Pharmacol 36 (1989): 67-70[14] Maclean D, Mitchell ET, Coulson RR, Fitzsimons TJ, McDevitt DG \"Atenolol-nifedipine combinations compared to atenolol alone in hypertension: efficacy and tolerability.\" Br J Clin Pharmacol 25 (1988): 425-31[15] Hossack KF \"Conduction abnormalities due to diltiazem.\" N Engl J Med 307 (1982): 953-4[16] Smith SR, Wilkins MR, Jack DB, Kendall MJ, Laugher S \"Pharmacokinetic interactions between felodipine and metoprolol.\" Eur J Clin Pharmacol 31 (1987): 575-8[17] Tateishi T, Ohashi K, Fujimura A, Ebihara A \"The influence of diltiazem versus cimetidine on propranolol metabolism.\" J Clin Pharmacol 32 (1992): 1099-104[18] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[19] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[20] Ohman KP, Weiner L, von Schenck H, Karlberg BE \"Antihypertensive and metabolic effects of nifedipine and labetalol alone and in combination in primary hypertension.\" Eur J Clin Pharmacol 29 (1985): 149-54[21] Vinceneux P, Canal M, Domart Y, Roux A, Cascio B, Orofiamma B, Larribaud J, Flouvat B, Carbon C \"Pharmacokinetic and pharmacodynamic interactions between nifedipine and propranolol or betaxolol.\" Int J Clin Pharmacol Ther Toxicol 24 (1986): 153-8[22] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[23] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[24] Takahashi H, Ohashi N, Motokawa K, Sato S, Naito H \"Poisoning caused by the combined ingestion of nifedipine and metoprolol.\" J Toxicol Clin Toxicol 31 (1993): 631-7[25] Rosenkranz B, Ledermann H, Frolich JC \"Interaction between nifedipine and atenolol: pharmacokinetics and pharmacodynamics in normotensive volunteers.\" J Cardiovasc Pharmacol 8 (1986): 943-9[26] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[27] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[32] \"Product Information. Procardia (nifedipine).\" Pfizer US Pharmaceuticals, New York, NY.[33] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[34] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[35] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[37] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[38] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[39] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[40] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[41] \"Product Information. Sular (nisoldipine).\" Zeneca Pharmaceuticals, Wilmington, DE.[42] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[43] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[44] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] \"Product Information. Plendil (felodipine).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Mibefradil", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Felodipine, Amlodipine, Indapamide, Verapamil", "updated_at": 1767369485}, {"id": 45017, "ingredient1": "Bisoprolol", "ingredient2": "Norepinephrine", "severity": "Moderate", "effect": "Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.", "mechanism_text": "Antagonism", "recommendation": "No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45087/", "reference_text": "[1] \"Product Information. Dobutrex (dobutamine).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Intropin (dopamine).\" DuPont Pharmaceuticals, Wilmington, DE.[3] Richards DA, Prichard BN, Hernandez R \"Circulatory effects of noradrenaline and adrenaline before and after labetalol.\" Br J Clin Pharmacol 7 (1979): 371-8", "alternatives_a": "Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, More", "updated_at": 1767369485}, {"id": 45018, "ingredient1": "Bisoprolol", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45088/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "Pindolol", "updated_at": 1767369485}, {"id": 45019, "ingredient1": "Bisoprolol", "ingredient2": "Octreotide", "severity": "Moderate", "effect": "Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).", "source": "DDInter", "management_text": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45089/", "reference_text": "[1] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[3] \"Product Information. Sandostatin (octreotide).\" Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] \"Product Information. Somatuline Depot (lanreotide).\" Ipsen Inc, Milford, MA.[5] Katz MD, Erstad BL \"Octreotide, a new somatostatin analogue.\" Clin Pharm 8 (1989): 255-73[6] Ho PJ, Boyajy LD, Greenstein E, Barkan AL \"Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.\" Dig Dis Sci 38 (1993): 309-15[7] Landgraf R, Landgraf-Leurs MM, Nusser J, et al \"Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.\" Transplantation 44 (1987): 724-5", "alternatives_a": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "alternatives_b": "Ivabradine, Moexipril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Indapamide", "updated_at": 1767369485}, {"id": 45020, "ingredient1": "Bisoprolol", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45090/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45021, "ingredient1": "Bisoprolol", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45091/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 45022, "ingredient1": "Bisoprolol", "ingredient2": "Olodaterol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45092/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 45023, "ingredient1": "Bisoprolol", "ingredient2": "Opium", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45093/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol", "alternatives_b": "Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 45024, "ingredient1": "Bisoprolol", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45094/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45025, "ingredient1": "Bisoprolol", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45095/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Ivabradine", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib", "updated_at": 1767369485}, {"id": 45026, "ingredient1": "Bisoprolol", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45096/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45027, "ingredient1": "Bisoprolol", "ingredient2": "Oxtriphylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45097/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Acetylsalicylic acid, Amlodipine, Ivabradine, Enalapril, Amlodipine, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, More", "alternatives_b": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "updated_at": 1767369485}, {"id": 45028, "ingredient1": "Bisoprolol", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45098/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Ivabradine, Esmolol, Trandolapril, Moexipril", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More", "updated_at": 1767369485}, {"id": 45029, "ingredient1": "Bisoprolol", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45099/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "alternatives_b": "Ivabradine, Penbutolol, Carteolol", "updated_at": 1767369485}, {"id": 45030, "ingredient1": "Bisoprolol", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "The risk of transient bradycardia and atrioventricular (AV) block may be increased during initiation of ozanimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Ozanimod can cause a decrease in heart rate during initiation of therapy.", "source": "DDInter", "management_text": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. In addition, advice from a cardiologist should be sought if coadministration of ozanimod is considered in patients with significant QT prolongation (QTcF greater than 450 msec in males or 470 msec in females), patients with arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic agents, patients with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, or uncontrolled hypertension. Use of ozanimod in patients with a history of second-degree Mobitz type II or higher AV block, sick-sinus syndrome, or sinoatrial heart block is considered contraindicated unless the patient has a functioning pacemaker.", "mechanism_text": "Synergism", "recommendation": "Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45100/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45031, "ingredient1": "Bisoprolol", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45101/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 45032, "ingredient1": "Bisoprolol", "ingredient2": "Pancuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45102/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine, Moexipril, Perindopril, Benazepril, Quinapril, Trandolapril, Fosinopril", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45033, "ingredient1": "Bisoprolol", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45103/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Carteolol, Felodipine", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45034, "ingredient1": "Bisoprolol", "ingredient2": "Pasireotide", "severity": "Moderate", "effect": "The risk of significant bradycardia and atrioventricular (AV) block may be increased during concomitant treatment of pasireotide with other drugs that slow heart rate or AV conduction such as beta-blockers, calcium channel blockers, atazanavir, digitalis, flecainide, lacosamide, mefloquine, moricizine, and propafenone.", "source": "DDInter", "management_text": "Pasireotide has not been studied in patients receiving other bradycardic drugs. Because bradycardia and AV block are recognized risk factors for torsade de pointes arrhythmia, electrocardiographic monitoring is recommended prior to initiation of pasireotide and during treatment. Dose adjustments of beta blockers and calcium channel blockers or correction of electrolyte disturbances may be necessary.", "mechanism_text": "Synergism", "recommendation": "Pasireotide has not been studied in patients receiving other bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45104/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Signifor (pasireotide).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, More", "alternatives_b": "Norethisterone, Nafarelin, Elagolix, Cetrorelix, Ganirelix, Relugolix, Gonadorelin", "updated_at": 1767369485}, {"id": 45035, "ingredient1": "Bisoprolol", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45105/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 45036, "ingredient1": "Bisoprolol", "ingredient2": "Pentoxifylline", "severity": "Moderate", "effect": "Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is used in combination with hypotensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45106/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Ivabradine", "alternatives_b": "Cyclandelate, Isoxsuprine, Tolazoline, Phentolamine, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, More", "updated_at": 1767369485}, {"id": 45037, "ingredient1": "Bisoprolol", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45107/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45038, "ingredient1": "Bisoprolol", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45108/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "updated_at": 1767369485}, {"id": 45039, "ingredient1": "Bisoprolol", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45109/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45040, "ingredient1": "Bisoprolol", "ingredient2": "Phenoxybenzamine", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45110/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Felodipine, Amlodipine, Verapamil, Hydrochlorothiazide, Indapamide", "alternatives_b": "Cyclandelate, Isoxsuprine, Tolazoline, Phentolamine", "updated_at": 1767369485}, {"id": 45041, "ingredient1": "Bisoprolol", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45111/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Carteolol, Felodipine, Amlodipine, Verapamil", "alternatives_b": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45042, "ingredient1": "Bisoprolol", "ingredient2": "Phenylephrine (ophthalmic)", "severity": "Moderate", "effect": "A case report suggests that beta-blockers may enhance the pressor response to phenylephrine. The proposed mechanism involves blockade of beta-2 adrenergic receptors in the peripheral vasculature, resulting in unopposed alpha-adrenergic effect of phenylephrine that is responsible for vasoconstriction. Additionally, beta-blockers may desensitize baroreceptors that normally modulate heart rate in response to blood pressure elevations by increasing vagal activity on the sinoauricular node.", "source": "DDInter", "management_text": "Until more information is available, caution should be exercised when phenylephrine is used in combination with beta-blockers including ophthalmic formulations, which may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Monitoring of blood pressure should be considered, particularly when phenylephrine is administered intravenously or intraocularly.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, caution should be exercised when phenylephrine is used in combination with beta-blockers including ophthalmic formulations, which may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45112/", "reference_text": "[1] Myers MG, Iazzetta JJ \"Intranasally administered phenylephrine and blood pressure.\" Can Med Assoc J 127 (1982): 365-6[2] Cass E, Kadar D, Stein HA \"Hazards of phenylephrine topical medication in persons taking propranolol.\" Can Med Assoc J 120 (1979): 1261-2", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45043, "ingredient1": "Bisoprolol", "ingredient2": "Physostigmine", "severity": "Moderate", "effect": "Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.", "source": "DDInter", "management_text": "The patient's hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.", "mechanism_text": "Others", "recommendation": "The patient's hemodynamic status should be monitored during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45113/", "reference_text": "[1] Eldor J, Hoffman B, Davidson JT \"Prolonged bradycardia and hypotension after neostigmine administration in a patient receiving atenolol.\" Anaesthesia 42 (1987): 1294-7", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Hydrochlorothiazide, More", "alternatives_b": "Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, Brimonidine, Timolol, More", "updated_at": 1767369485}, {"id": 45044, "ingredient1": "Bisoprolol", "ingredient2": "Pilocarpine", "severity": "Moderate", "effect": "The concomitant use of oral pilocarpine and beta blockers may lead to cardiac conduction disturbances. The mechanism is unknown.", "source": "DDInter", "management_text": "If these drugs must be given together, consider the possibility for arrhythmias and administer with caution. Patients should be advised to notify their physician if they experience irregular or slow heartbeats, palpitations, or syncope.", "mechanism_text": "Others", "recommendation": "If these drugs must be given together, consider the possibility for arrhythmias and administer with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45114/", "reference_text": "[1] \"Product Information. Salagen Tablets (pilocarpine).\" Boehringer-Ingelheim, Ridgefield, CT.", "alternatives_a": "Felodipine, Felodipine, Moexipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril, Indapamide", "alternatives_b": "Ambenonium, Bethanechol, Pyridostigmine, Methazolamide, Acetylcholine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "updated_at": 1767369485}, {"id": 45045, "ingredient1": "Bisoprolol", "ingredient2": "Pipecuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45115/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45046, "ingredient1": "Bisoprolol", "ingredient2": "Pirbuterol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45116/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Nifedipine, Felodipine, Moexipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 45047, "ingredient1": "Bisoprolol", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45117/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Fluorometholone", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45048, "ingredient1": "Bisoprolol", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45118/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Esmolol, Carteolol, Penbutolol, Felodipine, Hydrochlorothiazide, Indapamide, Verapamil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "updated_at": 1767369485}, {"id": 45049, "ingredient1": "Bisoprolol", "ingredient2": "Prazosin", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45119/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Deserpidine", "alternatives_b": "Felodipine, Ivabradine, Felodipine", "updated_at": 1767369485}, {"id": 45050, "ingredient1": "Bisoprolol", "ingredient2": "Prednisolone", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45120/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, More", "updated_at": 1767369485}, {"id": 45051, "ingredient1": "Bisoprolol", "ingredient2": "Prednisone", "severity": "Moderate", "effect": "Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.", "source": "DDInter", "management_text": "Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.", "mechanism_text": "Metabolism, Antagonism", "recommendation": "Patients on prolonged (i.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45121/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ivabradine, Esmolol", "alternatives_b": "Cromoglicic acid, Olsalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine", "updated_at": 1767369485}, {"id": 45052, "ingredient1": "Bisoprolol", "ingredient2": "Procarbazine", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45122/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 45053, "ingredient1": "Bisoprolol", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45123/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45054, "ingredient1": "Bisoprolol", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45124/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45055, "ingredient1": "Bisoprolol", "ingredient2": "Promazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45125/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Acetylsalicylic acid, Carteolol", "updated_at": 1767369485}, {"id": 45056, "ingredient1": "Bisoprolol", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45126/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45057, "ingredient1": "Bisoprolol", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45127/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, More", "alternatives_b": "Papaverine, Alosetron, Isometheptene", "updated_at": 1767369485}, {"id": 45058, "ingredient1": "Bisoprolol", "ingredient2": "Propiomazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45128/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45059, "ingredient1": "Dextropropoxyphene", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45129/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 45060, "ingredient1": "Bisoprolol", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45130/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "alternatives_b": "Felodipine, Acetylsalicylic acid, Nifedipine, Felodipine, Indapamide, Ramipril", "updated_at": 1767369485}, {"id": 45061, "ingredient1": "Bisoprolol", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45131/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "updated_at": 1767369485}, {"id": 45062, "ingredient1": "Bisoprolol", "ingredient2": "Quazepam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45132/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Nifedipine, Ivabradine, Indapamide", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45063, "ingredient1": "Bisoprolol", "ingredient2": "Quetiapine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45133/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45064, "ingredient1": "Bisoprolol", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Quinidine may increase serum levels of some oral beta-blockers. The proposed mechanism is inhibition of CYP450 2D6 first-pass metabolism and decreased hepatic clearance of hepatically metabolized beta-blockers. Quinidine and beta-blockers may also have additive negative inotropic effects, which can be beneficial when used to treat atrial fibrillation. However, adverse effects have been reported with quinidine and propranolol.", "source": "DDInter", "management_text": "Patients should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45134/", "reference_text": "[1] Edeki TI, He H, Wood AJ \"Pharmacogenetic explanation for excessive B-blockade following timolol eye drops.\" JAMA 274 (1995): 1611-3[2] Leemann T, Dayer P, Meyer UA \"Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.\" Eur J Clin Pharmacol 29 (1986): 739-41[3] Loon NR, Wilcox CS, Folger W \"Orthostatic hypotension due to quinidine and propranolol.\" Am J Med 81 (1986): 1101-4[4] Manolis AS, Estes NA \"Orthostatic hypotension due to quinidine and atenolol.\" Am J Med 82 (1987): 1083-4[5] Kessler KM, Humphries WC, Black M, Spann JF \"Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.\" Am Heart J 96 (1978): 627-35[6] Ochs HR, Greenblatt DJ, Woo E, et al \"Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans.\" Pharmacology 17 (1978): 301-6[7] Dinai Y, Sharir M, Floman NN, Halkin H \"Bradycardia induced by interaction between quinidine and ophthalmic timolol.\" Ann Intern Med 103 (1985): 890-1[8] Fenster P, Perrier D, Mayersohn M, Marcus FI \"Kinetic evaluation of the propranolol-quinidine combination.\" Clin Pharmacol Ther 27 (1980): 450-3[9] Zhou HH, Wood AJ \"Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)- propranolol.\" Clin Pharmacol Ther 47 (1990): 719-23[10] Dorian P, Newman D, Berman N, Hardy J, Mitchell J \"Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.\" J Am Coll Cardiol 22 (1993): 106-13[11] Zhou HH, Anthony LB, Roden DM, Wood AJ \"Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.\" Clin Pharmacol Ther 47 (1990): 686-93[12] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[13] Ace LN, Jaffe JM, Kunka RL \"Effect of food and an antacid on quinidine bioavailability.\" Biopharm Drug Dispos 4 (1983): 183-90[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[15] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F \"In vitro inhibition of midazolam and quinidine metabolism by flavonoids.\" Eur J Clin Pharmacol 48 (1995): 367-71", "alternatives_a": "Trandolapril, Captopril, Moexipril", "alternatives_b": "Propafenone, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 45065, "ingredient1": "Bisoprolol", "ingredient2": "Racepinephrine", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45135/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45066, "ingredient1": "Bisoprolol", "ingredient2": "Rapacuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45136/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45067, "ingredient1": "Bisoprolol", "ingredient2": "Rasagiline", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45137/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Pramipexole, Amantadine", "updated_at": 1767369485}, {"id": 45068, "ingredient1": "Bisoprolol", "ingredient2": "Remimazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45138/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45069, "ingredient1": "Bisoprolol", "ingredient2": "Repaglinide", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45139/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Ivabradine", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, More", "updated_at": 1767369485}, {"id": 45070, "ingredient1": "Bisoprolol", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45140/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Deserpidine, Deserpidine", "alternatives_b": "Felodipine, Acetylsalicylic acid, Amlodipine, Ivabradine, Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Lisinopril, Perindopril, More", "updated_at": 1767369485}, {"id": 45071, "ingredient1": "Bisoprolol", "ingredient2": "Rifampicin", "severity": "Moderate", "effect": "Rifampin may decrease serum levels and effects of some oral beta-blockers. The proposed mechanism is increased CYP450 oxidative metabolism of beta-blockers that are hepatically metabolized. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact.", "source": "DDInter", "management_text": "Patients should be monitored for clinical response and tolerance when rifampin is added to or discontinued from a beta-blocker regimen. The beta-blocker dosage may require adjustment.", "mechanism_text": "Metabolism", "recommendation": "Patients should be monitored for clinical response and tolerance when rifampin is added to or discontinued from a beta-blocker regimen.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45141/", "reference_text": "[1] Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE \"Interaction of bisoprolol with cimetidine and rifampicin.\" Eur J Clin Pharmacol 31 (1986): 59-62[2] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P \"Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers.\" J Cardiovasc Pharmacol 18 (1991): 28-34[3] \"Product Information. Tenormin (atenolol).\" ICN Pharmaceuticals Inc, Cost Mesa, CA.[4] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y \"Pharmacokinetics of carteolol in patients with impaired renal function.\" Eur J Clin Pharmacol 43 (1992): 417-21[5] Collste P, Seideman P, Borg K, Haglund K, Von Bahr C \"Influence of pentobarbital on effect and plasma levels of alprenolol and 4-hydroxy-alprenolol.\" Clin Pharmacol Ther 25 (1979): 423-7[6] Borcherding SM, Baciewicz AM, Self TH \"Update on rifampin drug interactions.\" Arch Intern Med 152 (1992): 711-6[7] Seffart G ed. \"Drug Dosage in Renal Insufficiency.\" Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[8] Janku I, Perlik F, Tkaczykova M, Brodanova M \"Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects.\" Eur J Clin Pharmacol 42 (1992): 337-40[9] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F \"Effect of aging on the pharmacokinetics of acebutolol enantiomers.\" J Clin Pharmacol 32 (1992): 148-56[10] Strayhorn VA, Baciewicz AM, Self TH \"Update on rifampin drug interactions, III.\" Arch Intern Med 157 (1997): 2453-8[11] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW \"Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.\" Clin Pharmacol Ther 38 (1985): 409-13[12] Stagni G, Davis PJ, Ludden TM \"Human pharmacokinetics of betaxolol enantiomers.\" J Pharm Sci 80 (1991): 321-4[13] McTavish D, Campoli-Richards D, Sorkin EM \"Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.\" Drugs 45 (1993): 232-58[14] \"Product Information. Levatol (penbutolol).\" Reed and Carnrick, Jersey City, NJ.[15] \"Product Information. Brevibloc (esmolol).\" DuPont Pharmaceuticals, Wilmington, DE.[16] \"Product Information. Blocadren (timolol).\" Merck & Co, Inc, West Point, PA.[17] Bennett PN, John VA, Whitmarsh VB \"Effect of rifampicin on metoprolol and antipyrine kinetics.\" Br J Clin Pharmacol 13 (1982): 387-91[18] Shaheen O, Biollaz J, Koshakji R, Wilkinson GR, Wood AJ \"Effect of debrisoquine (D) phenotype on the inducibility of propranolol (P) metabolism.\" Clin Pharmacol Ther 41 (1987): 158[19] Morgan T \"Clinical pharmacokinetics and pharmacodynamics of carvedilol.\" Clin Pharmacokinet 26 (1994): 335-46[20] Hardman JG, Gilman AG, Limbird LE eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 9th ed.\" New York, NY: McGraw-Hill (1995):[21] \"Product Information. Cartrol (carteolol).\" Abbott Pharmaceutical, Abbott Park, IL.[22] \"Product Information. Inderal (propranolol).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[23] Venkatesan K \"Pharmacokinetic drug interactions with rifampicin.\" Clin Pharmacokinet 22 (1992): 47-65[24] \"Product Information. Corgard (nadolol).\" Bristol-Myers Squibb, Princeton, NJ.[25] Smith RL \"Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance.\" Eur J Clin Pharmacol 28 (1985): 77-84[26] \"Product Information. Betapace (sotalol).\" Berlex, Richmond, CA.[27] Branch RA, Herman RJ \"Enzyme induction and beta-adrenergic receptor blocking drugs.\" Br J Clin Pharmacol 17 (1984): s77-84[28] \"Product Information. Normodyne (labetalol).\" Schering Laboratories, Kenilworth, NJ.", "alternatives_a": "Nebivolol, Sotalol, Nadolol, Nebivolol, Sotalol, Nadolol, Esmolol, Betaxolol, Nebivolol, Carteolol, Sotalol, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "updated_at": 1767369485}, {"id": 45072, "ingredient1": "Bisoprolol", "ingredient2": "Riociguat", "severity": "Moderate", "effect": "Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.", "source": "DDInter", "management_text": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45142/", "reference_text": "[1] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] \"Product Information. Adempas (riociguat).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Bosentan, Ambrisentan, Macitentan, Metyrosine", "updated_at": 1767369485}, {"id": 45073, "ingredient1": "Bisoprolol", "ingredient2": "Risperidone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45143/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45074, "ingredient1": "Bisoprolol", "ingredient2": "Ritodrine", "severity": "Major", "effect": "The use of a nonselective beta blocker with ritodrine (a beta-2 agonist) may result in mutually antagonistic effects, negating the effect of one or both drugs.", "source": "DDInter", "management_text": "In general, the use of beta blockers with ritodrine is discouraged. Selective beta blockers (e.g. acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable if the use of a beta blocker is unavoidable.", "mechanism_text": "Antagonism", "recommendation": "In general, the use of beta blockers with ritodrine is discouraged.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45144/", "reference_text": "[1] \"Product Information. Yutopar (ritodrine).\" Astra USA, Westborough, MA.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Hydrochlorothiazide, More", "alternatives_b": "Bremelanotide, Black cohosh, Flibanserin", "updated_at": 1767369485}, {"id": 45075, "ingredient1": "Bisoprolol", "ingredient2": "Rivastigmine", "severity": "Moderate", "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.", "source": "DDInter", "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45145/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes.\" Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL \"Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary).\" Drug Saf 30 (2007): 1063-71[5] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril", "alternatives_b": "Memantine, Ginkgo biloba, Aducanumab", "updated_at": 1767369485}, {"id": 45076, "ingredient1": "Bisoprolol", "ingredient2": "Rocuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45146/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine, Enalapril, Moexipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45077, "ingredient1": "Bisoprolol", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45147/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Pramipexole, Amantadine", "updated_at": 1767369485}, {"id": 45078, "ingredient1": "Bisoprolol", "ingredient2": "Salmeterol", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45148/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Trandolapril, Moexipril", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 45079, "ingredient1": "Bisoprolol", "ingredient2": "Salsalate", "severity": "Minor", "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45149/", "reference_text": "[1] Keber I, Jerse M, Keber D, Stegnar M \"The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.\" Br J Clin Pharmacol 7 (1979): 287-91[2] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002): 1015-1022[3] Sziegoleit W, Rausch J, Polak G, et al \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol in humans.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30[4] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[5] Spahn H, Langguth P, Kirch W, et al \"Pharmacokinetics of salicylates administered with metoprolol.\" Arzneimittelforschung 36 (1986): 1697-9[6] Sziegoleit W, Rausch J , Polak G, Gyorgy M, Dekov E, Bekes M \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30", "alternatives_a": "Ivabradine, Hydrochlorothiazide, Indapamide", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 45080, "ingredient1": "Bisoprolol", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Saquinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, digoxin, diltiazem, lacosamide, mefloquine, verapamil) may result in additive effects and increased risk of bradycardia and heart block.", "source": "DDInter", "management_text": "Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.", "mechanism_text": "Synergism", "recommendation": "Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45150/", "reference_text": "[1] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.[2] Biondi L \"Health Canada endorsed important safety information on Invirase (saquinavir mesylate). Available from: URL: http://hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/prof/2010/invirase_hpc-cps-eng.pdf.\" ([2010 Apr 14]):[3] FDA. U.S. Food and Drug Administration \"FDA drug safety communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal heart rhythms. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm201221.h\" ([2010 Feb 23]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krahenbuhl S \"Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.\" Br J Clin Pharmacol 45 (1998): 355-9[8] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[9] \"Product Information. Invirase (saquinavir).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Indapamide", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 45081, "ingredient1": "Bisoprolol", "ingredient2": "Scopolamine", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45151/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Nifedipine, Ivabradine, Esmolol, Felodipine, Moexipril, Verapamil, Ramipril, Perindopril, Benazepril, Quinapril, More", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45082, "ingredient1": "Bisoprolol", "ingredient2": "Secobarbital", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45152/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "alternatives_b": "Acetylsalicylic acid, Carteolol, Benazepril", "updated_at": 1767369485}, {"id": 45083, "ingredient1": "Bisoprolol", "ingredient2": "Selegiline", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45153/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Ivabradine", "alternatives_b": "Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Pramipexole, Amantadine", "updated_at": 1767369485}, {"id": 45084, "ingredient1": "Bisoprolol", "ingredient2": "Selexipag", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45154/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 45085, "ingredient1": "Bisoprolol", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45155/", "reference_text": "[1] \"Product Information. Stendra (avanafil).\" Vivus Inc, Mountain View, CA.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45086, "ingredient1": "Bisoprolol", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45156/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Acetylsalicylic acid, Amlodipine, Nifedipine, Ivabradine, Amlodipine, Hydrochlorothiazide, Indapamide", "alternatives_b": "Tamsulosin, Dutasteride, Solifenacin", "updated_at": 1767369485}, {"id": 45087, "ingredient1": "Bisoprolol", "ingredient2": "Siponimod", "severity": "Major", "effect": "The risk of severe bradycardia and atrioventricular (AV) block may be increased during initiation of siponimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis.", "source": "DDInter", "management_text": "Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. Treatment with siponimod should generally not be initiated in patients who are concurrently treated with heart rate-lowering drugs. Advice from a cardiologist should be sought if coadministration of siponimod and drugs that slow heart rate or AV conduction is considered.", "mechanism_text": "Synergism", "recommendation": "Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45157/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45088, "ingredient1": "Bisoprolol", "ingredient2": "Nitrous acid", "severity": "Moderate", "effect": "Coadministration with antihypertensive agents, diuretics, vasodilators, or phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of sodium nitrite. Since sodium nitrite can cause serious hypotension and methemoglobin formation, patients may be at increased risk for complications related to inadequate perfusion and oxygenation.", "source": "DDInter", "management_text": "Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors. Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs. In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible.", "mechanism_text": "Synergism", "recommendation": "Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45158/", "reference_text": "[1] \"Product Information. Sodium Nitrite (sodium nitrite).\" Hope Pharmaceuticals, Scottsdale, AZ.[2] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[3] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[5] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[6] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[7] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[8] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[9] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[10] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[15] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[16] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[17] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[19] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[20] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[24] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[25] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[26] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[27] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[28] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[29] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[30] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[31] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[32] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[33] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "updated_at": 1767369485}, {"id": 45089, "ingredient1": "Bisoprolol", "ingredient2": "Sodium oxybate", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45159/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, More", "updated_at": 1767369485}, {"id": 45090, "ingredient1": "Bisoprolol", "ingredient2": "Salicylic acid (sodium)", "severity": "Minor", "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45160/", "reference_text": "[1] Keber I, Jerse M, Keber D, Stegnar M \"The influence of combined treatment with propranolol and acetylsalicylic acid on platelet aggregation in coronary heart disease.\" Br J Clin Pharmacol 7 (1979): 287-91[2] Zanchetti A, Hansson L, Leonetti G, et al. \"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy.\" J Hypertens 20 (2002): 1015-1022[3] Sziegoleit W, Rausch J, Polak G, et al \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol in humans.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30[4] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[5] Spahn H, Langguth P, Kirch W, et al \"Pharmacokinetics of salicylates administered with metoprolol.\" Arzneimittelforschung 36 (1986): 1697-9[6] Sziegoleit W, Rausch J , Polak G, Gyorgy M, Dekov E, Bekes M \"Influence of acetylsalicylic acid on acute circulatory effects of the beta-blocking agents pindolol and propranolol.\" Int J Clin Pharmacol Ther Toxicol 20 (1982): 423-30", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol, Hydrochlorothiazide, Indapamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45091, "ingredient1": "Bisoprolol", "ingredient2": "Spironolactone", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45161/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Amiloride", "alternatives_b": "Ivabradine, Esmolol, Carteolol, Penbutolol", "updated_at": 1767369485}, {"id": 45092, "ingredient1": "Bisoprolol", "ingredient2": "Succinylcholine", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45162/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Botulinum toxin type A", "alternatives_b": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "updated_at": 1767369485}, {"id": 45093, "ingredient1": "Bisoprolol", "ingredient2": "Sucralfate", "severity": "Minor", "effect": "Concurrent administration with aluminum and magnesium antacids has been shown to decrease the oral bioavailability of certain beta-blockers, although data are conflicting. The exact mechanism of interaction is unknown but may involve cation binding of beta-blockers or a reduction in the dissolution rate due to increased gastric pH. Based on available data, the clinical significance of this potential interaction is difficult to determine. As a precaution, patients may want to consider separating the administration times of beta-blockers and antacids or other aluminum- or magnesium-containing products by at least 2 hours.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45163/", "reference_text": "[1] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[2] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[3] Hong CY, Hu SC, Lin SJ, Chiang BN \"Lack of influence of aluminum hydroxide on the bioavailability and beta-adrenoceptor blocking activity of propranolol.\" Int J Clin Pharmacol Ther Toxicol 23 (1985): 244-6[4] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[5] Laer S, Neumann J, Scholz H \"Interaction between sotalol and an antacid preparation.\" Br J Clin Pharmacol 43 (1997): 269-72[6] Gugler R, Allgayer H \"Effects of antacids on the clinical pharmacokinetics of drugs. An update.\" Clin Pharmacokinet 18 (1990): 210-9[7] Dobbs JH, Skoutakis VA, Acchiardo SR, Dobbs BR \"Effects of aluminum hydroxide on the absorption of propranolol.\" Curr Ther Res Clin Exp 21 (1977): 887-92", "alternatives_a": "Tinidazole, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Nizatidine, Esomeprazole, Vonoprazan, Levofloxacin", "alternatives_b": "Ivabradine, Esmolol, Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril, Indapamide", "updated_at": 1767369485}, {"id": 45094, "ingredient1": "Bisoprolol", "ingredient2": "Sufentanil", "severity": "Moderate", "effect": "In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.", "source": "DDInter", "management_text": "Patients should be carefully observed for clinically significant alterations in hemodynamics.", "mechanism_text": "Synergism", "recommendation": "Patients should be carefully observed for clinically significant alterations in hemodynamics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45164/", "reference_text": "[1] Thomson IR, MacAdams CL, Hudson RJ, Rosenbloom M \"Drug interactions with sufentanil: hemodynamic effects of premedication and muscle relaxants.\" Anesthesiology 76 (1992): 922-9[2] \"Product Information. Sufenta (sufentanil).\" Janssen Pharmaceutica, Titusville, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Indapamide", "alternatives_b": "Halothane, Thiopental, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, Etomidate, Ketamine", "updated_at": 1767369485}, {"id": 45095, "ingredient1": "Bisoprolol", "ingredient2": "Sulfinpyrazone", "severity": "Minor", "effect": "Sulfinpyrazone may reduce the antihypertensive effect of beta-blockers. The mechanism may be related to induction of beta-blocker metabolism or inhibition of prostaglandin synthesis by sulfinpyrazone.", "source": "DDInter", "management_text": "-", "mechanism_text": "Antagonism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45165/", "reference_text": "[1] Ferrara LA, Mancini M, Marotta T, Pasanisi F, Fasano ML \"Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol.\" Eur J Clin Pharmacol 29 (1986): 717-9", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Nebivolol, Nebivolol, Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 45096, "ingredient1": "Bisoprolol", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45166/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45097, "ingredient1": "Bisoprolol", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "There is clinical evidence that sunitinib can prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, calcium channel blockers, atazanavir, lopinavir, digoxin, lacosamide, mefloquine) may result in additive effects and increased risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "Caution is advised if sunitinib is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.g., marked first-degree AV block; second-degree or higher AV block; sick sinus syndrome without pacemaker) or severe cardiac disease such as myocardial ischemia or heart failure. Patients should be advised to notify their doctor if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if sunitinib is used concomitantly with other agents that prolong the PR interval, especially in the elderly and patients with known conduction problems (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45167/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[3] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 45098, "ingredient1": "Bisoprolol", "ingredient2": "Tacrine", "severity": "Moderate", "effect": "Since acetylcholinesterase inhibitors can cause bradycardia and heart block due to vagotonic effects on the sinoatrial and atrioventricular nodes, additive effects may occur with other agents that also possess bradycardic effects such as beta-blockers, calcium channel blockers, digitalis, some protease inhibitors (atazanavir, lopinavir-ritonavir, saquinavir), amiodarone, dronedarone, moricizine, lacosamide, and mefloquine.", "source": "DDInter", "management_text": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs. Patients with underlying structural heart disease, preexisting conduction system abnormalities, ischemic heart disease, or cardiomyopathies may be at increased risk for developing cardiac conduction disturbances and atrioventricular block. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if acetylcholinesterase inhibitors are used concomitantly with bradycardic drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45168/", "reference_text": "[1] \"Product Information. Razadyne (galantamine).\" Johnson and Johnson Medical Inc, Arlington, TX.[2] \"Product Information. Cognex (tacrine).\" Parke-Davis, Morris Plains, NJ.[3] Tiseo PJ, Perdomo CA, Friedhoff LT \"Concurrent administration of donepezil HCI and digoxin: assessment of pharmacokinetic changes.\" Br J Clin Pharmacol 46(Suppl 1) (1998): 40-4[4] Tavassoli N, Sommet A, Lapeyre-Mestre M, Bagheri H, Montrastruc JL \"Drug interactions with cholinesterase inhibitors : an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (vidal, british national formulary).\" Drug Saf 30 (2007): 1063-71[5] \"Product Information. Exelon (rivastigmine)\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Aricept (donepezil).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Memantine, Ginkgo biloba, Aducanumab", "alternatives_b": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, More", "updated_at": 1767369485}, {"id": 45099, "ingredient1": "Bisoprolol", "ingredient2": "Tadalafil", "severity": "Minor", "effect": "Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45169/", "reference_text": "[1] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Rapaflo (silodosin).\" Watson Pharmaceuticals, Corona, CA.[3] \"Product Information. Cialis (tadalafil).\" Lilly, Eli and Company, Indianapolis, IN.[4] \"Product Information. Adcirca (tadalafil).\" United Therapeutics Corporation, Silver Spring, MD.", "alternatives_a": "Ivabradine", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More", "updated_at": 1767369485}, {"id": 45100, "ingredient1": "Bisoprolol", "ingredient2": "Temazepam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45170/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45101, "ingredient1": "Bisoprolol", "ingredient2": "Terazosin", "severity": "Moderate", "effect": "Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.", "source": "DDInter", "management_text": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45171/", "reference_text": "[1] Holtzman JL, Kaihlanen PM, Rider JA, Lewin AJ, Spindler JS, Oberlin JA \"Concomitant administration of terazosin and atenolol for the treatment of essential hypertension.\" Arch Intern Med 148 (1988): 539-43[2] Chrysant SG \"Experience with terazosin administered in combination with other antihypertensive agents.\" Am J Med 80 (1986): 55-61[3] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[4] Pool JL \"Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.\" Am Heart J 122 (1991): 926-31[5] Rubin P, Jackson G, Blaschke T \"Studies on the clinical pharmacology of prazosin II: the influence of indomethacin and of propranolol on the action and disposition of prazosin.\" Br J Clin Pharmacol 10 (1980): 33-9[6] Elliott HL, McLean K, Sumner DJ, Meredith PA, Reid JL \"Immediate cardiovascular responses to oral prazosin: effects of concurrent beta-blockers.\" Clin Pharmacol Ther 29 (1981): 303-9[7] Seideman P, Grahnen A, Haglund K, Lindstrom B, Von Bahr C \"Prazosin first dose phenomenon during combined treatment with a B-adrenoceptor blocker in hypertensive patients.\" Br J Clin Pharmacol 13 (1982): 865-70[8] Stokes GS, Mennie BA, Gellatly R, Hill A \"On the combination of alpha- and beta-adrenoceptor blockade in hypertension.\" Clin Pharmacol Ther 34 (1983): 576-82", "alternatives_a": "Ivabradine", "alternatives_b": "Tamsulosin, Dutasteride, Solifenacin", "updated_at": 1767369485}, {"id": 45102, "ingredient1": "Bisoprolol", "ingredient2": "Terbutaline", "severity": "Moderate", "effect": "Although cardioselective beta-blockers do not generally inhibit the bronchodilating effect of beta-2 adrenergic agonists, they may worsen pulmonary function in patients with asthma or other obstructive airway diseases. Cardioselective beta-blockers can occasionally precipitate acute bronchospasm in these patients, despite relative selectivity for beta-1 receptors in cardiac tissues. Presumably, beta-1 selectivity is dose-dependent and may be lost given a sufficient dose of the beta-blocker in susceptible patients. Other mechanisms may also be involved in bronchoconstriction that are unrelated to beta-2 blockade--for example, their effects on cholinergic M2 receptors and alpha-1 adrenoreceptors.", "source": "DDInter", "management_text": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases. However, given their demonstrated benefit in such conditions as heart failure, myocardial infarction, cardiac arrhythmias and hypertension, cardioselective beta-blockers may be administered with caution to those who do not respond to or tolerate alternative treatment. The benefits generally outweigh the risks in patients with mild or moderate reactive airway disease that is well controlled on inhaled corticosteroids and beta-2 agonists, provided they have no prior history suggesting a predisposition to severe exacerbations.", "mechanism_text": "Others", "recommendation": "Beta-blockers, including those with relative cardioselectivity, should generally be avoided in patients with bronchospastic diseases.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45172/", "reference_text": "[1] Hollenberg NK \"The role of beta-blockers as a cornerstone of cardiovascular therapy.\" Am J Hypertens 18(12 Pt 2) (2005): 165S-168S[2] Chodosh S, Tuck J, Blasucci DJ \"The effects of dilevalol, metoprolol, and placebo on ventilatory function in asthmatics.\" J Cardiovasc Pharmacol 11 (1988): s18-24[3] Baselli LM, Oswald MA, Nashelsky JM \"Do beta-blockers worsen respiratory status for patients with COPD?\" J Fam Pract 54 (2005): 472-3[4] Cazzola M, Noschese P, D'Amato M, D'Amato G \"Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma.\" Chest 118 (2000): 1322-6[5] Johnsson G, Svedmyr N, Thiringer G \"Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics.\" Eur J Clin Pharmacol 8 (1975): 175-80[6] Salpeter SR, Ormiston TM, Salpeter EE \"Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis.\" Ann Intern Med 137 (2002): 715-25[7] Gold MR, Dec GW, Cocca-Spofford D, Thompson BT \"Esmolol and ventilatory function in cardiac patients with COPD.\" Chest 100 (1991): 1215-8[8] Ruffin RE, Frith PA, Anderton RC, Kumana CR, Newhouse MT, Hargreave FE \"Selectivity of beta adrenoreceptor antagonist drugs assessed by histamine bronchial provocation.\" Clin Pharmacol Ther 25 (1979): 536-40[9] De Bono G, Kaye CM, Roland E, Summers AJ \"Acebutolol: ten years of experience.\" Am Heart J 109 (1985): 1211-3[10] Mooss AN, Hilleman DE, Mohiuddin SM, Hunter CB \"Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.\" Ann Pharmacother 28 (1994): 701-3[11] Cazzola M, Noschese P, D'Amato G, Matera MG \"The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction.\" Chest 121 (2002): 230-41[12] van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R \"Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers.\" Chest 127 (2005): 818-24[13] Rasch D, Holt J, Wilson M, Smith RB \"Bronchospasm following intraocular injection of acetylcholine in a patient taking metoprolol.\" Anesthesiology 59 (1983): 583-5[14] Ashrafian H, Violaris AG \"Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint.\" Prim Care Respir J 14 (2005): 236-41[15] Craig TJ \"Drugs to be used with caution in patients with asthma.\" Am Fam Physician 54 (1996): 947-53[16] Falliers CJ, Vincent ME, Medakovic M \"Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol.\" J Asthma 23 (1986): 251-60[17] Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates D \"Cardioselective beta-blockers for chronic obstructive pulmonary disease.\" Cochrane Database Syst Rev 2 (2002): CD0003566[18] Sheppard D, DiStefano S, Byrd RC, Eschenbacher WL, Bell V, Steck J, Laddu A \"Effects of esmolol on airway function in patients with asthma.\" J Clin Pharmacol 26 (1986): 169-74[19] Tafreshi MJ, Weinacker AB \"Beta-adrenergic-blocking agents in broncospastic diseases: a therapeutic dilemma.\" Pharmacotherapy 19 (1999): 974-8[20] Macquin-Mavier I, Roudot-Thorval F, Clerici C, George C, Harf A \"Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction.\" Br J Clin Pharmacol 26 (1988): 279-84[21] Thiringer G, Svedmyr N \"Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics.\" Eur J Clin Pharmacol 10 (1976): 163-70[22] Bloom B, Chalmers PC, Danker PR, Kumar S, Sheikh F \"Cardiovascular collapse and refractory bronchospasm following administration of vancomycin, esmolol, and heparin.\" J Cardiothorac Anesth 3 (1989): 748-51[23] Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, Cherniak RM \"The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.\" Am Rev Respir Dis 133 (1986): 264-8[24] Brooks AM, Burden JG, Gillies WE \"The significance of reactions to betaxolol reported by patients.\" Aust N Z J Ophthalmol 17 (1989): 353-5[25] Brooks AM, Gillies WE \"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.\" Drugs Aging 2 (1992): 208-21[26] Chafin CC, Soberman JE, Demirkan K, Self T \"Beta-blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?.\" Cardiology 92 (1999): 99-105", "alternatives_a": "Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, More", "alternatives_b": "Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate", "updated_at": 1767369485}, {"id": 45103, "ingredient1": "Bisoprolol", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45173/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Acetylsalicylic acid, Penbutolol, Carteolol", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 45104, "ingredient1": "Bisoprolol", "ingredient2": "Tetrofosmin", "severity": "Moderate", "effect": "Drugs such as beta-blockers, calcium channel blockers, and nitrates may influence myocardial function and blood flow.", "source": "DDInter", "management_text": "Clinicians should consider concomitant medications that may influence myocardial function and blood flow when assessing images.", "mechanism_text": "Others", "recommendation": "Clinicians should consider concomitant medications that may influence myocardial function and blood flow when assessing images.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45174/", "reference_text": "[1] \"Product Information. Myoview (tetrofosmin).\" GE Healthcare, Princeton, NJ.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45105, "ingredient1": "Bisoprolol", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can cause bradycardia and may have additive effects with other drugs that decrease heart rate. Cases of bradycardia have been associated with thalidomide use, some requiring medical interventions. The clinical significance and underlying etiology of the bradycardia observed with thalidomide treatment have not been established. However, the potential for additive bradycardic effects should be considered when used with other drugs that slow cardiac conduction such as beta-blockers, calcium channel blockers, digitalis, flecainide, moricizine, and propafenone. Non-cardiac drugs that may also cause bradycardia include atazanavir, lacosamide, lithium, mefloquine, succinylcholine, H2-receptor antagonists, tricyclic antidepressants, and anticholinesterase or cholinergic agents. Because bradycardia is a risk factor for torsade de pointes arrhythmia, concerns also exist when thalidomide is used with drugs that prolong the QT interval or cause torsade de pointes.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia. Patients should be monitored for bradycardia, atrioventricular block and syncope, and advised to seek medical attention if they experience dizziness, lightheadedness, fainting, shortness of breath, or slow or irregular heartbeat. A dose reduction of thalidomide or discontinuation may be required.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with drugs that can slow the heart rate or induce torsade de pointes arrhythmia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45175/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[6] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[7] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45106, "ingredient1": "Bisoprolol", "ingredient2": "Thallous Chloride", "severity": "Moderate", "effect": "Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference by these drugs.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference by these drugs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45176/", "reference_text": "[1] \"Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201).\" GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy \"Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl.\" ([cited Feb2015]):", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45107, "ingredient1": "Bisoprolol", "ingredient2": "Theophylline", "severity": "Major", "effect": "The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.", "source": "DDInter", "management_text": "Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.", "mechanism_text": "Antagonism", "recommendation": "Oral and ophthalmic nonselective beta-blockers (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45177/", "reference_text": "[1] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part II).\" Clin Pharmacokinet 20 (1991): 135-50[2] Mue S, Sasaki T, Shibahara S, et alT \"Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.\" Int J Clin Pharmacol Biopharm 17 (1979): 346-50[3] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL \"The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance.\" J Clin Pharmacol 27 (1987): 523-9[4] Horvath JS, Woolcock AJ, Tiller DJ, Donnelly P, Armstrong J, Caterson R \"A comparison of metoprolol and propranolol on blood pressure and respiratory function in patients with hypertension.\" Aust N Z J Med 8 (1978): 1-6[5] Conrad KA, Nyman DW \"Effects of metoprolol and propranolol on theophylline elimination.\" Clin Pharmacol Ther 28 (1980): 463-7", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Mepolizumab, Roflumilast, Zafirlukast, Bromotheophylline", "alternatives_b": "Ivabradine, Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril, Indapamide", "updated_at": 1767369485}, {"id": 45108, "ingredient1": "Bisoprolol", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45178/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "alternatives_b": "Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 45109, "ingredient1": "Bisoprolol", "ingredient2": "Thioridazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45179/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 45110, "ingredient1": "Bisoprolol", "ingredient2": "Thiothixene", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45180/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Ivabradine", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 45111, "ingredient1": "Bisoprolol", "ingredient2": "Thyroid, porcine", "severity": "Minor", "effect": "Thyroid hormone therapy may reverse decreased hepatic blood flow associated with hypothyroidism. Increased hepatic metabolism and decreased serum levels of some beta-blockers may result. Data are available for propranolol only. No special precautions are necessary. When hypothyroidism is converted to a euthyroid state, a decrease in beta-blocking effectiveness is possible.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45181/", "reference_text": "[1] Aro A, Antila M, Korhonen T, Sundquist H \"Pharmacokinetics of propranolol and sotalol in hyperthyroidism.\" Eur J Clin Pharmacol 21 (1982): 373-7[2] Wells PG, Feely J, Wilkinson GR, Wood AJ \"Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing.\" Clin Pharmacol Ther 33 (1983): 603-8[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[5] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Acetylsalicylic acid, Nebivolol, Nebivolol, Felodipine, Enalapril, Amlodipine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45112, "ingredient1": "Bisoprolol", "ingredient2": "Ticagrelor", "severity": "Minor", "effect": "Ventricular pauses and bradycardia, mostly asymptomatic, have been observed in clinical studies with ticagrelor.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45182/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Indapamide", "alternatives_b": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "updated_at": 1767369485}, {"id": 45113, "ingredient1": "Bisoprolol", "ingredient2": "Timolol (ophthalmic)", "severity": "Moderate", "effect": "Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.", "source": "DDInter", "management_text": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.", "mechanism_text": "Synergism", "recommendation": "Blood pressure and intraocular pressure monitoring is recommended during concurrent use.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45183/", "reference_text": "[1] \"Product Information. Timoptic (timolol ophthalmic).\" Merck & Co, Inc, West Point, PA.[2] \"Product Information. Acupress (carteolol ophthalmic).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Nadolol, Labetalol, Propranolol, Esmolol, Betaxolol, Nebivolol, Penbutolol, Bisoprolol, Carteolol, Sotalol, Pindolol, More", "alternatives_b": "Acetylsalicylic acid, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "updated_at": 1767369485}, {"id": 45114, "ingredient1": "Bisoprolol", "ingredient2": "Tizanidine", "severity": "Major", "effect": "Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.", "source": "DDInter", "management_text": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.", "mechanism_text": "Synergism", "recommendation": "A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45184/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics, Hawthorne, NY.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45115, "ingredient1": "Bisoprolol", "ingredient2": "Tocainide", "severity": "Moderate", "effect": "The concomitant use of tocainide and beta-blockers may have additive effects on cardiac index, left ventricular function, and pulmonary wedge pressure. While significant interactions have not been reported in studies, cases of asystole have been reported in patients with preexisting electrophysiologic abnormalities after tocainide and metoprolol were coadministered. The mechanism is not known, but may be related to an additive effect on the sinus node or conduction system, especially in patients with sick sinus syndrome. Cases of confusion and paranoia have also been reported after coadministration of tocainide and propranolol.", "source": "DDInter", "management_text": "The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome. This combination should be used cautiously in other patients, with careful dose titration and close clinical and electrocardiographic monitoring for efficacy and safety.", "mechanism_text": "Synergism", "recommendation": "The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45185/", "reference_text": "[1] Roden DM, Woosley RL \"Tocainide.\" N Engl J Med 315 (1986): 41-5[2] Rubino M, Jackson E \"Severe paranoia with concomitant tocainide and propranolol therapy.\" Clin Pharm 1 (1982): 177-9[3] Ikram H \"Hemodynamic and electrophysiologic interactions between antiarrhythmic drugs and beta blockers, with special reference to tocainide.\" Am Heart J 100 (1980): 1076-80", "alternatives_a": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Acetylsalicylic acid, Nebivolol, Nebivolol, Felodipine, Enalapril, Amlodipine, More", "alternatives_b": "Propafenone, Procainamide, Dofetilide, Bretylium, Moricizine, Ibutilide", "updated_at": 1767369485}, {"id": 45116, "ingredient1": "Bisoprolol", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Tofacitinib has been shown to decrease heart rate and prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta-blockers, digoxin, alpha-2 adrenoceptor agonists) may result in elevated risk of conduction disturbances and atrioventricular block.", "source": "DDInter", "management_text": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible. Caution is advised if concomitant use is necessary, particularly in patients with known conduction problems or severe cardiac disease. An ECG should be considered in these patients before initiating concomitant therapy and after titration to steady-state. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeats.", "mechanism_text": "Synergism", "recommendation": "According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45186/", "reference_text": "[1] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45117, "ingredient1": "Bisoprolol", "ingredient2": "Tolazamide", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45187/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Felodipine, Amlodipine, Verapamil", "alternatives_b": "Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, Linagliptin, More", "updated_at": 1767369485}, {"id": 45118, "ingredient1": "Bisoprolol", "ingredient2": "Tolbutamide", "severity": "Moderate", "effect": "Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine's effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.", "source": "DDInter", "management_text": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.", "mechanism_text": "Others", "recommendation": "In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45188/", "reference_text": "[1] Zaman R, Kendall MJ, Biggs PI \"The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.\" Br J Clin Pharmacol 13 (1982): 507-12[2] Shepherd AM, Lin M-S, Keeton TK \"Hypoglycemia-induced hypertension in a diabetic patient on metoprolol.\" Ann Intern Med 94 (1981): 357-8[3] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects.\" Metabolism 29 (1980): 866-72[4] Viberti GC, Keen H, Bloom SR \"Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in insulin-dependent diabetics.\" Metabolism 29 (1980): 873-9[5] Ostman J \"B-adrenergic blockade and diabetes mellitus.\" Acta Med Scand 672 (1983): 69-77[6] Groop L, Totterman KJ, Harno K, Gordin A \"Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus.\" Acta Med Scand 211 (1982): 7-12[7] Sinclair AJ, Davies IB, Warrington SJ \"Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin.\" Br J Clin Pharmacol 30 (1990): 699-702[8] Popp DA, Tse TF, Shah SD, et al \"Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus.\" Diabetes Care 7 (1984): 243-7[9] Mann SJ, Krakoff LR \"Hypertensive crisis caused by hypoglycemia and propranolol.\" Arch Intern Med 144 (1984): 2427-8[10] Deacon SP, Karunanayake A, Barnett D \"Acebutolol, atenolol, and propranolol and metabolic responses to acute hypoglycaemia in diabetes.\" Br Med J 12 (1977): 1255-7[11] Pollare T, Lithell H, Selinus I, Berne C \"Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients.\" BMJ 298 (1989): 1152-7[12] Munroe WP, Rindone JP, Kershner RM \"Systemic side effects associated with the ophthalmic administratiion of timolol.\" Drug Intell Clin Pharm 19 (1985): 85-9[13] Micossi P, Pollavini G, Raggi U, et al \"Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus.\" Horm Metab Res 16 (1984): 59-63[14] \"New Zealand Committee on Adverse Drug Reactions. Ninth Annual Report.\" N Z Dent J 71 (1975): 28-32[15] Smith U \"Beta blockade in diabetes.\" N Engl J Med 299 (1978): 1467[16] Newman RJ \"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.\" Br Med J 2 (1976): 447-9[17] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[18] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.[19] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[20] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[23] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[24] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[25] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[26] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6", "alternatives_a": "Felodipine, Amlodipine, Ivabradine, Felodipine, Amlodipine, Verapamil", "alternatives_b": "Methylene blue, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More", "updated_at": 1767369485}, {"id": 45119, "ingredient1": "Bisoprolol", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.", "source": "DDInter", "management_text": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45189/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs.\" Ann Intern Med 107 (1987): 628-35[2] Hartmann D, Stief G, Lingenfelder M, Guzelhan C, Horsch AK \"Study on the possible interaction between tenoxicam and atenolol in hypertensive patients.\" Arzneimittelforschung 45-1 (1995): 494-8[3] Abate MA, Neely JL, Layne RD, D'Allessandri R \"Interaction of indomethacin and sulindac with labetalol.\" Br J Clin Pharmacol 31 (1991): 363-6[4] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11[5] Wong DG, Spence JD, Lamki L, Freeman D, McDonald JW \"Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics.\" Lancet 1 (1986): 997-1001[6] Ylitalo P, Pitkajarvi T, Pyykonen ML, Nurmi AK, Seppala E, Vapaatalo H \"Inhibition of prostaglandin synthesis by indomethacin interacts with the antihypertensive effect of atenolol.\" Clin Pharmacol Ther 38 (1985): 443-9[7] Durao V, Prata MM, Concalves LM \"Modification of antihypertensive effect of B-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[8] Salvetti A, Arzilli F, Pedrinelli R, Beggi P, Motolese M \"Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.\" Eur J Clin Pharmacol 22 (1982): 197-201[9] Durao V, Prata MM, Goncalves LM \"Modification of antihypertensive effect of beta-adrenoceptor-blocking agents by inhibition of endogenous prostaglandin synthesis.\" Lancet 2 (1977): 1005-7[10] Salvetti A, Pedrinelli R, Alberici P, Magagna A, Abdel-Haq B \"The influence of indomethacin and sulindac on some pharmacological actions of atenolol in hypertensive patients.\" Br J Clin Pharmacol 17 Suppl 1 (1984): s108-11", "alternatives_a": "Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Valdecoxib, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45120, "ingredient1": "Bisoprolol", "ingredient2": "Tolterodine", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45190/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Ivabradine, Esmolol, Trandolapril", "alternatives_b": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More", "updated_at": 1767369485}, {"id": 45121, "ingredient1": "Bisoprolol", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45191/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45122, "ingredient1": "Bisoprolol", "ingredient2": "Tranylcypromine", "severity": "Moderate", "effect": "Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.", "source": "DDInter", "management_text": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45192/", "reference_text": "[1] \"Product Information. Marplan (isocarboxazid)\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Matulane (procarbazine).\" Roche Laboratories, Nutley, NJ.[3] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH \"Blood pressure effects of phenelzine.\" J Clin Psychopharmacol 3 (1983): 307-10[4] \"Product Information. Nardil (phenelzine).\" Parke-Dvis, Morris Plains, NJ.[5] Golwyn DH, Sevlie CP \"Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension.\" J Clin Psychopharmacol 13 (1993): 77-8[6] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham, Philadelphia, PA.[7] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965): 561-5[8] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968): 442-7[9] \"Product Information. Hylorel (guanadrel).\" Rhone-Poulenc Rorer, Collegeville, PA.[10] Reggev A, Vollhardt BR \"Bradycardia induced by an interaction between phenelzine and beta blockers.\" Psychosomatics 30 (1989): 106-8[11] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964): 456-62[12] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[13] Kraus RP \"Pindolol augmentation of tranylcypromine in psychotic depression.\" J Clin Psychopharmacol 17 (1997): 225-6", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "updated_at": 1767369485}, {"id": 45123, "ingredient1": "Bisoprolol", "ingredient2": "Trazodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45193/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Felodipine", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "updated_at": 1767369485}, {"id": 45124, "ingredient1": "Bisoprolol", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.", "source": "DDInter", "management_text": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45194/", "reference_text": "[1] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[2] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Buchdahl RM, Taylor P, Warner JD \"Nebulised ribavirin for adenovirus pneumonia.\" Lancet 2 (1985): 1070-1[5] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45125, "ingredient1": "Bisoprolol", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45195/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Amiloride", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Carteolol, Penbutolol, Felodipine, Amlodipine, Verapamil, More", "updated_at": 1767369485}, {"id": 45126, "ingredient1": "Bisoprolol", "ingredient2": "Triazolam", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45196/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Ivabradine, Timolol, Timolol, Felodipine, Trandolapril, Indapamide", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45127, "ingredient1": "Bisoprolol", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.", "source": "DDInter", "management_text": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.", "mechanism_text": "Synergism", "recommendation": "Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45197/", "reference_text": "[1] Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA \"Nadolol in combination with indapamide and xipamide in resistant hypertensives.\" Eur J Clin Pharmacol 28 (1985): 29-33[2] Dornhorst A, Powell SH, Pensky J \"Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion.\" Lancet 1 (1985): 123-6[3] \"Product Information. Lozol (indapamide).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] Marcy TR, Ripley TL \"Aldosterone antagonists in the treatment of heart failure.\" Am J Health Syst Pharm 63 (2006): 49-58[5] Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B \"Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.\" Eur J Clin Pharmacol 24 (1983): 801-6", "alternatives_a": "Felodipine, Acetylsalicylic acid, Nifedipine, Ivabradine, Carteolol, Felodipine, Hydrochlorothiazide, Indapamide, Verapamil", "alternatives_b": "Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Ciclopirox, Vemurafenib, More", "updated_at": 1767369485}, {"id": 45128, "ingredient1": "Bisoprolol", "ingredient2": "Trifluoperazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45198/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid", "alternatives_b": "Droperidol, Pimozide, Pimavanserin", "updated_at": 1767369485}, {"id": 45129, "ingredient1": "Bisoprolol", "ingredient2": "Triflupromazine", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45199/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "Acetylsalicylic acid, Carteolol", "updated_at": 1767369485}, {"id": 45130, "ingredient1": "Bisoprolol", "ingredient2": "Trihexyphenidyl", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45200/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Felodipine, Ivabradine, Esmolol, Felodipine, Moexipril, Verapamil, Ramipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45131, "ingredient1": "Alimemazine", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45201/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Acetylsalicylic acid, Carteolol", "alternatives_b": "Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More", "updated_at": 1767369485}, {"id": 45132, "ingredient1": "Bisoprolol", "ingredient2": "Trimipramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45202/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Nifedipine", "alternatives_b": "Desvenlafaxine, St. John's Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, Fluvoxamine, Escitalopram", "updated_at": 1767369485}, {"id": 45133, "ingredient1": "Bisoprolol", "ingredient2": "Trospium", "severity": "Moderate", "effect": "Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.", "source": "DDInter", "management_text": "Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism, Absorption", "recommendation": "Patients should be monitored for potentially excessive CNS adverse effects (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45203/", "reference_text": "[1] Regardh CG, Lundborg P, Persson BA \"The effect of antacid, metoclopramide, and propantheline on the bioavailability of metoprolol and atenolol.\" Biopharm Drug Dispos 2 (1981): 79-87[2] Briant RH, Dorrington RE, Ferry DG, Paxton JW \"Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine.\" Eur J Clin Pharmacol 25 (1983): 353-6[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[4] Clark JM, Seager SJ \"Gastric emptying following premedication with glycopyrrolate or atropine.\" Br J Anaesth 55 (1983): 1195-9", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More", "alternatives_b": "Felodipine, Amlodipine, Nifedipine, Ivabradine, Acetylsalicylic acid, Esmolol, Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, More", "updated_at": 1767369485}, {"id": 45134, "ingredient1": "Bisoprolol", "ingredient2": "Tubocurarine", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45204/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45135, "ingredient1": "Bisoprolol", "ingredient2": "Tyropanoic acid", "severity": "Moderate", "effect": "Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.", "source": "DDInter", "management_text": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.", "mechanism_text": "Synergism", "recommendation": "Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45205/", "reference_text": "[1] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[2] Costa N \"Understanding contrast media.\" J Infus Nurs 27 (2004): 302-12[3] \"Product Information. Visipaque (iodixanol).\" Nycomed Inc, Princeton, NJ.[4] \"Product Information. Ultravist (iopromide).\" Berlex, Richmond, CA.", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Carteolol, Enalapril, Moexipril, Ramipril, Hydrochlorothiazide, Lisinopril, Perindopril, Benazepril, Quinapril, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45136, "ingredient1": "Bisoprolol", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "In the Valsartan Heart Failure Trial, the combination of valsartan with a beta-blocker and an ACE inhibitor was associated with unfavorable outcomes on morbidity and mortality in heart failure patients. The mechanism is unknown.", "source": "DDInter", "management_text": "The manufacturer recommends that the triple combination of valsartan with a beta-blocker and an ACE inhibitor be avoided in heart failure patients.", "mechanism_text": "Others", "recommendation": "The manufacturer recommends that the triple combination of valsartan with a beta-blocker and an ACE inhibitor be avoided in heart failure patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45206/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Diovan (valsartan).\" Novartis Pharmaceuticals, East Hanover, NJ.[6] \"Product Information. Cozaar (losartan).\" Merck & Co, Inc, West Point, PA.", "alternatives_a": "Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Eprosartan, Lovastatin, Bempedoic acid, Azilsartan medoxomil, Candesartan, Eprosartan, Olmesartan", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45137, "ingredient1": "Bisoprolol", "ingredient2": "Vardenafil", "severity": "Moderate", "effect": "Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.", "source": "DDInter", "management_text": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45207/", "reference_text": "[1] \"Product Information. Stendra (avanafil).\" Vivus Inc, Mountain View, CA.[2] \"Product Information. Viagra (sildenafil).\" Pfizer US Pharmaceuticals, New York, NY.[3] \"Product Information. Levitra (vardenafil).\" Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. \"Effects of grapefruit juice on the pharmacokinetics of sildenafil.\" Clin Pharmacol Ther 71 (2002): 21-29", "alternatives_a": "Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45138, "ingredient1": "Bisoprolol", "ingredient2": "Vecuronium", "severity": "Moderate", "effect": "Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.", "source": "DDInter", "management_text": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.", "mechanism_text": "Synergism", "recommendation": "Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45208/", "reference_text": "[1] Loan PB, Connolly FM, Mirakhur RK, Kumar N, Farling P \"Neuromuscular effects of rocuronium in patients receiving beta-adrenoreceptor blocking, calcium entry blocking and anticonvulsant drugs.\" Br J Anaesth 78 (1997): 90-1[2] Harrah MD, Way WL, Katzung BG \"The interaction of d-tubocurarine with antiarrhythmic drugs.\" Anesthesiology 33 (1970): 406-10[3] Rozen MS, Whan FM \"Prolonged curarization associated with propranolol.\" Med J Aust 1 (1972): 467-8[4] Murthy VS, Patel KD, Elangovan RG, Hwang TF, Solochek SM, Steck JD, Laddu AR \"Cardiovascular and neuromuscular effects of esmolol during induction of anesthesia.\" J Clin Pharmacol 26 (1986): 351-7[5] Glynne GL \"Drug interaction?\" Anaesthesia 39 (1984): 293[6] Herishanu Y, Rosenberg P \"Beta-blockers and myasthenia gravis.\" Ann Intern Med 83 (1975): 834-5[7] Yate B, Mostafa SM \"Drug interaction?\" Anaesthesia 39 (1984): 728-9[8] Chapple DJ, Clark JS, Hughes R \"Interaction between atracurium and drugs used in anaesthesia.\" Br J Anaesth 55 Suppl 1 (1983): s17-22", "alternatives_a": "Ivabradine, Moexipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "Botulinum toxin type A", "updated_at": 1767369485}, {"id": 45139, "ingredient1": "Bisoprolol", "ingredient2": "Verapamil", "severity": "Major", "effect": "Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers, especially verapamil and diltiazem, are used concomitantly with beta blockers. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. Ventricular asystole, sinus arrest, and heart block have also been reported.", "source": "DDInter", "management_text": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary. Patients should be advised to promptly report any symptoms including fatigue, headache, fainting, swelling of the extremities, weight gain, shortness of breath, chest pain, increased or decreased heartbeat, or irregular heartbeat.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring of patient hemodynamic response and tolerance is recommended if these agents are used together, and the dosage of one or both agents adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45209/", "reference_text": "[1] Packer M \"Combined beta-adrenergic and calcium-entry blockage in angina pectoris.\" N Engl J Med 320 (1989): 709-18[2] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[3] Rocha P, Guerret M, David D, Marchand X, Kahn JC \"Kinetics and hemodynamic effects of intravenous nicardipine modified by previous propranolol oral treatment.\" Cardiovasc Drugs Ther 4 (1990): 1525-32[4] Misra M, Thakur R, Bhandari K \"Sinus arrest caused by atenolol-verapamil combination.\" Clin Cardiol 10 (1987): 365-7[5] Nievel JG, Havard CW, Douglas-Jones AP \"Comparison of concomitant nicardipine hydrochloride and propranolol with propranolol alone in patients with essential hypertension.\" Eur J Clin Pharmacol 33 (1987): 21-5[6] Keech AC, Harper RW, Harrison PM, et al \"Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.\" Eur J Clin Pharmacol 35 (1988): 363-6[7] Strauss WE, Parisi AF \"Combines use of calcium-channel and beta-adrenergic blockers for the treatment of chronic stable angina.\" Ann Intern Med 109 (1988): 570-81[8] Carruthers SG, Freeman DJ, Bailey DG \"Synergistic adverse hemodynamic interaction between oral verapamil and propranolol.\" Clin Pharmacol Ther 46 (1989): 469-77[9] Winniford MD, Fulton KL, Hillis LD \"Symptomatic sinus bradycardia during concomitant propranolol-verapamil administration.\" Am Heart J 110 (1985): 498[10] McLean AJ, Knight R, Harrison PM, Harper RW \"Clearance-based oral drug interaction between verapamil and metoprolol and comparison with atenolol.\" Am J Cardiol 55 (1985): 1628-9[11] Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ \"Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.\" Eur J Clin Pharmacol 35 (1988): 363-6[12] Wayne VS, Harper RW, Laufer E, et al \"Adverse interaction between beta-adrenergic blocking drugs and verapamil: report of three cases.\" Aust N Z J Med 12 (1982): 285-9[13] Eisenberg JN, Oakley GD \"Probable adverse interaction between oral metoprolol and verapamil.\" Postgrad Med J 60 (1984): 705-6[14] Murdoch DL, Thomson GD, Thompson GG, et al \"Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.\" Br J Clin Pharmacol 31 (1991): 323-32[15] Sagie A, Strasberg B, Kusnieck J, Sclarovsky S \"Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers.\" Clin Cardiol 14 (1991): 314-6[16] Pringle SD, MacEwen CJ \"Severe bradycardia due to interaction of timolol eye drops and verapamil.\" Br Med J 294 (1987): 155-6[17] Keech AC, Harper RW, Harrison PM, Pitt A, McLean AJ \"Extent and pharmacokinetic mechanisms of oral atenolol-verapamil interaction in man.\" Eur J Clin Pharmacol 35 (1988): 363-6[18] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[19] Leon MB, Rosing DR, Bonow RO, Epstein SE \"Combination therapy with calcium-channel blockers and beta blockers for chronic stable angina pectoris.\" Am J Cardiol 55 (1985): b69-80[20] Minish T, Herd A \"Symptomatic bradycardia secondary to interaction between topical timolol maleate, verapamil, and flecainide: a case report.\" J Emerg Med 22 (2002): 247-9[21] Anastassiades CJ \"Nifedipine and beta-blocker drugs.\" Br Med J 281 (1980): 1251-2[22] Pieper JA, Miller JH \"Serum protein binding interactions between propranolol and calcium channel blockers.\" Drug Intell Clin Pharm 18 (1984): 492[23] Lee TH, Salomon DR, Rayment CM, Antman EM \"Hypotension and sinus arrest with exercise-induced hyperkalemia and combined verapamil-propranolol therapy.\" Am J Med 80 (1986): 1203-4[24] Hunt BA, Bottorff MB, Herring VL, Self Th, Lalonde RL \"Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers.\" Clin Pharmacol Ther 47 (1990): 584-91[25] McCourty JC, Silas JH, Tucker GT, Lennard MS \"The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.\" Br J Clin Pharmacol 25 (1988): 349-57[26] Schoors DF, Vercruysse I, Musch G, Massart DL, Dupont AG \"Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.\" Br J Clin Pharmacol 29 (1990): 497-501[27] Ronn O, Bengtsson B, Edgar B, Raner S \"Acute haemodynamic effects of felodipine and verapamil in man, singly and with metoprolol.\" Drugs 29 (1985): 16-25[28] \"Product Information. Toprol-XL (metoprolol)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[29] Lee TH, Salomon DR, Rayment CM, Antman EM \"Hypotension and sinus arrest with exercise-induced hyperkalemia and combined verapamil/propranolol therapy.\" Am J Med 80 (1986): 1203-4[30] Reddy PS, Uretsky BF, Steinfeld M \"The hemodynamic effects of intravenous verapamil in patients on chronic propranolol therapy.\" Am Heart J 107 (1984): 97-101[31] Zatuchni J \"Bradycardia and hypotension after propranolol HCI and verapamil.\" Heart Lung 14 (1985): 94-5[32] Sinclair NI, Benzie JL \"Timolol eye drops and verapamil: a dangerous combination.\" Med J Aust 1 (1983): 548[33] McCourty JC, Silas JH, Tucker GT, Lennard MS \"The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.\" Br J Clin Pharmacol 25 (1988): 349-57[34] Bailey DG, Carruthers SG \"Interaction between oral verapamil and beta-blockers during submaximal exercise: relevance of ancillary properties.\" Clin Pharmacol Ther 49 (1991): 370-6[35] Bleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman DP, Shea MJ \"Evaluation of dosage-release formulations on inhibition of drug clearance - effect of sustained-release and immediate-release verapamil on propranolol pharmacokinetic parameters.\" Ther Drug Monit 16 (1994): 216-20[36] Pouleur H, Etienne J, Van Mechelen H, et al \"Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease.\" Postgrad Med J 60 (1984): 23-8[37] Levine MA, Ogilvie RI, Leenen FH \"Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.\" Clin Pharmacol Ther 43 (1988): 39-48[38] McTavish D, Sorkin EM \"Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.\" Drugs 38 (1989): 19-76[39] Bailey DG, Dresser GK \"Natural products and adverse drug interactions.\" Can Med Assoc J 170 (2004): 1531-2[40] Ho PC, Ghose K, Saville D, Wanwimolruk S \"Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.\" Eur J Clin Pharmacol 56 (2000): 693-8[41] Pillai U, Muzaffar J, Sandeep S, Yancey A \"Grapefruit juice and verapamil: a toxic cocktail.\" South Med J 102 (2009): 308-9[42] McAllister RG, Jr \"Clinical pharmacology of slow channel blocking agents.\" Prog Cardiovasc Dis 25 (1982): 83-102[43] \"Product Information. Covera-HS (verapamil).\" Searle, Skokie, IL.[44] Fuhr U, Muller-Peltzer H, Kern R, et al. \"Effects of grapefruit juice and smoking on verapamil concentrations in steady state.\" Eur J Clin Pharmacol 58 (2002): 45-53[45] Arayne MS, Sultana N, Bibi Z \"Review: grape fruit juice - drug interactions.\" Pak J Pharm Sci 18 (2005): 45-57[46] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions. 1998.\" Br J Clin Pharmacol 58 (2004): S831-40; discussion S841-3[47] Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A \"The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil.\" Eur J Clin Pharmacol 54 (1998): 337-40", "alternatives_a": "Verapamil", "alternatives_b": "Trandolapril, Moexipril, Bisoprolol, Benazepril", "updated_at": 1767369485}, {"id": 45140, "ingredient1": "Bisoprolol", "ingredient2": "Zaleplon", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45210/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Felodipine, Nifedipine, Ivabradine, Felodipine", "alternatives_b": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "updated_at": 1767369485}, {"id": 45141, "ingredient1": "Bisoprolol", "ingredient2": "Zileuton", "severity": "Moderate", "effect": "Zileuton is believed to inhibit the hepatic metabolism of propranolol. Propranolol serum concentrations may increase by as much as 100% with a resultant increase in beta blockade.", "source": "DDInter", "management_text": "It is unknown if this interaction will occur with other beta-blockers; however, if zileuton and a beta-blocker must be given concomitantly, the patient should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "mechanism_text": "Metabolism", "recommendation": "It is unknown if this interaction will occur with other beta-blockers; however, if zileuton and a beta-blocker must be given concomitantly, the patient should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45211/", "reference_text": "[1] \"Product Information. Zylo Filmtab (zileuton).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Acetylsalicylic acid, Atenolol, Ivabradine, Sotalol, Nadolol, Atenolol, Sotalol, Nadolol, Esmolol, Carteolol, Sotalol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45142, "ingredient1": "Bisoprolol", "ingredient2": "Ziprasidone", "severity": "Moderate", "effect": "Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.", "source": "DDInter", "management_text": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.", "mechanism_text": "Synergism", "recommendation": "Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45212/", "reference_text": "[1] \"Product Information. Seroquel (quetiapine).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Risperdal (risperidone).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Abilify (aripiprazole).\" Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA \"Syncope associated with the combination of clozapine and enalapril.\" J Clin Psychopharmacol 14 (1994): 429-30[8] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R \"Severe hypotension associated with concurrent clonidine and antipsychotic medication.\" Am J Psychiatry 142 (1985): 274[10] \"Product Information. Geodon (ziprasidone).\" Pfizer US Pharmaceuticals, New York, NY.[11] White WB \"Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril.\" Arch Intern Med 146 (1986): 1833-4", "alternatives_a": "Droperidol, Pimozide, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45143, "ingredient1": "Bisoprolol", "ingredient2": "Zolmitriptan", "severity": "Minor", "effect": "After one week of dosing with zolmitriptan and propranolol 160 mg/day, the Cmax and AUC of zolmitriptan increased 1.5 times while the Cmax and AUC of the N-desmethyl metabolite decreased by 30% and 15%, respectively. The mechanism of the interaction has not been described. It does not appear that any special precautions are necessary when coadministering zolmitriptan with beta-blockers, although further post-marketing studies will help to define this interaction.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45213/", "reference_text": "[1] \"Product Information. Zomig (zolmitriptan).\" Zeneca Pharmaceuticals, Wilmington, DE.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Frovatriptan, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Sumatriptan, Erenumab, More", "alternatives_b": "Felodipine, Amlodipine, Nebivolol, Nifedipine, Ivabradine, Nebivolol, Nebivolol, Felodipine, Enalapril, Amlodipine, Moexipril, More", "updated_at": 1767369485}, {"id": 45144, "ingredient1": "Bisoprolol", "ingredient2": "Zolpidem", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45214/", "reference_text": "[1] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[11] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, Zopiclone, More", "alternatives_b": "Ivabradine", "updated_at": 1767369485}, {"id": 45145, "ingredient1": "Anisindione", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45215/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45146, "ingredient1": "Anistreplase", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been reported in patients with acute myocardial infarction treated with argatroban or lepirudin and thrombolytic therapy (recombinant tPA or streptokinase). The mechanism may be attributable to complementary or synergistic effects of these agents on thrombin-dependent functions and activated partial thromboplastin time (aPPT).", "source": "DDInter", "management_text": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45216/", "reference_text": "[1] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Alteplase, Dicoumarol, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45147, "ingredient1": "Bivalirudin", "ingredient2": "Ardeparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45217/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45148, "ingredient1": "Bivalirudin", "ingredient2": "Argatroban", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45218/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Argatroban, Antithrombin III human, Lepirudin, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45149, "ingredient1": "Bivalirudin", "ingredient2": "Bismuth subsalicylate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45219/", "reference_text": "[1] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[2] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970): 403-8[3] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[4] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971): 547-58[5] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[6] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967): 620-4[7] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968): 2169-80[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44", "alternatives_a": "Alteplase, Dipyridamole, Caplacizumab, Cilostazol, Streptokinase, Defibrotide, Antithrombin III human, Tenecteplase, Protein C, Acenocoumarol, Selexipag, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45150, "ingredient1": "Bromfenac", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45220/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Abciximab, Tirofiban, Dicoumarol, Eptifibatide, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "updated_at": 1767369485}, {"id": 45151, "ingredient1": "Bromfenac (ophthalmic)", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45221/", "reference_text": "[1] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Product Information. Acular (ketorolac).\" Allergan Inc, Irvine, CA.[3] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals, Irvine, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Triamcinolone, Dexamethasone", "updated_at": 1767369485}, {"id": 45152, "ingredient1": "Cabozantinib", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45222/", "reference_text": "[1] \"Product Information. Cometriq (cabozantinib).\" Exelixis Inc, S San Francisco, CA.[2] \"Product Information. Cometriq (cabozantinib).\" Exelixis Inc, S San Francisco, CA.[3] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[4] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[5] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[6] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[7] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[8] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[9] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[10] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[11] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[12] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[13] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[15] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[16] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[17] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[18] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[19] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[20] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[21] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[22] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[23] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[24] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[25] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[26] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[27] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[28] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[29] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[30] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[31] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[32] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[33] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[34] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[35] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[36] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[37] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[38] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[39] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45153, "ingredient1": "Caplacizumab", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Concomitant use of caplacizumab with other agents that affect hemostasis such as anticoagulants, platelet aggregation inhibitors, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding.", "source": "DDInter", "management_text": "Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if caplacizumab must be used with other agents that affect hemostasis.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45223/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Cablivi (caplacizumab).\" Genzyme Corporation, Cambridge, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[5] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[6] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[7] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[8] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[9] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[10] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[11] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[12] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[13] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[14] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[15] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[16] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[17] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[18] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[19] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[20] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[21] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[22] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[23] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[24] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[25] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[26] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[27] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[28] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[29] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[30] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[31] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[32] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[33] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[34] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[35] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[36] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[37] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[38] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[39] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[40] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Acenocoumarol, Caplacizumab, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45154, "ingredient1": "Capsicum", "ingredient2": "Bivalirudin", "severity": "Minor", "effect": "Theoretically, capsicum may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Animal and limited human data suggest that capsicum may increase fibrinolytic activity, lower plasma fibrinogen levels, increase plasma antithrombin III levels, inhibit platelet aggregation, and prolong bleeding time. In patients who have used capsicum extensively prior to receiving anticoagulation, antiplatelet, or thrombolytic therapy, the potential for an interaction should be considered. Clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45224/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45155, "ingredient1": "Chamomile", "ingredient2": "Bivalirudin", "severity": "Minor", "effect": "Some herbs such as chamomile and fenugreek have coumarin constituents. Theoretically, ingesting large quantities of these herbs may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. However, their effects on the coagulation system have not been studied, and bleeding complications have not been reported in humans. Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used chamomile or fenugreek extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45225/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[3] Lambert JP, Cormier J \"Potential interaction between warfarin and boldo-fenugreek.\" Pharmacotherapy 21 (2001): 509-12", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45156, "ingredient1": "Choline salicylate", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45226/", "reference_text": "[1] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[2] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970): 403-8[3] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[4] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971): 547-58[5] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[6] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967): 620-4[7] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968): 2169-80[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Ziconotide, Methoxyflurane", "updated_at": 1767369485}, {"id": 45157, "ingredient1": "Cilostazol", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Concomitant use of thrombin inhibitors and antiplatelet agents may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Coadministration of thrombin inhibitors and antiplatelet agents should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration of thrombin inhibitors and antiplatelet agents should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45227/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] \"Product Information. Acova (argatroban)\" SmithKline Beecham, Philadelphia, PA.[3] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Cilostazol, Dicoumarol, Antithrombin III human, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45158, "ingredient1": "Citalopram", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45228/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45159, "ingredient1": "Clomipramine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45229/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dalteparin, Danaparoid, Protein C, Tinzaparin, Acenocoumarol, Selexipag, Enoxaparin", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45160, "ingredient1": "Clopidogrel", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45230/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Vorapaxar, Antithrombin III human, Protein C, Clopidogrel", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45161, "ingredient1": "Clove", "ingredient2": "Bivalirudin", "severity": "Minor", "effect": "Clove and clove oil may potentiate the effects of anticoagulants and other drugs that may affect hemostasis such as platelet inhibitors, thrombolytic agents, and nonsteroidal anti-inflammatory drugs, possibly increasing the risk of bleeding. Eugenol, the active constituent of clove and clove oil, has been shown to be an inhibitor of platelet activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45231/", "reference_text": "[1] Srivasta KC \"Antiplatelet principles from a food spice clove (Syzygium aromaticum L) [corrected]\" Prostaglandins Leukot Essent Fatty Acids 48 (1993): 363-72[2] Saeed SA, Gilani AH \"Antithrombotic activity of clove oil.\" J Pak Med Assoc 44 (1994): 112-5[3] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[4] Srivstava KC, Malhotra N \"Acetyl eugenol, a component of oil of cloves (Syzygium aromaticum L.) inhibits aggregation and alters arachidonic acid metabolism in human blood platelets.\" Prostaglandins Leukot Essent Fatty Acids 42 (1991): 73-81", "alternatives_a": "Iloprost, Treprostinil, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45162, "ingredient1": "Collagenase clostridium histolyticum", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of collagenase clostridium histolyticum in patients currently receiving, or within 7 days of receiving, anticoagulant medications other than low-dose aspirin (e.g., up to 150 mg/day) is unknown. Theoretically, the risk of bleeding complications may be increased.", "source": "DDInter", "management_text": "Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.", "mechanism_text": "Synergism", "recommendation": "Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45232/", "reference_text": "[1] \"Product Information. Xiaflex (collagenase clostridium histolyticum).\" Auxilium Pharmaceuticals Inc, Norristown, PA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Risdiplam, Onasemnogene abeparvovec, Quinine, Hyaluronic acid", "updated_at": 1767369485}, {"id": 45163, "ingredient1": "Dalteparin", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45233/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Dalteparin, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45164, "ingredient1": "Danaparoid", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45234/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Danaparoid, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45165, "ingredient1": "Dasatinib", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with dasatinib is associated with severe thrombocytopenia.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for the first 2 months, then monthly thereafter or as clinically indicated. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45235/", "reference_text": "[1] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb, Princeton, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45166, "ingredient1": "Deferasirox", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration with drugs that have known ulcerogenic or hemorrhagic potential may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Fatal gastrointestinal hemorrhages have been reported during deferasirox therapy, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts.", "source": "DDInter", "management_text": "Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, hematemesis, anorexia, and/or black, tarry stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if deferasirox is prescribed with drugs that have known ulcerogenic or hemorrhagic potential, including but not limited to NSAIDs, salicylates, corticosteroids, oral bisphosphonates, platelet inhibitors, anticoagulants, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45236/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Protein C, Acenocoumarol", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45167, "ingredient1": "Defibrotide", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of defibrotide with anticoagulants may increase the risk of bleeding. In vitro, defibrotide increased the activity of fibrinolytic enzymes; therefore, it may enhance the pharmacologic effects of antithrombotic agents.", "source": "DDInter", "management_text": "Concomitant use of defibrotide with systemic anticoagulants (except for routine maintenance or reopening of central venous lines) is considered contraindicated. Anticoagulants should be discontinued prior to initiation of defibrotide. Preferably, defibrotide administration should be delayed until the effects of anticoagulant therapy have subsided. Some authorities recommend avoiding use of anticoagulants within 24 hours of defibrotide administration, or within 12 hours in the case of unfractionated heparin. Patients should be monitored for signs of bleeding during defibrotide therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of defibrotide with systemic anticoagulants (except for routine maintenance or reopening of central venous lines) is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45237/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Defitelio (defibrotide).\" Jazz Pharmaceuticals, Palo Alto, CA.[3] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[4] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[5] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[6] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[7] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[8] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[9] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[10] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[11] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[12] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[13] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[15] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[16] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[17] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[18] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[19] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[20] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[21] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[22] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[23] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[24] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[25] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[26] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[27] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[28] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[29] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[30] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[31] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[32] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[33] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[34] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[35] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[36] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[37] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[38] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[39] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Defibrotide, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45168, "ingredient1": "Deoxycholic acid", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Coadministration with agents that alter hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytics, or agents that commonly cause thrombocytopenia may increase the risk of submental hematoma or bruising in association with deoxycholic acid administration.", "source": "DDInter", "management_text": "Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.", "mechanism_text": "Synergism", "recommendation": "Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45238/", "reference_text": "[1] \"Product Information. Kybella (deoxycholic acid).\" Kythera Biopharmaceuticals, Inc., Westlake Village, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Defibrotide, Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Tacrolimus, Minoxidil, Calcium gluconate, Glycopyrronium, Magnesium sulfate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More", "updated_at": 1767369485}, {"id": 45169, "ingredient1": "Desirudin", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextrans, systemic glucocorticoids, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of desirudin. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during desirudin therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended. The effects of desirudin and unfractionated heparins on prolongation of activated partial thromboplastin time (aPTT) are additive. In general, any agent which may enhance the risk of hemorrhage should be discontinued prior to initiation of desirudin therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "During prophylaxis of venous thromboembolism, concomitant treatment with heparins or dextrans is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45239/", "reference_text": "[1] \"Product Information. Ipravask (desirudin).\" Aventis Pharmaceuticals, Swiftwater, PA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45170, "ingredient1": "Desvenlafaxine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45240/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45171, "ingredient1": "Dexfenfluramine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45241/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 45172, "ingredient1": "Diclofenac", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45242/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 45173, "ingredient1": "Diclofenac (ophthalmic)", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45243/", "reference_text": "[1] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Product Information. Acular (ketorolac).\" Allergan Inc, Irvine, CA.[3] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals, Irvine, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 45174, "ingredient1": "Dicoumarol", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45244/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Warfarin, Cilostazol, Dicoumarol, Antithrombin III human, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45175, "ingredient1": "Diflunisal", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45245/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Ziconotide, Methoxyflurane", "updated_at": 1767369485}, {"id": 45176, "ingredient1": "Drotrecogin alfa", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).", "source": "DDInter", "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.", "mechanism_text": "Synergism", "recommendation": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45246/", "reference_text": "[1] \"Product Information. Xigris (drotrecogin alfa).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45177, "ingredient1": "Duloxetine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45247/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45178, "ingredient1": "Edoxaban", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Concomitant use of edoxaban with other anticoagulants may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during edoxaban therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis.", "source": "DDInter", "management_text": "Due to increased bleeding risk, the use of edoxaban with other anticoagulants should generally be avoided except during therapeutic transition periods where patients should be observed closely. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). In patients undergoing neuraxial intervention, the use of edoxaban should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.", "mechanism_text": "Synergism", "recommendation": "Due to increased bleeding risk, the use of edoxaban with other anticoagulants should generally be avoided except during therapeutic transition periods where patients should be observed closely.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45248/", "reference_text": "[1] \"Product Information. Savaysa (edoxaban).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Acenocoumarol, Selexipag, Edoxaban", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45179, "ingredient1": "Enoxaparin", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45249/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Acenocoumarol, Selexipag, Enoxaparin", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45180, "ingredient1": "Epoprostenol", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45250/", "reference_text": "[1] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Epoprostenol, Treprostinil", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45181, "ingredient1": "Eptifibatide", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45251/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Eptifibatide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45182, "ingredient1": "Escitalopram", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45252/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45183, "ingredient1": "Etodolac", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45253/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45184, "ingredient1": "Fedratinib", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Concomitant use of thrombin inhibitors and antiplatelet agents may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Coadministration of thrombin inhibitors and antiplatelet agents should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration of thrombin inhibitors and antiplatelet agents should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45254/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] \"Product Information. Acova (argatroban)\" SmithKline Beecham, Philadelphia, PA.[3] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Streptokinase, Eptifibatide, Selexipag, Abciximab, Dicoumarol, Tenecteplase, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45185, "ingredient1": "Fenfluramine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45255/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Brivaracetam, Topiramate, Ezogabine, More", "updated_at": 1767369485}, {"id": 45186, "ingredient1": "Fenoprofen", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45256/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45187, "ingredient1": "Fluoxetine", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45257/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Amitriptyline, Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, More", "updated_at": 1767369485}, {"id": 45188, "ingredient1": "Flurbiprofen", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45258/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Bacitracin, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 45189, "ingredient1": "Flurbiprofen (ophthalmic)", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45259/", "reference_text": "[1] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Product Information. Acular (ketorolac).\" Allergan Inc, Irvine, CA.[3] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals, Irvine, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Lidocaine, Bacitracin, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 45190, "ingredient1": "Garlic", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45260/", "reference_text": "[1] Legnani C, Frascaro M, Guazzaloca G, Ludovici S, Cesarano G, Coccheri S \"Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects.\" Arzneimittelforschung 43 (1993): 119-22[2] Steiner M, Lin RS \"Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract.\" J Cardiovasc Pharmacol 31 (1998): 904-8[3] Burnham BE \"Garlic as a possible risk for postoperative bleeding.\" Plast Reconstr Surg 95 (1995): 213[4] Chutani SK, Bordia A \"The effect of fried versus raw garlic on fibrinolytic activity in man.\" Atherosclerosis 38 (1981): 417-21[5] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[6] Apitz-Castro R, Escalante J, Vargas R, Jain MK \"Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets.\" Thromb Res 42 (1986): 303-11[7] Mulrow C, Lawrence V, Ackermann R, et al. Agency for Healthcare Research and Quality \"Garlic: effects on cardiovascular risks and disease, protective effects against cancer, and clinical adverse effects. Evidence Report/Technology Assessment Number 20. AHRQ Publication No. 01-E023 Available from: URL: http://www.ahrq.gov/clinics/garlicsum.\" ([2000 Oct]):[8] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[9] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000): 229-32[10] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[11] German K, Kumar U, Blackford HN \"Garlic and the risk of TURP bleeding.\" Br J Urol 76 (1996): 518[12] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[13] Kiesewetter H, Jung F, Jung EM, Mrowietz C, Kosciehlny J, Wenzel E \"Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack.\" Eur J Clin Pharmacol 45 (1993): 333-6[14] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Morris J, Burke V, Mori TA, Vandongen R, Beilin LJ \"Effects of garlic extract on platelet aggregation: a randomized placebo-controlled double-blind study.\" Clin Exp Pharmacol Physiol 22 (1995): 414-7", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45191, "ingredient1": "Ginger", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45261/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45192, "ingredient1": "Ginkgo biloba", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, and thrombolytic agents. Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45262/", "reference_text": "[1] Benjamin J, Muir T, Briggs K, Pentland B \"A case of cerebral haemorrhage - can Ginkgo biloba be implicated?.\" Postgrad Med J 77 (2001): 112-3[2] Jayasekera N, Moghal A, Kashif F, Karalliedde L \"Herbal medicines and postoperative haemorrhage.\" Anaesthesia 60 (2005): 725-6[3] Evans V \"Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use.\" J Neurosci Nurs 32 (2000): 229-32[4] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[5] Rowin J, Lewis SL \"Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion.\" Neurology 46 (1996): 1775-6[6] Cupp MJ \"Herbal remedies: adverse effects and drug interactions.\" Am Fam Physician 59 (1999): 1239-45[7] Engelsen J, Nielsen JD, Winther K \"Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial.\" Thromb Haemost 87 (2002): 1075-6[8] Matthews MK Jr \"Association of Ginko biloba with intracerebral hemorrhage.\" Neurology 50 (1998): 1933-4[9] Sierpina VS, Wollschlaeger B, Blumenthal M \"Ginkgo biloba.\" Am Fam Physician 68 (2003): 923-6[10] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[11] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[12] Chung KF, McCusker M, Page CP, Dent G, Guinot P, Barnes PJ \"Effect of ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet acitivating factor in man.\" Lancet 1 (1987): 248-51[13] Rosenblatt M, Mindel J \"Spontaneous hyphema associated with ingestion of Ginkgo biloba extract.\" N Engl J Med 336 (1997): 1108[14] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[15] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[16] Fessenden JM, Wittenborn W, Clarke L \"Gingko biloba: A case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy.\" Am Surg 67 (2001): 33-5[17] Fong KC, Kinnear PE \"Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion.\" Postgrad Med J 79 (2003): 531-2[18] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75", "alternatives_a": "Desirudin, Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "updated_at": 1767369485}, {"id": 45193, "ingredient1": "Ginseng", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Ginseng may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. In vitro studies have shown that one or more of the active constituents of ginseng, known as ginsenosides, can decrease platelet aggregation, although it is not known whether these constituents are absorbed or are bioactive in humans. Bleeding complications secondary to antiplatelet activity have not been reported.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of ginseng supplements and large amounts of ginseng should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45263/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Ang-Lee MK, Moss J, Yuan CS \"Herbal medicines and perioperative care.\" JAMA 286 (2001): 208-16[3] Hodges PJ, Kam PC \"The peri-operative implications of herbal medicines.\" Anaesthesia 57 (2002): 889-99[4] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001): 2163-75[5] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[6] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[7] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000): 134-8[8] Janetzky K, Morreale AP \"Probable interaction between warfarin and ginseng.\" Am J Health Syst Pharm 54 (1997): 692-3[9] Yuan CS, Wei G, Dey L, et al. \"Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled Trial.\" Ann Intern Med 141 (2004): 23-7", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45194, "ingredient1": "Hemin", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Hemin has exhibited mild, transient anticoagulant effects during clinical studies.", "source": "DDInter", "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided. Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "The use of hemin with concurrent anticoagulant therapy should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45264/", "reference_text": "[1] \"Product Information. Panhematin (hemin).\" Recordati Rare Diseases Inc, Lebanon, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "updated_at": 1767369485}, {"id": 45195, "ingredient1": "Heparin", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45265/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Selexipag, Heparin", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor, Ascorbic acid, Cyclosporine, Sirolimus, Potassium Iodide, Vitamin A, More", "updated_at": 1767369485}, {"id": 45196, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of ibritumomab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation. Close clinical and laboratory observation for bleeding complications is recommended during and after ibritumomab therapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45266/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab).\" IDEC Pharmaceuticals Corporation, San Diego, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45197, "ingredient1": "Ibrutinib", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45267/", "reference_text": "[1] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Imbruvica (ibrutinib).\" Pharmacyclics Inc, Sunnyvale, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45198, "ingredient1": "Icosapent", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.", "source": "DDInter", "management_text": "In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.", "mechanism_text": "Synergism", "recommendation": "In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45268/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Li XL, Steiner M \"Fish oil: a potent inhibitor of platelet adhesiveness.\" Blood 76 (1990): 938-45[3] \"Product Information. Vascepa (icosapent).\" Amarin Pharmaceuticals Inc, Warren, NJ.[4] Vanschoonbeek K, Feijge MA, Paquay J, et al \"Variable hypocoagulant effect of fish oil intake in humans: modulation of fibrinogen level and thrombin generation.\" Arterioscler Thromb Vasc Biol 24 (2004): 1734-40[5] \"Product Information. Omacor (omega-3 polyunsaturated fatty acids).\" Abbott Pharmaceutical, Abbott Park, IL.[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] Buckley MS, Goff AD, Knapp WE \"Fish oil interaction with warfarin.\" Ann Pharmacother 38 (2004): 50-3", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45199, "ingredient1": "Iloprost", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45269/", "reference_text": "[1] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.", "alternatives_a": "Iloprost, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45200, "ingredient1": "Indomethacin", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45270/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Prednisolone, Betamethasone, Fluorometholone, Methylprednisolone, Dexamethasone, Rabeprazole, Misoprostol, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 45201, "ingredient1": "Inotersen", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "Coadministration of inotersen and drugs that interfere with platelet function or coagulation may potentiate the risk of serious, potentially life-threatening bleeding complications, including spontaneous intracranial and intrapulmonary hemorrhage. Inotersen causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised when inotersen is prescribed with antiplatelet agents, anticoagulants, or other medications that commonly cause thrombocytopenia or bleeding. A platelet count should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should not be administered in patients with a platelet count below 100 x 10^9/L or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of thrombocytopenia and to seek medical attention if they occur, including any unusual or prolonged bleeding (e.g., petechiae, easy bruising, hematoma, subconjunctival bleeding, gingival bleeding, epistaxis, hemoptysis, irregular or heavier than normal menstrual bleeding, hematemesis, hematuria, hematochezia, melena), neck stiffness, or atypical severe headache.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when inotersen is prescribed with antiplatelet agents, anticoagulants, or other medications that commonly cause thrombocytopenia or bleeding.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45271/", "reference_text": "[1] \"Product Information. Tegsedi (inotersen).\" Akcea Therapeutics, Cambridge, MA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 45202, "ingredient1": "Bivalirudin", "ingredient2": "Tositumomab (I-131)", "severity": "Major", "effect": "Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.", "source": "DDInter", "management_text": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.", "mechanism_text": "Synergism", "recommendation": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45272/", "reference_text": "[1] \"Product Information. BexxarTherapy (tositumomab).\" GlaxoSmithKline Inc, Oakville, IA.[2] \"Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45203, "ingredient1": "Ipilimumab", "ingredient2": "Bivalirudin", "severity": "Major", "effect": "The concomitant use of ipilimumab and anticoagulants may increase the risk of gastrointestinal hemorrhage. Both drugs have been individually associated with this adverse reaction.", "source": "DDInter", "management_text": "If anticoagulant treatment is required, caution and close monitoring for gastrointestinal bleeding is advisable.", "mechanism_text": "Synergism", "recommendation": "If anticoagulant treatment is required, caution and close monitoring for gastrointestinal bleeding is advisable.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45273/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[4] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[5] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[6] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[7] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[8] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[9] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[10] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[11] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[12] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[13] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[15] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[16] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[17] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[18] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[19] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[20] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[21] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[22] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[23] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[24] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[25] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[26] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[27] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[28] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[29] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[30] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[31] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[32] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[33] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[34] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[35] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[36] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[37] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[38] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[39] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45204, "ingredient1": "Bivalirudin", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45274/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45205, "ingredient1": "Bivalirudin", "ingredient2": "Lepirudin", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45275/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "alternatives_b": "Argatroban, Antithrombin III human, Lepirudin, Acenocoumarol, Selexipag", "updated_at": 1767369485}, {"id": 45206, "ingredient1": "Bivalirudin", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45276/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45207, "ingredient1": "Bivalirudin", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45277/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45208, "ingredient1": "Bivalirudin", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45278/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Tirofiban, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45209, "ingredient1": "Bivalirudin", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45279/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More", "updated_at": 1767369485}, {"id": 45210, "ingredient1": "Bivalirudin", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Concomitant use of anticoagulants may exacerbate mifepristone-induced vaginal bleeding in women. Prolonged, potentially heavy bleeding lasting approximately 9 to 30 days typically follows mifepristone use in termination of pregnancy. Because it is a progesterone receptor antagonist, mifepristone can also promote unopposed endometrial proliferation that may result in endometrium thickening, cystic dilatation of endometrial glands, and vaginal bleeding when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome.", "source": "DDInter", "management_text": "Concurrent anticoagulant therapy is considered a contraindication in the use of mifepristone for pregnancy termination. When used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome, mifepristone treatment should be administered cautiously in women who are receiving anticoagulant therapy. Patients who experience vaginal bleeding should be referred to a gynecologist for further evaluation.", "mechanism_text": "Synergism", "recommendation": "Concurrent anticoagulant therapy is considered a contraindication in the use of mifepristone for pregnancy termination.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45280/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[2] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[3] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[4] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Alteplase, Dipyridamole, Abciximab, Tirofiban, Caplacizumab, Acetylsalicylic acid, Iloprost, Streptokinase, Eptifibatide, Antithrombin III human, Tenecteplase, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 45211, "ingredient1": "Bivalirudin", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45281/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45212, "ingredient1": "Bivalirudin", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45282/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45213, "ingredient1": "Bivalirudin", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45283/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Rabeprazole, Misoprostol, More", "updated_at": 1767369485}, {"id": 45214, "ingredient1": "Bivalirudin", "ingredient2": "Nepafenac (ophthalmic)", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45284/", "reference_text": "[1] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Product Information. Acular (ketorolac).\" Allergan Inc, Irvine, CA.[3] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals, Irvine, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45215, "ingredient1": "Bivalirudin", "ingredient2": "Nintedanib", "severity": "Moderate", "effect": "Coadministration of nintedanib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Vascular endothelial growth factor receptor (VEGFR) inhibitors like nintedanib can cause bleeding.", "source": "DDInter", "management_text": "Concomitant use of nintedanib and medications that interfere with platelet function or coagulation should be approached cautiously. Close clinical and laboratory observation for bleeding complications is recommended for patients on full anticoagulation therapy, and the anticoagulant dose adjusted as necessary. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of nintedanib and medications that interfere with platelet function or coagulation should be approached cautiously.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45285/", "reference_text": "[1] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.[2] \"Product Information. Ofev (nintedanib).\" Boehringer Ingelheim, Ridgefield, CT.", "alternatives_a": "Iloprost, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Treprostinil", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45216, "ingredient1": "Bivalirudin", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration of niraparib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of anticoagulants or other medications known to reduce platelet count should be approached with caution. For hematologic adverse reactions requiring transfusion, withhold niraparib and consider interrupting any drugs that interfere with platelet function or coagulation. any signs or symptoms of bleeding to their primary care provider.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of anticoagulants or other medications known to reduce platelet count should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45286/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 45217, "ingredient1": "Bivalirudin", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Major", "effect": "Coadministration of omacetaxine and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with omacetaxine is associated with a high frequency of thrombocytopenia.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient's platelet count is less than 50,000 per microliter. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The CBC and platelet count should be monitored according to the manufacturer's recommendations.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient's platelet count is less than 50,000 per microliter.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45287/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Drotrecogin alfa", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 45218, "ingredient1": "Bivalirudin", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45288/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45219, "ingredient1": "Bivalirudin", "ingredient2": "Panobinostat", "severity": "Major", "effect": "Coadministration of panobinostat and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with panobinostat has been associated with severe thrombocytopenia and hemorrhage (including gastrointestinal and pulmonary hemorrhage) with fatal outcomes. The risk may be increased in patients with coagulation disorders or those on chronic anticoagulation therapy.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood cell count should be performed prior to and at least weekly during treatment according to treatment protocols, including monitoring for thrombocytopenia. Dose modifications may be required based on individual patient tolerability. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45289/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Cerner Multum, Inc. \"Australian Product Information.\" O 0[7] \"Product Information. Farydak (panobinostat).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Protein C, Dicoumarol, Acenocoumarol, Selexipag", "alternatives_b": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 45220, "ingredient1": "Bivalirudin", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45290/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45221, "ingredient1": "Bivalirudin", "ingredient2": "Pentosan polysulfate", "severity": "Moderate", "effect": "Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if pentosan polysulfate sodium is used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentosan polysulfate sodium is used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45291/", "reference_text": "[1] \"Product Information. Elmiron (pentosan polysulfate sodium).\" Baker Norton Pharmaceuticals, Miami, FL.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Darifenacin, Vardenafil, Tadalafil, Ammonium chloride, Apomorphine, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Calcium chloride, Trospium, More", "updated_at": 1767369485}, {"id": 45222, "ingredient1": "Bivalirudin", "ingredient2": "Pentoxifylline", "severity": "Moderate", "effect": "The use of pentoxifylline has been associated with bleeding and/or prolongation in prothrombin time. Theoretically, the risk of bleeding may be increased by concomitant treatment with anticoagulants or other agents that affect hemostasis such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, thrombin inhibitors, thrombolytic agents, and dextran. There have been postmarketing reports of increased anticoagulant activity in patients receiving vitamin K antagonists in combination with pentoxifylline.", "source": "DDInter", "management_text": "Caution is advised if pentoxifylline is administered with anticoagulants or other agents that affect hemostasis. Patients on vitamin K antagonists such as warfarin should have more frequent monitoring of INR following initiation or dosage change of pentoxifylline, while patients receiving other agents that affect hemostasis should have periodic examinations for bleeding including hematocrit and/or hemoglobin.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pentoxifylline is administered with anticoagulants or other agents that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45292/", "reference_text": "[1] \"Product Information. Trental (pentoxifylline).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Niacin, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, More", "updated_at": 1767369485}, {"id": 45223, "ingredient1": "Bivalirudin", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45293/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Clopidogrel, Dicoumarol, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "Acetylsalicylic acid, Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45224, "ingredient1": "Bivalirudin", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45294/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 45225, "ingredient1": "Bivalirudin", "ingredient2": "Ponatinib", "severity": "Major", "effect": "Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with ponatinib is associated with severe, sometimes fatal hemorrhage including cerebral and gastrointestinal hemorrhage.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45295/", "reference_text": "[1] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] \"Product Information. Iclusig (ponatinib).\" Ariad Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45226, "ingredient1": "Bivalirudin", "ingredient2": "Prasugrel", "severity": "Major", "effect": "Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, nonsteroidal anti-inflammatory agents (chronic), or agents that commonly cause thrombocytopenia may increase the risk of bleeding. Prasugrel may be used with aspirin, heparin, or glycoprotein IIb/IIIa inhibitors.", "source": "DDInter", "management_text": "Caution is advised if prasugrel is used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prasugrel is used in combination with other drugs that affect hemostasis.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45296/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Prasugrel, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45227, "ingredient1": "Bivalirudin", "ingredient2": "Protein C", "severity": "Moderate", "effect": "Simultaneous administration of protein C concentrate with tissue plasminogen activators and/or anticoagulants may increase the risk of bleeding. The mechanism of interaction is unknown. Several bleeding episodes have been observed in clinical studies of protein C concentrate for which concurrent anticoagulant medication may have been responsible. However, a contributory effect by protein C cannot be completely ruled out.", "source": "DDInter", "management_text": "Caution is advised if protein C concentrate is used in combination with tissue plasminogen activators and/or anticoagulants. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Others", "recommendation": "Caution is advised if protein C concentrate is used in combination with tissue plasminogen activators and/or anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45297/", "reference_text": "[1] \"Product Information. Ceprotin (protein C).\" Baxter Healthcare Corporation, Deerfield, IL.", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Cangrelor, Dipyridamole, Prasugrel, Eptifibatide, Selexipag, Vorapaxar, More", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45228, "ingredient1": "Bivalirudin", "ingredient2": "Ramucirumab", "severity": "Major", "effect": "Coadministration of ramucirumab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Ramucirumab can cause bleeding, including severe and sometimes fatal hemorrhagic complications.", "source": "DDInter", "management_text": "Concomitant use of ramucirumab and medications that interfere with platelet function or coagulation should be approached cautiously. Close clinical and laboratory observation for bleeding complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Ramucirumab should be permanently discontinued in patients who experience severe bleeding.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ramucirumab and medications that interfere with platelet function or coagulation should be approached cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45298/", "reference_text": "[1] \"Product Information. Cyramza (ramucirumab).\" Eli Lilly and Company, Indianapolis, IN.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45229, "ingredient1": "Bivalirudin", "ingredient2": "Regorafenib", "severity": "Major", "effect": "Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with regorafenib is associated with a high frequency of hemorrhage and thrombocytopenia. Coadministration of regorafenib with strong UGT1A9 inhibitors such as mefenamic acid or diflunisal may theoretically increase systemic exposure to regorafenib.", "source": "DDInter", "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45299/", "reference_text": "[1] \"Product Information. Stivarga (regorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[5] \"Product Information. Stivarga (regorafenib).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45230, "ingredient1": "Bivalirudin", "ingredient2": "Reteplase", "severity": "Major", "effect": "The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been reported in patients with acute myocardial infarction treated with argatroban or lepirudin and thrombolytic therapy (recombinant tPA or streptokinase). The mechanism may be attributable to complementary or synergistic effects of these agents on thrombin-dependent functions and activated partial thromboplastin time (aPPT).", "source": "DDInter", "management_text": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45300/", "reference_text": "[1] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45231, "ingredient1": "Bivalirudin", "ingredient2": "Rivaroxaban", "severity": "Major", "effect": "Concomitant use of rivaroxaban with other anticoagulants may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during rivaroxaban therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis. The safety of long-term coadministration of these drugs has not been studied.", "source": "DDInter", "management_text": "Due to increased bleeding risk, the use of rivaroxaban with other anticoagulants should generally be avoided except during therapeutic transition periods where patients should be observed closely. Patients should be routinely evaluated for signs and symptoms suggesting blood loss such as a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress (in pregnant women). In patients undergoing neuraxial intervention, the use of rivaroxaban should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.", "mechanism_text": "Synergism", "recommendation": "Due to increased bleeding risk, the use of rivaroxaban with other anticoagulants should generally be avoided except during therapeutic transition periods where patients should be observed closely.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45301/", "reference_text": "[1] \"Product Information. Xarelto (rivaroxaban).\" Bayer Inc, Toronto, IA.", "alternatives_a": "Acenocoumarol, Selexipag, Rivaroxaban", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45232, "ingredient1": "Bivalirudin", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45302/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Drotrecogin alfa, Selexipag, Desirudin", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45233, "ingredient1": "Bivalirudin", "ingredient2": "Salsalate", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45303/", "reference_text": "[1] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[2] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970): 403-8[3] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[4] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971): 547-58[5] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[6] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967): 620-4[7] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968): 2169-80[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44", "alternatives_a": "Dipyridamole, Caplacizumab, Cilostazol, Defibrotide, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Cangrelor, Ticlopidine", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Ziconotide, Methoxyflurane", "updated_at": 1767369485}, {"id": 45234, "ingredient1": "Bivalirudin", "ingredient2": "Selumetinib", "severity": "Moderate", "effect": "Selumetinib capsules contain vitamin E and may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Close clinical and laboratory observation for hematologic complications may be appropriate when selumetinib is initiated in patients stabilized on anticoagulant or antiplatelet therapy. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory observation for hematologic complications may be appropriate when selumetinib is initiated in patients stabilized on anticoagulant or antiplatelet therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45304/", "reference_text": "[1] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[2] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[3] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8[4] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[5] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[6] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[7] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[8] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[9] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[10] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[11] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[12] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[13] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[14] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[15] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[16] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[17] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[18] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[19] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[20] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45235, "ingredient1": "Bivalirudin", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45305/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45236, "ingredient1": "Bivalirudin", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45306/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "updated_at": 1767369485}, {"id": 45237, "ingredient1": "Iodide I-123", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45307/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45238, "ingredient1": "Iodide I-131", "ingredient2": "Bivalirudin", "severity": "Moderate", "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45308/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45239, "ingredient1": "Bivalirudin", "ingredient2": "Salicylic acid (sodium)", "severity": "Moderate", "effect": "Theoretically, salicylates may potentiate the effects of anticoagulants and increase the risk of bleeding. Salicylates interfere with the action of vitamin K and induce a dose-dependent alteration in hepatic synthesis of coagulation factors VII, IX and X, occasionally increasing the prothrombin time. While these effects are generally slight for most salicylates (except aspirin) at recommended dosages, they may be of clinical significance when combined with the inhibitory effects of anticoagulants on the clotting cascade. Moreover, salicylates are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.", "source": "DDInter", "management_text": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. The same precaution should be observed with the use of salicylate-related agents such as salicylamide because of their structural and pharmacological similarities.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, products containing salicylates, especially if given chronically or in high dosages, should preferably be avoided in patients receiving anticoagulants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45309/", "reference_text": "[1] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[2] Fausa O \"Salicylate-induced hypoprothrombinemia: a report of four cases.\" Acta Med Scand 188 (1970): 403-8[3] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (first of two parts).\" N Engl J Med 285 (1971): 487-98[4] Koch-Weser J, Sellers EM \"Drug interactions with coumarin anticoagulants (second of two parts).\" N Engl J Med 285 (1971): 547-58[5] American Medical Association, Division of Drugs and Toxicology \"Drug evaluations annual 1994.\" Chicago, IL: American Medical Association; (1994):[6] Barrow MV, Quick DT, Cunningham RW \"Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases.\" Arch Intern Med 120 (1967): 620-4[7] Weiss HJ, Aledort LM, Kochwa S \"The effect of salicylates on the hemostatic properties of platelets in man.\" J Clin Invest 47 (1968): 2169-80[8] Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R \"Main comedications associated with major bleeding during anticoagulant therapy with coumarins.\" Eur J Clin Pharmacol 61 (2005): 439-44", "alternatives_a": "Cilostazol, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Streptokinase, Tinzaparin, Selexipag, Vorapaxar, Dicoumarol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45240, "ingredient1": "Bivalirudin", "ingredient2": "Streptokinase", "severity": "Major", "effect": "The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been reported in patients with acute myocardial infarction treated with argatroban or lepirudin and thrombolytic therapy (recombinant tPA or streptokinase). The mechanism may be attributable to complementary or synergistic effects of these agents on thrombin-dependent functions and activated partial thromboplastin time (aPPT).", "source": "DDInter", "management_text": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45310/", "reference_text": "[1] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Human C1-esterase inhibitor, More", "updated_at": 1767369485}, {"id": 45241, "ingredient1": "Bivalirudin", "ingredient2": "Sugammadex", "severity": "Moderate", "effect": "Sugammadex may potentiate the effects of anticoagulants. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Hemostasis and coagulation parameters should be closely monitored when sugammadex is administered to patients receiving therapeutic anticoagulation for a preexisting or comorbid condition; patients who have received thromboprophylaxis drugs other than heparin and LMWH; or patients who have received thromboprophylaxis with heparin or LMWH and subsequently administered 16 mg/kg of sugammadex.", "mechanism_text": "Others", "recommendation": "Hemostasis and coagulation parameters should be closely monitored when sugammadex is administered to patients receiving therapeutic anticoagulation for a preexisting or comorbid condition; patients who have received thromboprophylaxis drugs other than heparin and LMWH; or patients who have received thromboprophylaxis with heparin or LMWH and subsequently administered 16 mg/kg of sugammadex.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45311/", "reference_text": "[1] \"Product Information. Bridion (sugammadex).\" Merck & Company Inc, Whitehouse Station, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Ticagrelor, Clopidogrel, Cilostazol, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45242, "ingredient1": "Bivalirudin", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45312/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Dipyridamole, Abciximab, Tirofiban, Caplacizumab, Clopidogrel, Cilostazol, Prasugrel, Eptifibatide, Antithrombin III human, Protein C, Acenocoumarol, More", "alternatives_b": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid, Allopurinol", "updated_at": 1767369485}, {"id": 45243, "ingredient1": "Bivalirudin", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45313/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45244, "ingredient1": "Bivalirudin", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "The concomitant use of anticoagulants may theoretically increase the risk of sunitinib-induced bleeding. Severe and life-threatening tumor hemorrhage, hemoptysis, and pulmonary hemorrhage, and nonserious epistaxis have occurred during treatment with sunitinib.", "source": "DDInter", "management_text": "Monitoring for clinical and laboratory signs of bleeding is recommended during concomitant therapy, including INR/PT and complete blood counts. Patients should be advised to promptly report any potential signs of bleeding to their doctor, including nosebleeds, pain, swelling, or headache.", "mechanism_text": "Synergism", "recommendation": "Monitoring for clinical and laboratory signs of bleeding is recommended during concomitant therapy, including INR/PT and complete blood counts.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45314/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[3] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Ticagrelor, Clopidogrel, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, Eptifibatide, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45245, "ingredient1": "Bivalirudin", "ingredient2": "Suprofen (ophthalmic)", "severity": "Moderate", "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.", "source": "DDInter", "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45315/", "reference_text": "[1] \"Product Information. Nevanac (nepafenac ophthalmic).\" Alcon Laboratories Inc, Fort Worth, TX.[2] \"Product Information. Acular (ketorolac).\" Allergan Inc, Irvine, CA.[3] \"Product Information. Xibrom (bromfenac ophthalmic).\" ISTA Pharmaceuticals, Irvine, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45246, "ingredient1": "Bivalirudin", "ingredient2": "Temsirolimus", "severity": "Major", "effect": "According to the package labeling, patients receiving temsirolimus in combination with anticoagulation therapy may be at increased risk of developing intracerebral bleeding, including fatal outcomes. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.", "mechanism_text": "Others", "recommendation": "Patients receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding while on temsirolimus.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45316/", "reference_text": "[1] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] \"Product Information. Torisel (temsirolimus).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.", "alternatives_a": "Ticagrelor, Clopidogrel, Iloprost, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Prasugrel, Streptokinase, Eptifibatide, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45247, "ingredient1": "Bivalirudin", "ingredient2": "Tenecteplase", "severity": "Major", "effect": "The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been reported in patients with acute myocardial infarction treated with argatroban or lepirudin and thrombolytic therapy (recombinant tPA or streptokinase). The mechanism may be attributable to complementary or synergistic effects of these agents on thrombin-dependent functions and activated partial thromboplastin time (aPPT).", "source": "DDInter", "management_text": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45317/", "reference_text": "[1] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45248, "ingredient1": "Bivalirudin", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "The concomitant use of ticagrelor with other platelet inhibitors, anticoagulants, thrombolytic agents, or nonsteroidal anti-inflammatory drugs may increase the risk of bleeding.", "source": "DDInter", "management_text": "Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when these drugs are used concomitantly with ticagrelor or within 24 hours of ticagrelor dosing.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45318/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Ticagrelor, Protein C, Acenocoumarol, Selexipag, Cangrelor", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45249, "ingredient1": "Bivalirudin", "ingredient2": "Ticlopidine", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45319/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Dipyridamole, Antithrombin III human, Protein C, Acenocoumarol, Selexipag, Ticlopidine", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45250, "ingredient1": "Bivalirudin", "ingredient2": "Tinzaparin", "severity": "Major", "effect": "Drugs that can affect hemostasis such as dextran, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or other anticoagulants may potentiate the risk of bleeding complications associated with the use of a low molecular weight heparin (LMWH), heparinoid, or fondaparinux. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term or permanent paralysis.", "source": "DDInter", "management_text": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy. If coadministration is necessary, it should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended. Patients undergoing neuraxial intervention and treated with these agents should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. The optimal timing between the administration of anticoagulants and neuraxial procedures is not known.", "mechanism_text": "Synergism", "recommendation": "In general, any agent that can enhance the risk of hemorrhage including other anticoagulants should be discontinued prior to initiation of LMWH, heparinoid, or fondaparinux therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45320/", "reference_text": "[1] \"Product Information. Fragmin (dalteparin).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Normiflo (ardeparin).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] \"Product Information. Lovenox (enoxaparin).\" Rhone-Poulenc Rorer, Collegeville, PA.[4] \"Product Information. Innohep (tinzaparin)\" DuPont Pharmaceuticals, Wilmington, DE.[5] \"Product Information. Arixtra (fondaparinux).\" Organon, West Orange, NJ.[6] \"Product Information. Orgaran (danaparoid).\" Organon, West Orange, NJ.[7] Price AJ, Frcpath DO \"Is there a clinical interaction between low molecular weight heparin and non-steroidal analgesics after total hip replacement?\" Ann R Coll Surg Engl 77 (1995): 395", "alternatives_a": "Tinzaparin, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45251, "ingredient1": "Bivalirudin", "ingredient2": "Tipranavir", "severity": "Major", "effect": "Theoretically, tipranavir may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, high supplemental dosages of vitamin E, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if tipranavir/ritonavir is used in combination with other drugs that affect hemostasis.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45321/", "reference_text": "[1] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] \"Product Information. Aptivus (tipranavir).\" Boehringer-Ingelheim, Ridgefield, CT.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 45252, "ingredient1": "Bivalirudin", "ingredient2": "Tirofiban", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45322/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Tirofiban, Antithrombin III human, Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45253, "ingredient1": "Bivalirudin", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "The safety and efficacy of bivalirudin have not been established when used in conjunction with platelet inhibitors other than aspirin. Theoretically, the concomitant administration of bivalirudin (plus aspirin) and platelet inhibitors may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade. However, limited data from drug interaction studies do not suggest pharmacodynamic interactions with the platelet inhibitors, ticlopidine and abciximab.", "source": "DDInter", "management_text": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, the coadministration of bivalirudin and antiplatelet agents, and possibly other agents with antiplatelet activity such as nonsteroidal anti-inflammatory drugs (NSAIDs), should probably be undertaken with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45323/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole, Tolazoline, Rabeprazole, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45254, "ingredient1": "Bivalirudin", "ingredient2": "Tositumomab", "severity": "Major", "effect": "Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.", "source": "DDInter", "management_text": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.", "mechanism_text": "Synergism", "recommendation": "Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45324/", "reference_text": "[1] \"Product Information. BexxarTherapy (tositumomab).\" GlaxoSmithKline Inc, Oakville, IA.[2] \"Product Information. Bexxar I 131 Therapeutic (iodine I 131 tositumomab).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Dicoumarol, Desirudin, Protein C, Acenocoumarol, Selexipag, Anistreplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45255, "ingredient1": "Bivalirudin", "ingredient2": "Treprostinil", "severity": "Moderate", "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.", "source": "DDInter", "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45325/", "reference_text": "[1] \"Product Information. Ventavis (iloprost).\" Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] \"Product Information. Flolan (epoprostenol).\" Glaxo Wellcome, Research Triangle Park, NC.[3] \"Product Information. Remodulin (treprostinil).\" United Therapeutics Corp, Silver Spring, MD.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Epoprostenol, Treprostinil", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45256, "ingredient1": "Bivalirudin", "ingredient2": "Turmeric", "severity": "Minor", "effect": "Theoretically, turmeric may potentiate the effects of anticoagulants, platelet inhibitors, and thrombolytic agents, possibly increasing the risk of bleeding. In vitro data suggest that turmeric may inhibit platelet-activating factor and platelet aggregation. Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used turmeric extensively prior to receiving anticoagulation, antiplatelet, or thrombolytic therapy, the potential for an interaction should be considered. Clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "source": "DDInter", "management_text": "-", "mechanism_text": "Synergism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45326/", "reference_text": "[1] Abebe W \"Herbal medication: potential for adverse interactions with analgesic drugs.\" J Clin Pharm Ther 27 (2002): 391-401[2] Yang X, Thomas DP, Zhang X, et al \"Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation.\" Arterioscler Thromb Vasc Biol 26 (2006): 85-90[3] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45257, "ingredient1": "Bivalirudin", "ingredient2": "Urokinase", "severity": "Major", "effect": "The concomitant administration of thrombin inhibitors and thrombolytic agents may increase the risk of bleeding complications. Intracranial bleeding has been reported in patients with acute myocardial infarction treated with argatroban or lepirudin and thrombolytic therapy (recombinant tPA or streptokinase). The mechanism may be attributable to complementary or synergistic effects of these agents on thrombin-dependent functions and activated partial thromboplastin time (aPPT).", "source": "DDInter", "management_text": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Coadministration should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45327/", "reference_text": "[1] \"Product Information. Refludan (lepirudin).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Alteplase, Streptokinase, Antithrombin III human, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45258, "ingredient1": "Bivalirudin", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Anticoagulants, antiplatelet agents, and thrombolytics may potentiate the risk of gastrointestinal bleeding complications associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors.", "source": "DDInter", "management_text": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents. Gastroprotective agents such as H2-receptor antagonists or proton pump inhibitors may be appropriate in high risk patients.", "mechanism_text": "Synergism", "recommendation": "Although COX-2 inhibitors are often preferred over traditional, nonselective NSAIDs in patients who have increased risk for gastrointestinal toxicity, caution is advised during coadministration with anticoagulants or antiplatelet agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45328/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle, Chicago, IL.", "alternatives_a": "Drotrecogin alfa, Acenocoumarol, Selexipag, Desirudin", "alternatives_b": "Rabeprazole, Misoprostol, Chondroitin sulfate, Glucosamine, Esomeprazole", "updated_at": 1767369485}, {"id": 45259, "ingredient1": "Bivalirudin", "ingredient2": "Venlafaxine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45329/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45260, "ingredient1": "Bivalirudin", "ingredient2": "Verteporfin", "severity": "Moderate", "effect": "Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.", "source": "DDInter", "management_text": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.", "mechanism_text": "Antagonism", "recommendation": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45330/", "reference_text": "[1] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.", "alternatives_a": "Alteplase, Cilostazol, Streptokinase, Desirudin, Tenecteplase, Protein C, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase, Drotrecogin alfa", "alternatives_b": "Aflibercept, Bevacizumab", "updated_at": 1767369485}, {"id": 45261, "ingredient1": "Bivalirudin", "ingredient2": "Vilazodone", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45331/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45262, "ingredient1": "Bivalirudin", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "Vitamin E may potentiate the effects of anticoagulants and platelet inhibitors. Vitamin E is thought to inhibit the oxidation of reduced vitamin K and interfere with the functions of vitamin K-dependent clotting factors. These effects appear to be dose-dependent and greater in individuals with preexisting vitamin K deficiency.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E. Close clinical and laboratory observation for hematologic complications may be appropriate when vitamin E supplementation at dosages greater than 400 units/day is initiated in patients stabilized on anticoagulant or antiplatelet therapy. The dose of the anticoagulant or antiplatelet drug may require adjustment during and after treatment with vitamin E. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any nutritional supplements like vitamin E.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45332/", "reference_text": "[1] Helson L \"The effect of intravenous vitamin E and menadiol sodium diphosphate on vitamin K dependent clotting factors.\" Thromb Res 35 (1984): 11-8[2] Kakishita E, Suehiro A, Oura Y, Nagai K \"Inhibitory effect of vitamin E (alpha-tocopherol) on spontaneous platelet aggregation in whole blood.\" Thromb Res 60 (1990): 489-99[3] Gonzalez-Correa JA, Arrebola MM, Guerrero A, et al. \"Influence of vitamin E on the antiplatelet effect of acetylsalicylic acid in human blood.\" Platelets 16(3-4) (2005): 171-9[4] Stampfer MJ, Jakubowski JA, Faigel D, Vaillancourt R, Deykin D \"Vitamin E supplementation effect on human platelet function, arachidonic acid metabolism, and plasma prostacyclin levels.\" Am J Clin Nutr 47 (1988): 700-6[5] Kim JM, White RH \"Effect of vitamin E on the anticoagulant response to warfarin.\" Am J Cardiol 77 (1996): 545-6[6] \"Vitamin K, vitamin E and the coumarin drugs.\" Nutr Rev 40 (1982): 180-2[7] Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C \"Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis.\" Pharmacotherapy 27 (2007): 1237-47[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Corrigan JJ, Ulfers LL \"Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.\" Am J Clin Nutr 34 (1981): 1701-5[10] Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T \"Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms.\" Am J Clin Nutr 77 (2003): 700-6[11] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[12] \"Megavitamin E supplementation and vitamin K-dependent carboxylation.\" Nutr Rev 41 (1983): 268-70[13] Jandak J, Steiner M, Richardson PD \"Alpha-tocopherol, an effective inhibitor of platelet adhesion.\" Blood 73 (1989): 141-9[14] Celestini A, Pulcinelli FM, Pignatelli P, et al. \"Vitamin E potentiates the antiplatelet activity of aspirin in collagen-stimulated platelets.\" Haematologica 87 (2002): 420-6[15] Freedman JE, Farhat JH, Loscalzo J, Keaney JF \"Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C--dependent mechanism.\" Circulation 94 (1996): 2434-40[16] Corrigan JJ \"The effect of vitamin E on warfarin-induced vitamin K deficiency.\" Ann N Y Acad Sci 393 (1982): 361-8[17] Schrogie JJ \"Coagulopathy and fat-soluble vitamins.\" JAMA 232 (1975): 19[18] Mardla V, Kobzar G, Samel N \"Potentiation of antiaggregating effect of prostaglandins by alpha-tocopherol and quercetin.\" Platelets 15 (2004): 319-24[19] Murohara T, Ikeda H, Otsuka Y, Aoki M, Takajo Y, et al \"Inhibition of platelet adherence to Mononuclear cells by alpha-tocopherol: role of P-selection.\" Circulation 110 (2004): 141-8[20] Booth SL, Golly I, Sacheck JM, Roubenoff R, Dallal GE, et al \"Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status.\" Am J Clin Nutr 80 (2004): 143-8", "alternatives_a": "Alteplase, Streptokinase, Tenecteplase, Acenocoumarol, Selexipag, Urokinase, Anistreplase, Reteplase", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45263, "ingredient1": "Bivalirudin", "ingredient2": "Vorapaxar", "severity": "Major", "effect": "Coadministration of vorapaxar with other agents that affect hemostasis such as anticoagulants may increase the risk of bleeding complications, including intracranial hemorrhage and fatal bleeding.", "source": "DDInter", "management_text": "Concomitant use of vorapaxar with warfarin or other anticoagulants should generally be avoided.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of vorapaxar with warfarin or other anticoagulants should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45333/", "reference_text": "[1] \"Product Information. Zontivity (vorapaxar).\" Merck & Company Inc, Whitehouse Station, NJ.", "alternatives_a": "Clopidogrel, Protein C, Acenocoumarol, Selexipag, Vorapaxar, Acetylsalicylic acid", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45264, "ingredient1": "Bivalirudin", "ingredient2": "Vortioxetine", "severity": "Moderate", "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.", "source": "DDInter", "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45334/", "reference_text": "[1] Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG \"Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin.\" Acta Psychiatr Scand Suppl 350 (1989): 102-6[2] Skop BP, Brown TM \"Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors.\" Psychosomatics 37 (1996): 12-6[3] Settle EC \"Antidepressant drugs: disturbing and potentially dangerous adverse effects.\" J Clin Psychiatry 59 Suppl 16 (1998): 25-30[4] Layton D, Clark DWJ, Pearce GL, Shakir SAW \"Is there an association between selective serotonin reuptake inhibitors and risk of abnormal bleeding? Results from a cohort study based on prescription event monitoring in England.\" Eur J Clin Pharmacol 57 (2001): 167-76[5] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc, Marietta, GA.[6] Leung M, Shore R \"Fluvoxamine-associated bleeding.\" Can J Psychiatry 41 (1996): 604-5[7] \"Product Information. Prozac (fluoxetine).\" Dista Products Company, Indianapolis, IN.[8] Tata LJ, Fortun PJ, Hubbard RB, et al. \"Does concurrent prescription of selective serotonin reuptake inhibitors and non-steroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding?\" Aliment Pharmacol Ther 22 (2005): 175-81[9] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B \"Paroxetine decreases platelet serotonin storage and platelet function in human beings.\" Clin Pharmacol Ther 68 (2000): 435-42[11] de Abajo FJ, Rodriguez LA, Montero D \"Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study.\" BMJ 319 (1999): 1106-9[12] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals, St. Louis, MO.[13] Alderman CP, Moritz CK, Ben-Tovim DI \"Abnormal platelet aggregation associated with fluoxetine therapy.\" Ann Pharmacother 26 (1992): 1517-9[14] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[15] Krivy J, Wiener J \"Sertraline and platelet counts in idiopathic thrombocytopenia purpura.\" Lancet 345 (1995): 132[16] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC, New Haven, CT.[17] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals, St. Louis, MO.[18] Pai VB, Kelly MW \"Bruising associated with the use of fluoxetine.\" Ann Pharmacother 30 (1996): 786-8[19] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990): 213-7[20] Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ \"Fluoxetine and bleeding in obsessive-compulsive disorder.\" Am J Psychiatry 148 (1991): 949[21] Alderman CP, Seshadri P, Ben-Tovim DI \"Effects of serotonin reuptake inhibitors on hemostasis.\" Ann Pharmacother 30 (1996): 1232-4[22] Humphries JE, Wheby MS, VandenBerg SR \"Fluoxetine and the bleeding time.\" Arch Pathol Lab Med 114 (1990): 727-8[23] Woolfrey S, Gammack NS, Dewar MS, Brown PJ \"Fluoxetine-warfarin interaction.\" BMJ 307 (1993): 241[24] Messiha FS \"Fluoxetine - adverse effects and drug-drug interactions.\" J Toxicol Clin Toxicol 31 (1993): 603-30[25] Ford MA, Anderson ML, Rindone JP, Jaskar DW \"Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.\" J Clin Psychopharmacol 17 (1997): 110-2[26] Ottervanger JP, Stricker BH, Huls J, Weeda JN \"Bleeding attributed to the intake of paroxetine.\" Am J Psychiatry 151 (1994): 781-2[27] \"Product Information. Zoloft (sertraline).\" Roerig Division, New York, NY.[28] Dalton SO, Johansen C, Mellemkjaer L, Norgard B, Sorensen HT, Olsen JH \"Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study.\" Arch Intern Med 163 (2003): 59-64[29] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company, Indianapolis, IN.[30] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline, Research Triangle Park, NC.[31] Aranth J, Lindberg C \"Bleeding, a side effect of fluoxetine.\" Am J Psychiatry 149 (1992): 412[32] Cerner Multum, Inc. \"Australian Product Information.\" O 0[33] de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S \"Intracranial haemorrhage and use of selective serotonin reuptake inhibitors.\" Br J Clin Pharmacol 50 (2000): 43-7[34] de Maistre E, Allart C, Lecompte T, Bollaert PE \"Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.\" Am J Med 113 (2002): 530-2[35] Claire RJ, Servis ME, Cram DL Jr \"Potential interaction between warfarin sodium and fluoxetine.\" Am J Psychiatry 148 (1991): 1604[36] Dent LA, Orrock MW \"Warfarin-fluoxetine and diazepam-fluoxetine interaction.\" Pharmacotherapy 17 (1997): 170-2[37] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[38] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories, Philadelphia, PA.[39] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals, St. Louis, MO.[40] Mendelson J, Jones RT, Upton R, Jacob P 3rd \"Methamphetamine and ethanol interactions in humans.\" Clin Pharmacol Ther 57 (1995): 559-68[41] \"Product Information. Didrex (benzphetamine)\" Pharmacia and Upjohn, Kalamazoo, MI.[42] \"Product Information. Suprenza (phentermine).\" Akrimax Pharmaceuticals, Cranford, NJ.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Maprotiline, St. John's Wort, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, Desipramine, Tranylcypromine, More", "updated_at": 1767369485}, {"id": 45265, "ingredient1": "Bivalirudin", "ingredient2": "Warfarin", "severity": "Major", "effect": "The concomitant administration of bivalirudin and other anticoagulants may increase the risk of bleeding complications due to additive or synergistic effects on the clotting cascade.", "source": "DDInter", "management_text": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits. Close clinical and laboratory observation for bleeding complications is recommended.", "mechanism_text": "Synergism", "recommendation": "Until further data are available, coadministration of bivalirudin and all anticoagulants should be undertaken with caution and only after thorough assessment of risks and benefits.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45335/", "reference_text": "[1] \"Product Information. Angiomax (bivalirudin)\" The Medicines Compny, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Antithrombin III human, Dicoumarol, Warfarin, Selexipag", "alternatives_b": "Antithrombin III human, Bivalirudin, Acenocoumarol, Selexipag, Acetylsalicylic acid, Cangrelor", "updated_at": 1767369485}, {"id": 45266, "ingredient1": "Bivalirudin", "ingredient2": "Zanubrutinib", "severity": "Major", "effect": "Coadministration of zanubrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Concomitant use of zanubrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician. Discontinue zanubrutinib if intracranial hemorrhage of any grade occurs.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of zanubrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45336/", "reference_text": "[1] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Protein C, Acenocoumarol, Selexipag", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Larotrectinib, Bosutinib, More", "updated_at": 1767369485}, {"id": 45267, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45337/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45268, "ingredient1": "Bleomycin", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45338/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45269, "ingredient1": "Bleomycin", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45339/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45270, "ingredient1": "Bleomycin", "ingredient2": "Brentuximab vedotin", "severity": "Major", "effect": "Coadministration of brentuximab with bleomycin may increase the risk of pulmonary toxicity. The mechanism has not been described. Patients typically reported cough and dyspnea. Interstitial infiltration and/or inflammation were observed on radiographs and computed tomographic imaging of the chest. Most patients responded to corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of brentuximab and bleomycin is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of brentuximab and bleomycin is considered contraindicated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45340/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc, Bothell, WA.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45271, "ingredient1": "Busulfan", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45341/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45272, "ingredient1": "Canakinumab", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45342/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45273, "ingredient1": "Candida albicans", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45343/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45274, "ingredient1": "Capecitabine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45344/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Dactinomycin, Valrubicin, Plicamycin, Epirubicin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45275, "ingredient1": "Carboplatin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45345/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45276, "ingredient1": "Carmustine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45346/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Uracil mustard", "alternatives_b": "Ixabepilone, Dactinomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45277, "ingredient1": "Ceftazidime", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45347/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Cefepime, Imipenem, Aztreonam, Cefiderocol, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, More", "updated_at": 1767369485}, {"id": 45278, "ingredient1": "Certolizumab pegol", "ingredient2": "Bleomycin", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45348/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45279, "ingredient1": "Chlorambucil", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45349/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45280, "ingredient1": "Chloramphenicol", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.", "source": "DDInter", "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45350/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Sim SM, Back DJ, Breckenridge AM \"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.\" Br J Clin Pharmacol 32 (1991): 17-21[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Burger DM, Meenhorst PL, Koks CH, Beijnen JH \"Drug interactions with zidovudine.\" AIDS 7 (1993): 445-60[5] \"Product Information. Chloromycetin (chloramphenicol).\" Parke-Davis, Morris Plains, NJ.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, Rifamycin, More", "updated_at": 1767369485}, {"id": 45281, "ingredient1": "Chloramphenicol (ophthalmic)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.", "source": "DDInter", "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45351/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Sim SM, Back DJ, Breckenridge AM \"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.\" Br J Clin Pharmacol 32 (1991): 17-21[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Burger DM, Meenhorst PL, Koks CH, Beijnen JH \"Drug interactions with zidovudine.\" AIDS 7 (1993): 445-60[5] \"Product Information. Chloromycetin (chloramphenicol).\" Parke-Davis, Morris Plains, NJ.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, Rifamycin, More", "updated_at": 1767369485}, {"id": 45282, "ingredient1": "Bleomycin", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45352/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45283, "ingredient1": "Bleomycin", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Moderate", "effect": "There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45353/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[3] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45284, "ingredient1": "Cinoxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45354/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45285, "ingredient1": "Ciprofloxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45355/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Tetracycline, Chlorhexidine, More", "updated_at": 1767369485}, {"id": 45286, "ingredient1": "Cisplatin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45356/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45287, "ingredient1": "Cladribine", "ingredient2": "Bleomycin", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45357/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45288, "ingredient1": "Clofarabine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45358/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Dactinomycin, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45289, "ingredient1": "Clozapine", "ingredient2": "Bleomycin", "severity": "Major", "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.", "source": "DDInter", "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45359/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Valrubicin", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "updated_at": 1767369485}, {"id": 45290, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45360/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45291, "ingredient1": "Cyclophosphamide", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45361/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin, Epirubicin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45292, "ingredient1": "Cytarabine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45362/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine, Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 45293, "ingredient1": "Cytarabine (liposomal)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45363/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine, Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "updated_at": 1767369485}, {"id": 45294, "ingredient1": "Dacarbazine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45364/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45295, "ingredient1": "Dactinomycin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45365/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45296, "ingredient1": "Daunorubicin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45366/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Daunorubicin, Valrubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin, Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 45297, "ingredient1": "Daunorubicin (liposomal)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45367/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Daunorubicin, Valrubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin, Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, More", "updated_at": 1767369485}, {"id": 45298, "ingredient1": "Decitabine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45368/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45299, "ingredient1": "Deferiprone", "ingredient2": "Bleomycin", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45369/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "updated_at": 1767369485}, {"id": 45300, "ingredient1": "Delafloxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45370/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45301, "ingredient1": "Denosumab", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45371/", "reference_text": "[1] \"Product Information. Prolia (denosumab).\" Amgen USA, Thousand Oaks, CA.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "updated_at": 1767369485}, {"id": 45302, "ingredient1": "Digoxin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The use of some antineoplastic agents has been associated with decreased gastrointestinal absorption of digoxin. The suspected mechanism is alteration of the gastrointestinal mucosa. The risk of an interaction is expected to be less with digoxin solution in capsules because absorption occurs rapidly in the upper GI tract.", "source": "DDInter", "management_text": "Digoxin serum levels and effectiveness should be monitored closely following the initiation or discontinuation of antineoplastic agents, and the dosage adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Digoxin serum levels and effectiveness should be monitored closely following the initiation or discontinuation of antineoplastic agents, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45372/", "reference_text": "[1] Kuhlmann J, Wilke J, Rietbrock N \"Cytostatic drugs are without significant effect on digitoxin plasma level and renal excretion.\" Clin Pharmacol Ther 32 (1982): 646-51[2] Bjornsson TD, Huang AT, Roth P, Jacob DS, Christenson R \"Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations.\" Clin Pharmacol Ther 39 (1986): 25-8[3] \"Product Information. Lanoxicaps (digoxin).\" Glaxo Wellcome, Research Triangle Park, NC.[4] Kuhlmann J, Zilly W, Wilke J \"Effects of cytostatic drugs on plasma level and renal excretion of beta-acetyldigoxin.\" Clin Pharmacol Ther 30 (1981): 518-27[5] Rodin SM, Johnson BF \"Pharmacokinetic interactions with digoxin.\" Clin Pharmacokinet 15 (1988): 227-44[6] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[7] Becquemont L, Verstuyft C, Kerb R, et al. \"Effect of grapefruit juice on digoxin pharmacokinetics in humans.\" Clin Pharmacol Ther 70 (2001): 311-6", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Epirubicin", "alternatives_b": "Digitoxin", "updated_at": 1767369485}, {"id": 45303, "ingredient1": "Dimethyl fumarate", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45373/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45304, "ingredient1": "Diroximel fumarate", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45374/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45305, "ingredient1": "Docetaxel", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45375/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "updated_at": 1767369485}, {"id": 45306, "ingredient1": "Doxorubicin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45376/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Doxorubicin, Valrubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45307, "ingredient1": "Doxorubicin (liposomal)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45377/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Doxorubicin, Dactinomycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45308, "ingredient1": "Efalizumab", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45378/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45309, "ingredient1": "Enoxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45379/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45310, "ingredient1": "Epirubicin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45380/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45311, "ingredient1": "Etanercept", "ingredient2": "Bleomycin", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45381/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45312, "ingredient1": "Ethotoin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures. Other hydantoins may interact with chemotherapy in a similar manner. The mechanism of this interaction has not been clearly established.", "source": "DDInter", "management_text": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy. Intravenous phenytoin may be less likely to interact with chemotherapy. Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.", "mechanism_text": "Others", "recommendation": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45382/", "reference_text": "[1] Dofferhoff AS, Berendsen HH \"Decreased phenytoin level after carboplatin treatment.\" Am J Med 89 (1990): 247[2] Neef C, de Voogd-van der Straaten \"An interaction between cytostatic and anticonvulsant drugs.\" Clin Pharmacol Ther 43 (1988): 372-5[3] Bollini P, Riva R, Albani F, Ida et al \"Decreased phenytoin level during antineoplastic therapy: a case report.\" Epilepsia 24 (1983): 75-8[4] Fincham RW, Schottelius DD \"Decreased phenytoin levels in antineoplastic therapy.\" Ther Drug Monit 1 (1979): 277-83[5] Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA \"Impaired phenytoin bioavailability secondary to cisplantin, vinblastine, and bleomycin.\" Ther Drug Monit 6 (1984): 302-5[6] Grossman SA, Sheidler VR, Gilbert MR \"Decreased phenytoin levels in patients receiving chemotherapy.\" Am J Med 87 (1989): 505-10[7] Jarosinski PF, Moscow JA, Alexander MS, et al \"Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.\" J Pediatr 112 (1988): 996-9[8] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[12] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[13] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[14] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[15] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[16] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[17] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[18] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[19] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[20] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[21] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[22] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[23] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[24] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 45313, "ingredient1": "Etoposide", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45383/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "updated_at": 1767369485}, {"id": 45314, "ingredient1": "Filgrastim", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45384/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45315, "ingredient1": "Fingolimod", "ingredient2": "Bleomycin", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45385/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45316, "ingredient1": "Floxuridine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45386/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45317, "ingredient1": "Fludarabine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45387/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Dactinomycin, Valrubicin, Plicamycin, Epirubicin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45318, "ingredient1": "Fluorouracil", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45388/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45319, "ingredient1": "Gatifloxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45389/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 45320, "ingredient1": "Givosiran", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45390/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "updated_at": 1767369485}, {"id": 45321, "ingredient1": "Golimumab", "ingredient2": "Bleomycin", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45391/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45322, "ingredient1": "Grepafloxacin", "ingredient2": "Bleomycin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45392/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45323, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45393/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45324, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45394/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45325, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45395/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45326, "ingredient1": "Hydroxyurea", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45396/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45327, "ingredient1": "Idarubicin", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45397/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Idarubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45328, "ingredient1": "Ifosfamide", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45398/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45329, "ingredient1": "Imatinib", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45399/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 45330, "ingredient1": "Indium In-111 pentetreotide", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "Indium In-111 pentetreotide may accumulate in the lungs when given concomitantly with bleomycin.", "source": "DDInter", "management_text": "Clinicians should be aware of possible diagnostic interference in patients who are undergoing bleomycin treatment. To help reduce the radiation dose to the lungs and other target organs (e.g., thyroid, kidneys, bladder), patients should be well hydrated prior to the administration of indium In-111 pentetreotide. They should increase fluid intake and void frequently for one day after the scintigraphy. In addition, it is recommended that patients be given a mild laxative (e.g., bisacodyl or lactulose) before and after administration of indium In-111 pentetreotide.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of possible diagnostic interference in patients who are undergoing bleomycin treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45400/", "reference_text": "[1] \"Product Information. Octreoscan (indium pentetreotide In-111).\" Mallinckrodt Medical Inc, St. Louis, MO.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Capromab pendetide, Gallium Ga-68 gozetotide, Fludeoxyglucose (18F)", "updated_at": 1767369485}, {"id": 45331, "ingredient1": "Infliximab", "ingredient2": "Bleomycin", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45401/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45332, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45402/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45333, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45403/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45334, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45404/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45335, "ingredient1": "Interferon alfa-2b", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45405/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45336, "ingredient1": "Isatuximab", "ingredient2": "Bleomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45406/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45337, "ingredient1": "Bleomycin", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45407/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45338, "ingredient1": "Bleomycin", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45408/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45339, "ingredient1": "Bleomycin", "ingredient2": "Levofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45409/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, More", "updated_at": 1767369485}, {"id": 45340, "ingredient1": "Bleomycin", "ingredient2": "Lomefloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45410/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "updated_at": 1767369485}, {"id": 45341, "ingredient1": "Bleomycin", "ingredient2": "Lomustine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45411/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45342, "ingredient1": "Bleomycin", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45412/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45343, "ingredient1": "Bleomycin", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45413/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45344, "ingredient1": "Bleomycin", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45414/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45345, "ingredient1": "Bleomycin", "ingredient2": "Mechlorethamine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45415/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45346, "ingredient1": "Bleomycin", "ingredient2": "Melphalan", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45416/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45347, "ingredient1": "Bleomycin", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45417/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45348, "ingredient1": "Bleomycin", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures. Other hydantoins may interact with chemotherapy in a similar manner. The mechanism of this interaction has not been clearly established.", "source": "DDInter", "management_text": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy. Intravenous phenytoin may be less likely to interact with chemotherapy. Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.", "mechanism_text": "Others", "recommendation": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45418/", "reference_text": "[1] Dofferhoff AS, Berendsen HH \"Decreased phenytoin level after carboplatin treatment.\" Am J Med 89 (1990): 247[2] Neef C, de Voogd-van der Straaten \"An interaction between cytostatic and anticonvulsant drugs.\" Clin Pharmacol Ther 43 (1988): 372-5[3] Bollini P, Riva R, Albani F, Ida et al \"Decreased phenytoin level during antineoplastic therapy: a case report.\" Epilepsia 24 (1983): 75-8[4] Fincham RW, Schottelius DD \"Decreased phenytoin levels in antineoplastic therapy.\" Ther Drug Monit 1 (1979): 277-83[5] Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA \"Impaired phenytoin bioavailability secondary to cisplantin, vinblastine, and bleomycin.\" Ther Drug Monit 6 (1984): 302-5[6] Grossman SA, Sheidler VR, Gilbert MR \"Decreased phenytoin levels in patients receiving chemotherapy.\" Am J Med 87 (1989): 505-10[7] Jarosinski PF, Moscow JA, Alexander MS, et al \"Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.\" J Pediatr 112 (1988): 996-9[8] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[12] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[13] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[14] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[15] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[16] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[17] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[18] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[19] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[20] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[21] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[22] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[23] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[24] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 45349, "ingredient1": "Bleomycin", "ingredient2": "Mercaptopurine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45419/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine, Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, More", "updated_at": 1767369485}, {"id": 45350, "ingredient1": "Bleomycin", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45420/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45351, "ingredient1": "Bleomycin", "ingredient2": "Mitomycin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45421/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Mitomycin, Valrubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45352, "ingredient1": "Bleomycin", "ingredient2": "Mitoxantrone", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45422/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Mitoxantrone, Valrubicin, Plicamycin", "alternatives_b": "Ixabepilone, Bleomycin, Valrubicin, Plicamycin", "updated_at": 1767369485}, {"id": 45353, "ingredient1": "Bleomycin", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45423/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45354, "ingredient1": "Bleomycin", "ingredient2": "Moxifloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45424/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Netilmicin, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, Gentamicin, More", "alternatives_b": "Ixabepilone, Valrubicin", "updated_at": 1767369485}, {"id": 45355, "ingredient1": "Bleomycin", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45425/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45356, "ingredient1": "Bleomycin", "ingredient2": "Nalidixic acid", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45426/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45357, "ingredient1": "Bleomycin", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45427/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45358, "ingredient1": "Bleomycin", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45428/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45359, "ingredient1": "Bleomycin", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45429/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Dactinomycin, Valrubicin, Plicamycin, Epirubicin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45360, "ingredient1": "Bleomycin", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.", "source": "DDInter", "management_text": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45430/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45361, "ingredient1": "Bleomycin", "ingredient2": "Norfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45431/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 45362, "ingredient1": "Bleomycin", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45432/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45363, "ingredient1": "Bleomycin", "ingredient2": "Ofloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45433/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "updated_at": 1767369485}, {"id": 45364, "ingredient1": "Bleomycin", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45434/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45365, "ingredient1": "Bleomycin", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45435/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45366, "ingredient1": "Bleomycin", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45436/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45367, "ingredient1": "Bleomycin", "ingredient2": "Oxygen", "severity": "Major", "effect": "The use of oxygen in patients undergoing bleomycin treatment may increase the severity of bleomycin-associated pulmonary toxicity. Severe and fatal respiratory distress syndrome, pneumonitis, and pulmonary fibrosis have been reported. The interaction may be dose-dependent.", "source": "DDInter", "management_text": "The manufacturer considers the use of pulmonary function tests with 100% oxygen to be contraindicated in bleomycin-treated patients, and recommends the use of pulmonary function tests with less than 21% oxygen. During general anesthesia, it is recommended that bleomycin-treated patients receive oxygen concentrations less than 30%.", "mechanism_text": "Others", "recommendation": "The manufacturer considers the use of pulmonary function tests with 100% oxygen to be contraindicated in bleomycin-treated patients, and recommends the use of pulmonary function tests with less than 21% oxygen.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45437/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "updated_at": 1767369485}, {"id": 45368, "ingredient1": "Bleomycin", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45438/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45369, "ingredient1": "Bleomycin", "ingredient2": "Palifermin", "severity": "Moderate", "effect": "INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45439/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc, Florence, KY.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Promethazine, More", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45370, "ingredient1": "Bleomycin", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45440/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45371, "ingredient1": "Bleomycin", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45441/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45372, "ingredient1": "Bleomycin", "ingredient2": "Pentostatin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45442/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin, Ixabepilone, Dactinomycin, Epirubicin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45373, "ingredient1": "Bleomycin", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Cases have been reported in which patients receiving chemotherapy have experienced markedly reduced plasma phenytoin concentrations and seizures. Other hydantoins may interact with chemotherapy in a similar manner. The mechanism of this interaction has not been clearly established.", "source": "DDInter", "management_text": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy. Intravenous phenytoin may be less likely to interact with chemotherapy. Careful monitoring of patients for seizure activity is recommended, as is monitoring of plasma phenytoin levels.", "mechanism_text": "Others", "recommendation": "It may be necessary to increase phenytoin dosage during chemotherapy and to decrease it after or between courses of chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45443/", "reference_text": "[1] Dofferhoff AS, Berendsen HH \"Decreased phenytoin level after carboplatin treatment.\" Am J Med 89 (1990): 247[2] Neef C, de Voogd-van der Straaten \"An interaction between cytostatic and anticonvulsant drugs.\" Clin Pharmacol Ther 43 (1988): 372-5[3] Bollini P, Riva R, Albani F, Ida et al \"Decreased phenytoin level during antineoplastic therapy: a case report.\" Epilepsia 24 (1983): 75-8[4] Fincham RW, Schottelius DD \"Decreased phenytoin levels in antineoplastic therapy.\" Ther Drug Monit 1 (1979): 277-83[5] Sylvester RK, Lewis FB, Caldwell KC, Lobell M, Perri R, Sawchuk RA \"Impaired phenytoin bioavailability secondary to cisplantin, vinblastine, and bleomycin.\" Ther Drug Monit 6 (1984): 302-5[6] Grossman SA, Sheidler VR, Gilbert MR \"Decreased phenytoin levels in patients receiving chemotherapy.\" Am J Med 87 (1989): 505-10[7] Jarosinski PF, Moscow JA, Alexander MS, et al \"Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.\" J Pediatr 112 (1988): 996-9[8] \"Product Information. Oncovin (vincristine).\" Lilly, Eli and Company, Indianapolis, IN.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] Fleisher D, Sheth N, Kou JH \"Phenytoin interaction with enteral feedings administered through nasogastric tubes.\" JPEN J Parenter Enteral Nutr 14 (1990): 513-6[12] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM \"Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability.\" Epilepsia 28 (1987): 706-12[13] Haley CJ, Nelson J \"Phenytoin-enteral feeding interaction.\" DICP 23 (1989): 796-8[14] Faraji B, Yu PP \"Serum phenytoin levels of patients on gastrostomy tube feeding.\" J Neurosci Nurs 30 (1998): 55-9[15] Au Yeung SC, Ensom MH \"Phenytoin and enteral feedings: does evidence support an interaction?\" Ann Pharmacother 34 (2000): 896-905[16] Sandor P, Sellers EM, Dumbrell M, Khouw V \"Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics.\" Clin Pharmacol Ther 30 (1981): 390-7[17] Ozuna J, Friel P \"Effect of enteral tube feeding on serum phenytoin levels.\" J Neurosurg Nurs 16 (1984): 289-91[18] Guidry JR, Eastwood TF, Curry SC \"Phenytoin absorption in volunteers receiving selected enteral feedings.\" West J Med 150 (1989): 659-61[19] Marvel ME, Bertino JS \"Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension.\" JPEN J Parenter Enteral Nutr 15 (1991): 316-8[20] \"Product Information. Dilantin (phenytoin).\" Parke-Davis, Morris Plains, NJ.[21] Doak KK, Haas CE, Dunnigan KJ, et al. \"Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings.\" Pharmacotherapy 18 (1998): 637-45[22] Rodman DP, Stevenson TL, Ray TR \"Phenytoin malabsorption after jejunostomy tube delivery.\" Pharmacotherapy 15 (1995): 801-5[23] Sellers EM, Holloway MR \"Drug kinetics and alcohol ingestion.\" Clin Pharmacokinet 3 (1978): 440-52[24] Holtz L, Milton J, Sturek JK \"Compatibility of medications with enteral feedings.\" JPEN J Parenter Enteral Nutr 11 (1987): 183-6", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Idarubicin, Valrubicin, Plicamycin, Mitomycin, Daunorubicin, Dactinomycin", "updated_at": 1767369485}, {"id": 45374, "ingredient1": "Bleomycin", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45444/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin", "alternatives_b": "Kanamycin, Netilmicin, Streptomycin, Tobramycin, Gentamicin, Amikacin, Neomycin", "updated_at": 1767369485}, {"id": 45375, "ingredient1": "Bleomycin", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45445/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45376, "ingredient1": "Bleomycin", "ingredient2": "Radium Ra 223 dichloride", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and radium Ra 223 dichloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms. The safety and efficacy of concomitant use of chemotherapy have not been established.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with radium Ra 223 dichloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45446/", "reference_text": "[1] \"Product Information. Xofigo (radium Ra 223 dichloride).\" Bayer Pharmaceutical Inc, West Haven, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45377, "ingredient1": "Bleomycin", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45447/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45378, "ingredient1": "Bleomycin", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45448/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Valrubicin", "alternatives_b": "Theophylline, Omalizumab, Tezepelumab, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, Mepolizumab, More", "updated_at": 1767369485}, {"id": 45379, "ingredient1": "Bleomycin", "ingredient2": "Rotavirus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45449/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45380, "ingredient1": "Bleomycin", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45450/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45381, "ingredient1": "Bleomycin", "ingredient2": "Ruxolitinib", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45451/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Entrectinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 45382, "ingredient1": "Bleomycin", "ingredient2": "Samarium (153Sm) lexidronam", "severity": "Major", "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45452/", "reference_text": "[1] \"Product Information. Quadramet (samarium sm 153 lexidronam)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45383, "ingredient1": "Bleomycin", "ingredient2": "Sargramostim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45453/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Valrubicin", "updated_at": 1767369485}, {"id": 45384, "ingredient1": "Bleomycin", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45454/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45385, "ingredient1": "Bleomycin", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45455/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45386, "ingredient1": "Bleomycin", "ingredient2": "Sipuleucel-T", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45456/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Valrubicin", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Histamine, Pegademase, Peginterferon alfa-2b, Glatiramer", "updated_at": 1767369485}, {"id": 45387, "ingredient1": "Bleomycin", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45457/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45388, "ingredient1": "Bleomycin", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45458/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45389, "ingredient1": "Bleomycin", "ingredient2": "Sparfloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45459/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45390, "ingredient1": "Bleomycin", "ingredient2": "Streptozocin", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45460/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45391, "ingredient1": "Bleomycin", "ingredient2": "Strontium chloride Sr-89", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45461/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45392, "ingredient1": "Bleomycin", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45462/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Valrubicin", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "updated_at": 1767369485}, {"id": 45393, "ingredient1": "Bleomycin", "ingredient2": "Temozolomide", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45463/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Dactinomycin, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45394, "ingredient1": "Bleomycin", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Serious infections including sepsis, as well as opportunistic infections like Pneumocystis jiroveci pneumonia, pulmonary and extrapulmonary tuberculosis, and aspergillosis have been reported with the use of leflunomide, particularly in patients on concomitant hematotoxic therapy. Agents that may be significantly immuno- or myelosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids. Rare cases of pancytopenia, agranulocytosis, and thrombocytopenia have also occurred with leflunomide alone, but were most frequent in the presence of concomitant or recent use of methotrexate or other myelotoxic agents. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when hematotoxic agents are initiated after the discontinuation of leflunomide. Administering a washout procedure with cholestyramine or activated charcoal helps to accelerate elimination of the active metabolite from plasma and reduce the overlap of systemic exposure to these agents.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa. Platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If evidence of serious infection or bone marrow suppression occurs, treatment should be stopped, and cholestyramine or charcoal administered to accelerate elimination of leflunomide's active metabolite from plasma, which otherwise may take up to two years.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for the development of infection is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immuno- or myelosuppressive agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45464/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[2] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45395, "ingredient1": "Bleomycin", "ingredient2": "Thalidomide", "severity": "Major", "effect": "Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.", "source": "DDInter", "management_text": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.", "mechanism_text": "Synergism", "recommendation": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45465/", "reference_text": "[1] Fine HA, Wen PY, Maher EA, et al. \"Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas.\" J Clin Oncol 21 (2003): 2299-304[2] Zangari M, Siegel E, Barlogie B, et al \"Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.\" Blood 100 (2002): 1168-71[3] Figg WD, Arlen P, Gulley J, et al. \"A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.\" Semin Oncol 28(4 Suppl 15) (2001): 62-6[4] Desai AA, Vogelzang NJ, Rini BI, Ansari R, Krauss S, Stadler WM \"A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.\" Cancer 95 (2002): 1629-36[5] Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J \"Thromboembolic events during treatment with thalidomide.\" Blood 99 (2002): 4247-8[6] Lee CK, Barlogie B, Munshi N, et al \"DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma.\" J Clin Oncol 21 (2003): 2732-9[7] Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R \"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.\" J Clin Oncol 21 (2003): 16-9[8] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation, Warren, NJ.[9] Cavo M, Zamagni E, Cellini C, et al. \"Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy.\" Blood 100 (2002): 2272-3[10] Bennett CL, Nebeker JR, Samore MH, et al \"The Research on Adverse Drug Events and Reports (RADAR) project.\" JAMA 293 (2005): 2131-40[11] Zangari M, Anaissie E, Barlogie B, et al \"Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.\" Blood 98 (2001): 1614-5[12] Rajkumar SV, Hayman S, Gertz MA, et al. \"Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.\" J Clin Oncol 20 (2002): 4319-23[13] Osman K, Comenzo R, Rajkumar SV \"Deep venous thrombosis and thalidomide therapy for multiple myeloma.\" N Engl J Med 344 (2001): 1951-2[14] Zangari M, Barlogie B, Anaissie E, et al \"Deep vein thrombosis in patients with mutiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.\" Br J Haematol 126 (2004): 715-21[15] Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A \"Thalidomide and venous thrombosis.\" Ann Intern Med 136 (2002): 711[16] Bennett CL, Schumock GT, Desai AA, et al \"Thalidomide-associated deep vein thrombosis and pulmonary embolism.\" Am J Med 113 (2002): 603-6[17] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[18] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[19] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[20] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45396, "ingredient1": "Bleomycin", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45466/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Dactinomycin, Valrubicin, Plicamycin", "alternatives_b": "Azacitidine, Pralatrexate, Trifluridine", "updated_at": 1767369485}, {"id": 45397, "ingredient1": "Bleomycin", "ingredient2": "Thiotepa", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45467/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Ixabepilone, Valrubicin, Plicamycin", "alternatives_b": "Uracil mustard", "updated_at": 1767369485}, {"id": 45398, "ingredient1": "Bleomycin", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45468/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45399, "ingredient1": "Bleomycin", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45469/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Valrubicin", "alternatives_b": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "updated_at": 1767369485}, {"id": 45400, "ingredient1": "Bleomycin", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45470/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45401, "ingredient1": "Bleomycin", "ingredient2": "Trovafloxacin", "severity": "Minor", "effect": "Limited data suggest that chemotherapy with antineoplastic agents may reduce the plasma concentrations of oral quinolone antibiotics. The proposed mechanism is decreased quinolone absorption secondary to alteration of intestinal mucosa by cancer chemotherapy.", "source": "DDInter", "management_text": "-", "mechanism_text": "Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45471/", "reference_text": "[1] Johnson EJ, MacGowan AP, Potter MN, et al \"Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy.\" J Antimicrob Chemother 25 (1990): 837-42", "alternatives_a": "Ixabepilone, Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45402, "ingredient1": "Bleomycin", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45472/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45403, "ingredient1": "Bleomycin", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45473/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45404, "ingredient1": "Bleomycin", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45474/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45405, "ingredient1": "Bleomycin", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45475/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45406, "ingredient1": "Bleomycin", "ingredient2": "Ustekinumab", "severity": "Moderate", "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45476/", "reference_text": "[1] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.", "alternatives_a": "Valrubicin", "alternatives_b": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More", "updated_at": 1767369485}, {"id": 45407, "ingredient1": "Bleomycin", "ingredient2": "Valganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45477/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Valrubicin", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, More", "updated_at": 1767369485}, {"id": 45408, "ingredient1": "Bleomycin", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45478/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45409, "ingredient1": "Bleomycin", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45479/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "updated_at": 1767369485}, {"id": 45410, "ingredient1": "Bleomycin", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.", "mechanism_text": "Synergism", "recommendation": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45480/", "reference_text": "[1] \"Product Information. Fluorouracil injection (fluorouracil).\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Paraplatin (carboplatin).\" Bristol-Myers Squibb, Princeton, NJ.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb, Princeton, NJ.[9] \"Product Information. Zanosar (streptozocin).\" Pharmacia and Upjohn, Kalamazoo, MI.", "alternatives_a": "Valrubicin, Plicamycin", "alternatives_b": "Teniposide, Trabectedin, Cabazitaxel, Irinotecan", "updated_at": 1767369485}, {"id": 45411, "ingredient1": "Bleomycin", "ingredient2": "Vitamin E", "severity": "Moderate", "effect": "The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses could theoretically interfere with radiation therapy and chemotherapeutic agents whose cytotoxic mechanism depends on generation of reactive oxygen species (ROS) that damage DNA and proteins, including but not limited to alkylating agents (e.g., busulfan, cyclophosphamide, melphalan), anthracyclines (e.g., doxorubicin, epirubicin), platinum coordination complexes (e.g., cisplatin, carboplatin), DNA topoisomerase inhibitors (e.g., etoposide, teniposide, irinotecan, topotecan), and photodynamic agents (e.g., porfimer). On the other hand, vitamin E may help reduce oxidative stress associated with more aggressive cancers and protect non-cancer cells from oxidative damage generated by cancer treatments, which can enhance patient tolerance and lessen the need for reducing dosage or duration of treatment.", "source": "DDInter", "management_text": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment. Clinicians should closely monitor antitumor response if vitamin E is used in these patients. No specific dosing of vitamin E has been established for uses other than to treat vitamin E deficiency. There has been evidence suggesting possible adverse health effects including increased risk of heart failure and mortality in association with long-term use of 400 IU/day or greater.", "mechanism_text": "Others", "recommendation": "Until more information is available, vitamin E supplementation should preferably be avoided in patients undergoing cancer chemotherapy or radiation treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45481/", "reference_text": "[1] Conklin KA \"Cancer chemotherapy and antioxidants.\" J Nutr 134 (2004): 3201S-4S[2] Labriola D, Livingston R \"Possible interactions between dietary antioxidants and chemotherapy.\" Oncology (Williston Park) 13 (1999): 1003-8; discussion 1008, 1011-2[3] D'Andrea GM \"Use of antioxidants during chemotherapy and radiotherapy should be avoided.\" CA Cancer J Clin 55 (2005): 319-21[4] Pace A, Savarese A, Picardo M, et al \"Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.\" J Clin Oncol 21 (2003): 927-31[5] Therapeutic Research Faculty \"Natural Medicines Comprehensive Database. Available from: URL: http://www.naturaldatabase.com.\" ([1995-2008...]):[6] Prasad KN \"Rationale for using high-dose multiple dietary antioxidants as an adjunct to radiation therapy and chemotherapy.\" J Nutr 134 (2004): 3182S-3S[7] Whittaker JA, Al-Ismail SA \"Effect of digoxin and vitamin E in preventing cardiac damage caused by doxorubicin in acute myeloid leukaemia.\" Br Med J (Clin Res Ed) 288 (1984): 283-4[8] Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C \"Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials.\" Int J Cancer 123 (2008): 1227-39[9] Lonn E, Bosch J, Yusuf S, et al. \"Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.\" JAMA 293 (2005): 1338-47", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45412, "ingredient1": "Bleomycin", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45482/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Valrubicin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45413, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45483/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45414, "ingredient1": "Aminophylline", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45484/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45415, "ingredient1": "Blinatumomab", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45485/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45416, "ingredient1": "Blinatumomab", "ingredient2": "Bedaquiline", "severity": "Moderate", "effect": "Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.", "mechanism_text": "Synergism", "recommendation": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45486/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45417, "ingredient1": "Blinatumomab", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45487/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45418, "ingredient1": "Brentuximab vedotin", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45488/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc, Bothell, WA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45419, "ingredient1": "Calaspargase pegol", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45489/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45420, "ingredient1": "Canakinumab", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45490/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45421, "ingredient1": "Candida albicans", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45491/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45422, "ingredient1": "Cannabidiol", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of cannabidiol with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cannabidiol causes dose-related elevations of liver transaminases, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST).", "source": "DDInter", "management_text": "Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa. Serum transaminases and total bilirubin levels should be obtained prior to initiating cannabidiol, and patients with elevated baseline transaminase levels above 3 times the ULN accompanied by elevations in bilirubin above 2 times the ULN should be evaluated. Patients who develop clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, jaundice, dark urine) should have serum transaminases and total bilirubin measured promptly, and cannabidiol treatment interrupted or discontinued as appropriate. Cannabidiol should be discontinued in patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Also consider dosage adjustment or discontinuation of any coadministered medication that is known to affect the liver.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45492/", "reference_text": "[1] \"Product Information. Epidiolex (cannabidiol).\" Greenwich Biosciences Inc, Carlsbad, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Epidiolex (cannabidiol).\" Greenwich Biosciences Inc, Carlsbad, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "updated_at": 1767369485}, {"id": 45423, "ingredient1": "Carbamazepine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45493/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45424, "ingredient1": "Certolizumab pegol", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45494/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45425, "ingredient1": "Chloramphenicol", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.", "source": "DDInter", "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45495/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Sim SM, Back DJ, Breckenridge AM \"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.\" Br J Clin Pharmacol 32 (1991): 17-21[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Burger DM, Meenhorst PL, Koks CH, Beijnen JH \"Drug interactions with zidovudine.\" AIDS 7 (1993): 445-60[5] \"Product Information. Chloromycetin (chloramphenicol).\" Parke-Davis, Morris Plains, NJ.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Panitumumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Nivolumab, More", "updated_at": 1767369485}, {"id": 45426, "ingredient1": "Chloramphenicol (ophthalmic)", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of chloramphenicol hematologic toxicity. Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia and granulocytopenia) have been reported after the administration of chloramphenicol.", "source": "DDInter", "management_text": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concurrent use of chloramphenicol with other bone marrow depressing agents should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45496/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Sim SM, Back DJ, Breckenridge AM \"The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes.\" Br J Clin Pharmacol 32 (1991): 17-21[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Burger DM, Meenhorst PL, Koks CH, Beijnen JH \"Drug interactions with zidovudine.\" AIDS 7 (1993): 445-60[5] \"Product Information. Chloromycetin (chloramphenicol).\" Parke-Davis, Morris Plains, NJ.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, Sacituzumab govitecan, More", "updated_at": 1767369485}, {"id": 45427, "ingredient1": "Blinatumomab", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45497/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45428, "ingredient1": "Blinatumomab", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Moderate", "effect": "There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45498/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[3] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45429, "ingredient1": "Cladribine", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45499/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45430, "ingredient1": "Clofarabine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.", "source": "DDInter", "management_text": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45500/", "reference_text": "[1] \"Product Information. Clolar (clofarabine).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45431, "ingredient1": "Clozapine", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.", "source": "DDInter", "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45501/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, More", "updated_at": 1767369485}, {"id": 45432, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45502/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45433, "ingredient1": "Colchicine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45503/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Sulfinpyrazone, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45434, "ingredient1": "Cyclosporine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45504/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45435, "ingredient1": "Deferiprone", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45505/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45436, "ingredient1": "Denosumab", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45506/", "reference_text": "[1] \"Product Information. Prolia (denosumab).\" Amgen USA, Thousand Oaks, CA.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45437, "ingredient1": "Dicoumarol", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45507/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45438, "ingredient1": "Dimethyl fumarate", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45508/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45439, "ingredient1": "Diroximel fumarate", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45509/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 45440, "ingredient1": "Disopyramide", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45510/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45441, "ingredient1": "Dyphylline", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45511/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45442, "ingredient1": "Efalizumab", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45512/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45443, "ingredient1": "Efavirenz", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of efavirenz with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Efavirenz has been associated with hepatotoxicity during postmarketing use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; other HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of liver function tests should occur before and during treatment, especially in patients with underlying hepatic disease (including hepatitis B or C coinfection) or marked transaminase elevations.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when efavirenz is used in combination with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45513/", "reference_text": "[1] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals, Wilmington, DE.[2] Elsharkawy AM, Schwab U, McCarron B, et al. \"Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.\" J Clin Virol 58 (2013): 331-3[3] \"Product Information. Sustiva (efavirenz).\" DuPont Pharmaceuticals, Wilmington, DE.[4] \"Product Information. Retrovir (zidovudine).\" Glaxo Wellcome, Research Triangle Park, NC.[5] Lotterer E, Ruhnke M, Trautman M, et al \"Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal.\" Eur J Clin Pharmacol 40 (1991): 305-8[6] Unadkat JD, Collier AC, Crosby SS, et al \"Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal.\" AIDS 4 (1990): 229-32[7] Sahai J, Gallicano K, Garber G, et al. \"The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients.\" Br J Clin Pharmacol 33 (1992): 657-60", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45444, "ingredient1": "Epirubicin", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.", "source": "DDInter", "management_text": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45514/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Idarubicin, Valrubicin, Plicamycin, Ixabepilone, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45445, "ingredient1": "Etanercept", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45515/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45446, "ingredient1": "Everolimus", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45516/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45447, "ingredient1": "Filgrastim", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45517/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45448, "ingredient1": "Fingolimod", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45518/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45449, "ingredient1": "Fluphenazine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The risk of seizures may be increased during coadministration of fluphenazine with any substance that can reduce the seizure threshold, such as aminophylline, antidepressants, antipsychotics, opioids, carbapenems, etc. These agents are often individually epileptogenic and may have additive effects when combined. Many of these agents also exhibit CNS- and/or respiratory-depressant effects, which may be enhanced during their concomitant use with fluphenazine.", "source": "DDInter", "management_text": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if fluphenazine is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45519/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Haloperidol, Thiothixene, Risperidone, Amisulpride, Quetiapine, Prochlorperazine, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45450, "ingredient1": "Ginkgo biloba", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45520/", "reference_text": "[1] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002): 325-7[2] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001): 523-5[3] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[4] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001): 344[5] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006): 323-9[6] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001): 524-32[7] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001): 280-1[8] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005): 755-8", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45451, "ingredient1": "Golimumab", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45521/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45452, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45522/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45453, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45523/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45454, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45524/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45455, "ingredient1": "Hydrocodone", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45525/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Dextromethorphan, Clofedanol, Benzonatate, Pentoxyverine, Codeine", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45456, "ingredient1": "Idelalisib", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45526/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Olaratumab, Avelumab, Tafasitamab, Amivantamab, Belantamab mafodotin, Ofatumumab, Pembrolizumab, Rituximab, Cemiplimab", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 45457, "ingredient1": "Infliximab", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45527/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45458, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45528/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45459, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45529/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45460, "ingredient1": "Interferon beta-1a", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45530/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45461, "ingredient1": "Interferon beta-1b", "ingredient2": "Blinatumomab", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45531/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45462, "ingredient1": "Iohexol", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45532/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45463, "ingredient1": "Iopamidol", "ingredient2": "Blinatumomab", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45533/", "reference_text": "[1] \"Product Information. Amipaque (metrizamide)\" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health, Princeton, NJ.[4] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc, Lachine, QC.[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc, Princeton, NJ.", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45464, "ingredient1": "Blinatumomab", "ingredient2": "Lactobacillus acidophilus", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45534/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45465, "ingredient1": "Blinatumomab", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45535/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45466, "ingredient1": "Blinatumomab", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity. Seizures have been reported after excessive use or oral ingestion of lindane. There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections). Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45536/", "reference_text": "[1] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000): 690-2[2] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981): 98-9[3] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[4] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982): 662-3[5] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979): 1224-5[6] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991): 41-3[7] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991): 394-5[8] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995): 291-6[9] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977): 1050-4", "alternatives_a": "Disulfiram", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45467, "ingredient1": "Blinatumomab", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.", "source": "DDInter", "management_text": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45537/", "reference_text": "[1] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45468, "ingredient1": "Blinatumomab", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45538/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45469, "ingredient1": "Blinatumomab", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45539/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45470, "ingredient1": "Blinatumomab", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45540/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45471, "ingredient1": "Blinatumomab", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45541/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Diamorphine, Acamprosate, Lofexidine, Varenicline, Disulfiram, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine, Oxymorphone, Pentazocine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45472, "ingredient1": "Blinatumomab", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45542/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Methotrexate (methotrexate).\" Lederle Laboratories, Wayne, NJ.[3] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45473, "ingredient1": "Blinatumomab", "ingredient2": "Mipomersen", "severity": "Major", "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.", "source": "DDInter", "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45543/", "reference_text": "[1] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Cholestyramine, Rosuvastatin, Fenofibrate, Evinacumab, Dextrothyroxine, Simvastatin, Probucol, Cerivastatin, Ezetimibe, Niacin, Atorvastatin, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45474, "ingredient1": "Blinatumomab", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45544/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45475, "ingredient1": "Blinatumomab", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45545/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45476, "ingredient1": "Blinatumomab", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45546/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oxymorphone, Pentazocine, Buprenorphine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, Naloxone, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45477, "ingredient1": "Blinatumomab", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45547/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45478, "ingredient1": "Blinatumomab", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.", "source": "DDInter", "management_text": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45548/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 45479, "ingredient1": "Blinatumomab", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45549/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 45480, "ingredient1": "Blinatumomab", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45550/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 45481, "ingredient1": "Blinatumomab", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45551/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Oxymorphone, Pentazocine, Buprenorphine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, Naloxone, More", "updated_at": 1767369485}, {"id": 45482, "ingredient1": "Blinatumomab", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45552/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45483, "ingredient1": "Blinatumomab", "ingredient2": "Oxtriphylline", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45553/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45484, "ingredient1": "Blinatumomab", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45554/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Oxymorphone, Pentazocine, Buprenorphine, Morphine, Butorphanol, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, Dihydrocodeine, Naloxone, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45485, "ingredient1": "Blinatumomab", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45555/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 45486, "ingredient1": "Blinatumomab", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45556/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45487, "ingredient1": "Blinatumomab", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45557/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45488, "ingredient1": "Blinatumomab", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45558/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "updated_at": 1767369485}, {"id": 45489, "ingredient1": "Blinatumomab", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45559/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "updated_at": 1767369485}, {"id": 45490, "ingredient1": "Blinatumomab", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45560/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45491, "ingredient1": "Blinatumomab", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45561/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45492, "ingredient1": "Blinatumomab", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Rare cases of generalized tonic-clonic seizures and/or loss of consciousness in association with low serum osmolality and electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia) have been reported with the use of bowel cleansing products in patients with no prior history of seizures. The condition resolved with correction of fluid and electrolyte abnormalities.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold. Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities. Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly. Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process. Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45562/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985): 177-9[2] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fleet Phospho Soda (sodium biphosphate-sodium phosphate).\" Fleet, CB, Lynchburg, VA.[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories, Braintree, MA.[7] \"Product Information. Visicol (sodium biphosphate-sodium phosphate).\" Salix Pharmaceuticals, Raleigh, NC.[8] \"Product Information. Golytely (polyethylene glycol electrolyte solution).\" Braintree, Braintree, MA.[9] \"Product Information. Prepopik (citric acid/Mg oxide/Na picosulfate).\" Ferring Pharmaceuticals Inc, Tarrytown, NY.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45493, "ingredient1": "Blinatumomab", "ingredient2": "Quinidine", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45563/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45494, "ingredient1": "Blinatumomab", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45564/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[3] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "updated_at": 1767369485}, {"id": 45495, "ingredient1": "Blinatumomab", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45565/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45496, "ingredient1": "Blinatumomab", "ingredient2": "Roflumilast", "severity": "Moderate", "effect": "The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite, roflumilast N-oxide, suppress the release of inflammatory mediators including leukotriene B4, reactive oxygen species, tumor necrosis factor alpha, interferon gamma, and granzyme B. Roflumilast also reduces sputum neutrophils and attenuates influx of neutrophils and eosinophils into the airways.", "source": "DDInter", "management_text": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.g., in the treatment of COPD exacerbations) should be avoided if possible. Due to a lack of clinical experience, treatment with roflumilast should not be initiated, or existing treatment should be stopped, in patients receiving immunosuppressive agents and in patients with severe acute infectious diseases, cancers (except basal cell carcinoma), or severe immunological diseases (e.g., HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).", "mechanism_text": "Synergism", "recommendation": "According to the product labeling for roflumilast in some countries , concomitant use with immunosuppressive agents such as methotrexate, azathioprine, infliximab, etanercept, and systemic corticosteroids (except when used short-term, e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45566/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Daxas (roflumilast).\" Nycomed Inc, Princeton, NJ.[5] \"Product Information. Daliresp (roflumilast).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45497, "ingredient1": "Blinatumomab", "ingredient2": "Rotavirus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45567/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45498, "ingredient1": "Blinatumomab", "ingredient2": "Rubella virus vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45568/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45499, "ingredient1": "Blinatumomab", "ingredient2": "Samarium (153Sm) lexidronam", "severity": "Major", "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.", "source": "DDInter", "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45569/", "reference_text": "[1] \"Product Information. Quadramet (samarium sm 153 lexidronam)\" Berlex Laboratories, Richmond, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45500, "ingredient1": "Blinatumomab", "ingredient2": "Sargramostim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45570/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Elotuzumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45501, "ingredient1": "Blinatumomab", "ingredient2": "Pfizer-BioNTech Covid-19 Vaccine", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45571/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45502, "ingredient1": "Blinatumomab", "ingredient2": "Siponimod", "severity": "Major", "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.", "source": "DDInter", "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45572/", "reference_text": "[1] \"Product Information. Mayzent (siponimod).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 45503, "ingredient1": "Blinatumomab", "ingredient2": "Sipuleucel-T", "severity": "Moderate", "effect": "Neither the leukapheresis procedure nor sipuleucel-T have been studied for use in combination with chemotherapy or immunosuppressive agents (e.g., systemic corticosteroids). Since sipuleucel-T is designed to stimulate the immune system, concurrent use of myelo- or immunosuppressive agents may alter the efficacy and/or safety of sipuleucel-T.", "source": "DDInter", "management_text": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "mechanism_text": "Others", "recommendation": "Patients should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue chemotherapy or immunosuppressive agents prior to treatment with sipuleucel-T.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45573/", "reference_text": "[1] \"Product Information. Provenge (sipuleucel-T).\" Dendreon Corporation, Seattle, WA.", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Elapegademase, Peginterferon alfa-2a, Interferon alfacon-1, Histamine, Aldesleukin, Pegademase, Interferon alfa-2b, Peginterferon alfa-2b, Glatiramer", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45504, "ingredient1": "Blinatumomab", "ingredient2": "Sirolimus", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45574/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45505, "ingredient1": "Blinatumomab", "ingredient2": "Smallpox (Vaccinia) Vaccine, Live", "severity": "Major", "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).", "mechanism_text": "Others", "recommendation": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45575/", "reference_text": "[1] \"Product Information. Dryvax (smallpox vaccine).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] CDC. Centers for Disease Control and Prevention \"Smallpox vaccination clinic guide. Logistical considerations and guidance for state and local planning for emergency, large-scale, voluntary administration of smallpox vaccine in response to a smallpox outbreak. Available from: URL: http://www.bt.cdc.gov\" ([2002 Oct 16]):", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45506, "ingredient1": "Blinatumomab", "ingredient2": "Sodium phosphate, monobasic (p32)", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and sodium phosphate P-32 may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with sodium phosphate P-32.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45576/", "reference_text": "[1] AnazaoHealth Corporation \"P32 Sodium Phosphate. Available from: URL: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=735f92e3-cc92-4d9b-afe8-f935a685ee78\" ([2012 Jun]):", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45507, "ingredient1": "Blinatumomab", "ingredient2": "Strontium chloride Sr-89", "severity": "Moderate", "effect": "The concomitant use of bone marrow depressants and strontium-89 chloride may have additive myelosuppressive effects.", "source": "DDInter", "management_text": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride. Dose reductions of the other bone marrow depressants may be necessary. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored for excessive bone marrow suppression during treatment with strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45577/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Multum Information Services, Inc. Expert Review Panel\"", "alternatives_a": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45508, "ingredient1": "Blinatumomab", "ingredient2": "Tacrolimus", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45578/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45509, "ingredient1": "Blinatumomab", "ingredient2": "Talimogene laherparepvec", "severity": "Major", "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.", "mechanism_text": "Synergism", "recommendation": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45579/", "reference_text": "[1] \"Product Information. Imlygic (talimogene laherparepvec).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Pertuzumab, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "updated_at": 1767369485}, {"id": 45510, "ingredient1": "Blinatumomab", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45580/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Fedratinib, Avapritinib, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45511, "ingredient1": "Blinatumomab", "ingredient2": "Teriflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45581/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, Nivolumab, Pembrolizumab, Cemiplimab", "updated_at": 1767369485}, {"id": 45512, "ingredient1": "Blinatumomab", "ingredient2": "Theophylline", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45582/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Pentoxifylline, Zafirlukast, Bromotheophylline", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45513, "ingredient1": "Blinatumomab", "ingredient2": "Tioguanine", "severity": "Moderate", "effect": "The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45583/", "reference_text": "[1] \"Product Information. Aubagio (teriflunomide).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Tabloid (thioguanine).\" Prasco Laboratories, Cincinnati, OH.", "alternatives_a": "Fluorouracil, Pemetrexed, Mercaptopurine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45514, "ingredient1": "Blinatumomab", "ingredient2": "Tofacitinib", "severity": "Major", "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45584/", "reference_text": "[1] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45515, "ingredient1": "Blinatumomab", "ingredient2": "Topotecan", "severity": "Moderate", "effect": "The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe neutropenia and neutropenic sepsis resulting in death were reported with topotecan and cisplatin.", "source": "DDInter", "management_text": "Caution is advised if topotecan is used with other cytotoxic agents. Dosage reductions may be required, and bone marrow function should be closely monitored. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, or signs of infection such as fever, chills, sore throat, body aches, and other influenza-like symptoms.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if topotecan is used with other cytotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45585/", "reference_text": "[1] \"Product Information. Hycamtin (topotecan).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45516, "ingredient1": "Blinatumomab", "ingredient2": "Trabectedin", "severity": "Moderate", "effect": "Coadministration of trabectedin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Monitoring of alkaline phosphatase, bilirubin, AST, and ALT should occur regularly during trabectedin treatment in accordance with the product labeling, or as often as necessary when clinical symptoms develop.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when trabectedin is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45586/", "reference_text": "[1] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Yondelis (trabectedin).\" Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45517, "ingredient1": "Blinatumomab", "ingredient2": "Trichophyton mentagrophytes", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45587/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45518, "ingredient1": "Blinatumomab", "ingredient2": "Tuberculin purified protein derivative", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45588/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45519, "ingredient1": "Blinatumomab", "ingredient2": "Typhoid vaccine (inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45589/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45520, "ingredient1": "Blinatumomab", "ingredient2": "Typhoid vaccine (live)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45590/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45521, "ingredient1": "Blinatumomab", "ingredient2": "Upadacitinib", "severity": "Major", "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.", "source": "DDInter", "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.", "mechanism_text": "Others", "recommendation": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45591/", "reference_text": "[1] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC, North Chicago, IL.", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "updated_at": 1767369485}, {"id": 45522, "ingredient1": "Blinatumomab", "ingredient2": "Ustekinumab", "severity": "Moderate", "effect": "The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.", "mechanism_text": "Others", "recommendation": "Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45592/", "reference_text": "[1] \"Product Information. Stelara (ustekinumab).\" Centocor Inc, Malvern, PA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "updated_at": 1767369485}, {"id": 45523, "ingredient1": "Blinatumomab", "ingredient2": "Valganciclovir", "severity": "Moderate", "effect": "The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or nephrotoxicity due to both additive pharmacodynamic effects and additive effects on the kidney. Ganciclovir alone may cause severe leucopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow depression, aplastic anemia, increased serum creatinine levels, and acute renal failure, and the risk may theoretically increase when coadministered with other myelotoxic or nephrotoxic therapy.", "source": "DDInter", "management_text": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks. Extreme caution is advised if they are used in patients who have recently received or are receiving treatment with myelotoxic and/or nephrotoxic drugs, and vice versa. If coadministration is required, reduced dosages of one or more of the drugs may be required, and the patient should be monitored for the development of hematologic and/or renal adverse effects both during and after discontinuation of therapy.", "mechanism_text": "Synergism", "recommendation": "Ganciclovir or its prodrug, valganciclovir, should generally not be combined with other drugs associated with myelosuppression and/or nephrotoxicity unless the benefits are anticipated to outweigh the potential risks.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45593/", "reference_text": "[1] \"Product Information. Valcyte (valganciclovir)\" Roche Laboratories, Nutley, NJ.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[5] \"Product Information. Cytovene (ganciclovir).\" Genentech, South San Francisco, CA.[6] Jung D, Griffy K, Dorr A \"Effect of food on high-dose oral ganciclovir disposition in HIV-positive subjects.\" J Clin Pharmacol 39 (1999): 161-5[7] Lavelle J, Follansbee S, Trapnell CB, Buhles WC, Griffy KG, Jung D, Dorr A, Conner J \"Effect of food on the relative bioavailability of oral ganciclovir.\" J Clin Pharmacol 36 (1996): 238-41", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "Pertuzumab, Cetuximab, Olaratumab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45524, "ingredient1": "Blinatumomab", "ingredient2": "Varicella Zoster Vaccine (Recombinant)", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45594/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45525, "ingredient1": "Blinatumomab", "ingredient2": "Vinblastine", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45595/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45526, "ingredient1": "Blinatumomab", "ingredient2": "Vincristine", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45596/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45527, "ingredient1": "Blinatumomab", "ingredient2": "Vincristine (liposome)", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45597/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45528, "ingredient1": "Blinatumomab", "ingredient2": "Vinorelbine", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45598/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Cabazitaxel, Paclitaxel, Teniposide, Irinotecan, Etoposide, Docetaxel", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45529, "ingredient1": "Blinatumomab", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Coadministration with blinatumomab may increase the plasma concentrations of drugs that are substrates of CYP450 isoenzymes. Initiation of blinatumomab treatment causes transient release of cytokines that may suppress CYP450 enzymes, although the potential for interaction has not been studied.", "source": "DDInter", "management_text": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics. Clinical and laboratory monitoring are recommended following the initiation of blinatumomab, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when blinatumomab is prescribed to patients receiving drugs that are metabolized by CYP450 isoenzymes, particularly those with a narrow therapeutic index such as carbamazepine, colchicine, cyclosporine, disopyramide, phenytoin, quinidine, theophylline, warfarin, macrolide immunosuppressants, vinca alkaloids, and some narcotic analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45599/", "reference_text": "[1] \"Product Information. Blincyto (blinatumomab).\" Amgen USA, Thousand Oaks, CA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 45530, "ingredient1": "Blinatumomab", "ingredient2": "Yellow Fever Vaccine", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45600/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Cetuximab, Avelumab, Trastuzumab emtansine, Panitumumab, Ipilimumab, Necitumumab, Bevacizumab, Dostarlimab, Amivantamab, Ramucirumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45531, "ingredient1": "Anisindione", "ingredient2": "Ginger", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45601/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45532, "ingredient1": "Anistreplase", "ingredient2": "Ginger", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45602/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45533, "ingredient1": "Ginger", "ingredient2": "Ardeparin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45603/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45534, "ingredient1": "Ginger", "ingredient2": "Argatroban", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45604/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45535, "ingredient1": "Calcium Phosphate", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45605/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45536, "ingredient1": "Calcium Phosphate", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45606/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45537, "ingredient1": "Calcium Phosphate", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45607/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Ascorbic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45538, "ingredient1": "Calcium Phosphate", "ingredient2": "Burosumab", "severity": "Major", "effect": "Concomitant use of burosumab with oral phosphate and/or active vitamin D analogs may increase the risk of hyperphosphatemia and hypervitaminosis D due to additive pharmacologic effects. Increases in serum phosphorus to above the upper limit of normal may be associated with an increased risk of nephrocalcinosis.", "source": "DDInter", "management_text": "Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment. Fasting serum phosphorus concentration should be below the reference range for age prior to initiation of treatment.", "mechanism_text": "Synergism", "recommendation": "Oral phosphate and active vitamin D analogs should be discontinued one week prior to initiation of burosumab treatment.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45608/", "reference_text": "[1] \"Product Information. Crysvita (burosumab).\" Ultragenyx Pharmaceutical, Novato, CA.", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium carbonate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium carbonate, Calcium acetate", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Romosozumab, Zoledronic acid, Pamidronic acid", "updated_at": 1767369485}, {"id": 45539, "ingredient1": "Butabarbital", "ingredient2": "Pyridoxine", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45609/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 45540, "ingredient1": "Butalbital", "ingredient2": "Pyridoxine", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45610/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 45541, "ingredient1": "Calcium Phosphate", "ingredient2": "Calcipotriol (topical)", "severity": "Moderate", "effect": "Elevations in serum calcium levels have been observed in patients treated with topical vitamin D analogs. Concomitant use with systemic vitamin D products, calcium supplements, or other agents that can increase serum calcium concentrations such as thiazide diuretics, estrogens, anabolic steroids, and parathyroid hormone or parathyroid hormone analogs may increase the risk of clinically significant hypercalcemia.", "source": "DDInter", "management_text": "Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.", "mechanism_text": "Synergism", "recommendation": "Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45611/", "reference_text": "[1] \"Product Information. Dovonex (calcipotriene).\" Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.[2] \"Product Information. Vectical (calcitriol topical).\" Galderma Laboratories Inc, Cranbury, NJ.", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Calcitriol, Methoxsalen", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45542, "ingredient1": "Calcium Phosphate", "ingredient2": "Calcitriol (topical)", "severity": "Moderate", "effect": "Elevations in serum calcium levels have been observed in patients treated with topical vitamin D analogs. Concomitant use with systemic vitamin D products, calcium supplements, or other agents that can increase serum calcium concentrations such as thiazide diuretics, estrogens, anabolic steroids, and parathyroid hormone or parathyroid hormone analogs may increase the risk of clinically significant hypercalcemia.", "source": "DDInter", "management_text": "Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.", "mechanism_text": "Synergism", "recommendation": "Calcium and vitamin D status should be monitored closely when topical vitamin D analogs are used in combination with systemic vitamin D products or other agents that can increase serum calcium levels.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45612/", "reference_text": "[1] \"Product Information. Dovonex (calcipotriene).\" Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.[2] \"Product Information. Vectical (calcitriol topical).\" Galderma Laboratories Inc, Cranbury, NJ.", "alternatives_a": "Tazarotene, Calcipotriol, Trioxsalen, Calcitriol, Methoxsalen, Ergocalciferol, Beta carotene, Vitamin A, Cholecalciferol, Dihydrotachysterol, Calcitriol, Calcifediol", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45543, "ingredient1": "Ginger", "ingredient2": "Cangrelor", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45613/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45544, "ingredient1": "Ginger", "ingredient2": "Caplacizumab", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45614/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45545, "ingredient1": "Carteolol", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45615/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45546, "ingredient1": "Carvedilol", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45616/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol, Acetylsalicylic acid, Ivabradine", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45547, "ingredient1": "Chlorothiazide", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45617/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45548, "ingredient1": "Chlorthalidone", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45618/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45549, "ingredient1": "Cinoxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45619/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45550, "ingredient1": "Ciprofloxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45620/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Polymyxin B, Chloramphenicol, More", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45551, "ingredient1": "Ginger", "ingredient2": "Clopidogrel", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45621/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45552, "ingredient1": "Ginger", "ingredient2": "Crizotinib", "severity": "Moderate", "effect": "Limited data suggests that coadministration with ginger may increase the plasma concentrations and the risk of toxicity of crizotinib. The proposed mechanism, based on in vitro data, may be attributed to decreased clearance due to ginger-mediated inhibition of CYP450 3A4 and/or P-glycoprotein (P-gp).", "source": "DDInter", "management_text": "Until more information is available, caution is advised when ginger is used concomitantly with crizotinib. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for crizotinib whenever ginger is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised when ginger is used concomitantly with crizotinib.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45622/", "reference_text": "[1] Revol B, Guitier-Veyret E, Arrive C, et.al \"Pharmacokinetic herb-drug interaction between ginger and crizotinib. Available from: URL: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.13862\" Br J Clin Pharmacol 0 (2019): [epub ahead of print][2] Kimura Y, Ito H, Hatano T \"Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity.\" Biol Pharm Bull 33 (2010): 1977-82[3] \"Product Information. Xalkori (crizotinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[7] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[12] Cerner Multum, Inc. \"Australian Product Information.\" O 0[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45553, "ingredient1": "Ginger", "ingredient2": "Dalteparin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45623/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45554, "ingredient1": "Ginger", "ingredient2": "Danaparoid", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45624/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45555, "ingredient1": "Deferiprone", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use with foods, mineral supplements, or antacids that contain polyvalent cations has not been studied.", "source": "DDInter", "management_text": "A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "A minimum 4-hour interval is recommended between the administration of deferiprone and mineral supplements or oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45625/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45556, "ingredient1": "Ginger", "ingredient2": "Defibrotide", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45626/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45557, "ingredient1": "Delafloxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45627/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45558, "ingredient1": "Demeclocycline", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45628/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tigecycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Chloramphenicol, Rifaximin, Gentamicin, Amikacin, Neomycin", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45559, "ingredient1": "Ginger", "ingredient2": "Dicoumarol", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45629/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45560, "ingredient1": "Digitoxin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Excessive administration of calcium can aggravate digitalis toxicity and precipitate serious cardiac arrhythmias in digitalised patients. The mechanism probably involves additive or synergistic inotropic effects of calcium and digitalis glycosides on the myocardium.", "source": "DDInter", "management_text": "Caution is advised if calcium preparations are used in patients receiving digitalis glycosides. Patients should be advised not to exceed the calcium dosage prescribed for them and to consult their healthcare provider before consuming additional products that may contain substantial amounts of calcium (e.g., over-the-counter supplements).", "mechanism_text": "Synergism", "recommendation": "Caution is advised if calcium preparations are used in patients receiving digitalis glycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45630/", "reference_text": "[1] \"Product Information. PhosLo (calcium acetate)\" Braintree, Braintree, MA.[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Ascorbic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45561, "ingredient1": "Digoxin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Excessive administration of calcium can aggravate digitalis toxicity and precipitate serious cardiac arrhythmias in digitalised patients. The mechanism probably involves additive or synergistic inotropic effects of calcium and digitalis glycosides on the myocardium.", "source": "DDInter", "management_text": "Caution is advised if calcium preparations are used in patients receiving digitalis glycosides. Patients should be advised not to exceed the calcium dosage prescribed for them and to consult their healthcare provider before consuming additional products that may contain substantial amounts of calcium (e.g., over-the-counter supplements).", "mechanism_text": "Synergism", "recommendation": "Caution is advised if calcium preparations are used in patients receiving digitalis glycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45631/", "reference_text": "[1] \"Product Information. PhosLo (calcium acetate)\" Braintree, Braintree, MA.[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Ascorbic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45562, "ingredient1": "Diltiazem", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45632/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Procaine, Prednisolone, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45563, "ingredient1": "Ginger", "ingredient2": "Edoxaban", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45633/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45564, "ingredient1": "Eltrombopag", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly reduce the gastrointestinal absorption of eltrombopag due to chelation.", "source": "DDInter", "management_text": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution), aluminum, calcium, iron, magnesium, zinc or other polyvalent cations.", "mechanism_text": "Absorption", "recommendation": "Eltrombopag should be taken on an empty stomach at least 2 hours before or 4 hours after oral medications that contain antacids (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45634/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Promacta (eltrombopag).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45565, "ingredient1": "Enoxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45635/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45566, "ingredient1": "Ginger", "ingredient2": "Enoxaparin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45636/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45567, "ingredient1": "Ginger", "ingredient2": "Eptifibatide", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45637/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45568, "ingredient1": "Erdafitinib", "ingredient2": "Calcium Phosphate", "severity": "Major", "effect": "Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be related to the pharmacodynamic effects of fibroblast growth factor receptor (FGFR) inhibition by erdafitinib. Inhibition of the FGFR receptor has been shown to lead to an increase in serum phosphate levels.", "source": "DDInter", "management_text": "The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels. After the initial dose increase period, an oral phosphate binder may be appropriate in the management of patients with serum phosphate levels greater than 7 mg/dL. If concomitant use with agents known to increase serum phosphate levels is required after this initial dose increase period, close monitoring of patient tolerability and serum phosphate levels is recommended.", "mechanism_text": "Others", "recommendation": "The manufacturer recommends that concomitant use of erdafitinib with agents that may alter serum phosphate levels be avoided before its initial dose increase period, which is between days 14 to 21 of starting erdafitinib therapy and is based on serum phosphate levels.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45638/", "reference_text": "[1] \"Product Information. Balversa (erdafitinib).\" Janssen Products, LP, Horsham, PA.", "alternatives_a": "Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Ascorbic acid, Calcium chloride", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 45569, "ingredient1": "Folic acid", "ingredient2": "Eslicarbazepine", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45639/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45570, "ingredient1": "Estramustine", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral calcium containing products may significantly decrease serum concentrations of estramustine. The mechanism of the interaction is not known.", "source": "DDInter", "management_text": "Estramustine should be taken at least 1 hour before or 2 hours after meals, milk, or calcium containing products.", "mechanism_text": "Others", "recommendation": "Estramustine should be taken at least 1 hour before or 2 hours after meals, milk, or calcium containing products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45640/", "reference_text": "[1] \"Product Information. Emcyt (estramustine).\" Pharmacia and Upjohn, Kalamazoo, MI.[2] \"Product Information. Emcyt (estramustine).\" Pharmacia and Upjohn, Kalamazoo, MI.[3] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45571, "ingredient1": "Folic acid", "ingredient2": "Ethosuximide", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45641/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45572, "ingredient1": "Folic acid", "ingredient2": "Ethotoin", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45642/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45573, "ingredient1": "Etidronic acid", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45643/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45574, "ingredient1": "Ginger", "ingredient2": "Everolimus", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.", "source": "DDInter", "management_text": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.", "mechanism_text": "Absorption", "recommendation": "The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45644/", "reference_text": "[1] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] \"Product Information. Mavyret (glecaprevir-pibrentasvir).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45575, "ingredient1": "Folic acid", "ingredient2": "Felbamate", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45645/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45576, "ingredient1": "Felodipine", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45646/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Celecoxib, Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45577, "ingredient1": "Folic acid", "ingredient2": "Fluorouracil", "severity": "Major", "effect": "Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although enhancement of 5-FU cytotoxicity may be used to advantage in some cancer patients, increased toxicity should also be considered. Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly leucovorin and fluorouracil.", "source": "DDInter", "management_text": "Caution is advised if 5-FU or any of its prodrugs (e.g., capecitabine, tegafur) are prescribed in combination with leucovorin. A lower dosage of 5-FU or the prodrug may be required. Therapy with leucovorin and fluorouracil should not be initiated or continued in patients with symptoms of gastrointestinal toxicity until such symptoms have resolved. Closely monitor patients with diarrhea until it resolves. Monitor for other potential toxicities of 5-FU such as neutropenia, thrombocytopenia, stomatitis, cutaneous reactions, and neuropathy. Patients should be instructed to avoid taking folic acid supplementation or multivitamin preparations containing folic acid without first speaking with their physician.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if 5-FU or any of its prodrugs (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45647/", "reference_text": "[1] Clippe C, Freyer G, Milano G, Trillet-Lenoir V \"Lethal toxicity of capecitabine due to abusive folic acid prescription?\" Clin Oncol (R Coll Radiol) 15 (2003): 299-300[2] \"Product Information. Xeloda (capecitabine).\" Roche Laboratories, Nutley, NJ.[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[5] Nobile MT, Rosso R, Sertoli MR, Rubagotti A, Vidili MG, Guglielmi A, Venturini M, Canobbio L, Fassio T, Gallo L, et al \"Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.\" Eur J Cancer 28a (1992): 1823-7[6] Schalhorn A, Kuhl M \"Clinical pharmacokinetics of fluorouracil and folinic acid.\" Semin Oncol 19 (1992): 82-92[7] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[8] Mainwaring P, Grygiel JJ \"Interaction of 5-fluorouracil with folates.\" Aust N Z J Med 25 (1995): 60[9] \"Product Information. Khapzory (LEVOleucovorin (levoleucovorin)).\" Acrotech Biopharma LLC, East Windsor, NJ.", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Cladribine, Clofarabine, Trifluridine, Floxuridine, Nelarabine, Pralatrexate, Decitabine, Azacitidine, Tioguanine", "updated_at": 1767369485}, {"id": 45578, "ingredient1": "Ginger", "ingredient2": "Fondaparinux", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45648/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45579, "ingredient1": "Fosphenytoin", "ingredient2": "Folic acid", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45649/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45580, "ingredient1": "Gatifloxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45650/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45581, "ingredient1": "Gemifloxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45651/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45582, "ingredient1": "Grepafloxacin", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45652/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45583, "ingredient1": "Heparin", "ingredient2": "Ginger", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45653/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa, Pentosan polysulfate, Ascorbic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45584, "ingredient1": "Hydroflumethiazide", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45654/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45585, "ingredient1": "Ibandronate", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45655/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45586, "ingredient1": "Indapamide", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45656/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Tamsulosin, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45587, "ingredient1": "Isradipine", "ingredient2": "Calcium Phosphate", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45657/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Celecoxib", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45588, "ingredient1": "Calcium Phosphate", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45658/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45589, "ingredient1": "Folic acid", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45659/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45590, "ingredient1": "Ginger", "ingredient2": "Lepirudin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45660/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45591, "ingredient1": "Calcium Phosphate", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45661/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Celecoxib", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45592, "ingredient1": "Pyridoxine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Pyridoxine doses of 5 mg/day or more antagonise the effects of levodopa. In the presence of pyridoxine, the peripheral metabolism of levodopa to dopamine is increased, resulting in less levodopa available to enter the CNS. The dopa-decarboxylase inhibitors carbidopa and benserazide reduce the peripheral metabolism of levodopa, even in the presence of high concentrations of pyridoxine, allowing more levodpa to enter the CNS.", "source": "DDInter", "management_text": "The concomitant use of pyridoxine and levodopa without dopa-decarboxylase inhibitors should be avoided. Patients should be advised against taking pyridoxine-containing vitamin supplements.", "mechanism_text": "Antagonism", "recommendation": "The concomitant use of pyridoxine and levodopa without dopa-decarboxylase inhibitors should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45662/", "reference_text": "[1] \"Product Information. Diclectin (doxylamine-pyridoxine).\" Duchesnay Inc, Laval, IN.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[6] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[7] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[9] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[12] Cerner Multum, Inc. \"Australian Product Information.\" O 0[13] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[14] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, More", "alternatives_b": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More", "updated_at": 1767369485}, {"id": 45593, "ingredient1": "Calcium Phosphate", "ingredient2": "Levofloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45663/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Sucralfate, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45594, "ingredient1": "Calcium Phosphate", "ingredient2": "Levothyroxine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of calcium-containing products may decrease the oral bioavailability of levothyroxine by one-third in some patients. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to calcium at acidic pH levels, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45664/", "reference_text": "[1] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[2] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[13] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Calcium glucoheptonate, Ascorbic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45595, "ingredient1": "Calcium Phosphate", "ingredient2": "Liothyronine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of calcium-containing products may decrease the oral bioavailability of levothyroxine by one-third in some patients. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to calcium at acidic pH levels, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45665/", "reference_text": "[1] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[2] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[13] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45596, "ingredient1": "Calcium Phosphate", "ingredient2": "Liotrix", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of calcium-containing products may decrease the oral bioavailability of levothyroxine by one-third in some patients. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to calcium at acidic pH levels, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45666/", "reference_text": "[1] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[2] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[13] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45597, "ingredient1": "Calcium Phosphate", "ingredient2": "Lomefloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45667/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45598, "ingredient1": "Ginger", "ingredient2": "Lurbinectedin", "severity": "Moderate", "effect": "Coadministration with a CYP450 3A4 inhibitor may increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity.", "source": "DDInter", "management_text": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin. Patients should be advised to contact their physician if they experience symptoms suggestive of myelosuppression or hepatotoxicity, such as fever or any other signs of infection, unusual bruising or bleeding; or nausea or vomiting, or pain on the right side of the abdomen.", "mechanism_text": "Metabolism", "recommendation": "Clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with lurbinectedin.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45668/", "reference_text": "[1] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[3] \"Product Information. Zepzelca (lurbinectedin).\" Jazz Pharmaceuticals, Palo Alto, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45599, "ingredient1": "Ginger", "ingredient2": "Lusutrombopag", "severity": "Moderate", "effect": "Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.", "source": "DDInter", "management_text": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.", "mechanism_text": "Distribution", "recommendation": "Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45669/", "reference_text": "[1] EMA. European Medicines Agency. European Union \"EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852\" ([2013 - ]):", "alternatives_a": "Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45600, "ingredient1": "Folic acid", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45670/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45601, "ingredient1": "Folic acid", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45671/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45602, "ingredient1": "Pyridoxine", "ingredient2": "Methohexital", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45672/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 45603, "ingredient1": "Folic acid", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of methotrexate with vitamin preparations containing folic acid, folinic acid (leucovorin) or their derivatives may diminish the therapeutic effects of methotrexate. The proposed mechanism involves pharmacodynamic antagonism and/or competitive inhibition at the receptor site.", "source": "DDInter", "management_text": "Although folic acid or folinic acid are frequently used along with methotrexate to reduce adverse effects or as an antidote to high dose methotrexate therapy, patients receiving methotrexate should be advised to avoid the inadvertent use of vitamin preparations containing folic acid or its derivatives.", "mechanism_text": "Antagonism", "recommendation": "Although folic acid or folinic acid are frequently used along with methotrexate to reduce adverse effects or as an antidote to high dose methotrexate therapy, patients receiving methotrexate should be advised to avoid the inadvertent use of vitamin preparations containing folic acid or its derivatives.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45673/", "reference_text": "[1] \"Product Information. Methotrexate Sodium (methotrexate).\" Teva Pharmaceuticals (formerly IVAX), Miami, FL.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45604, "ingredient1": "Folic acid", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45674/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45605, "ingredient1": "Calcium Phosphate", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45675/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Furosemide, Bumetanide, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45606, "ingredient1": "Calcium Phosphate", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45676/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45607, "ingredient1": "Calcium Phosphate", "ingredient2": "Minocycline", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45677/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Clindamycin, Vitamin A, Isotretinoin, Dexamethasone, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Methylprednisolone, Azelaic acid, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45608, "ingredient1": "Calcium Phosphate", "ingredient2": "Moxifloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45678/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45609, "ingredient1": "Calcium Phosphate", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45679/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45610, "ingredient1": "Calcium Phosphate", "ingredient2": "Nalidixic acid", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of nalidixic acid. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of nalidixic acid by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, nalidixic acid should be dosed at least 2 hours before or 2 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45680/", "reference_text": "[1] \"Product Information. NegGram (nalidixic acid).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45611, "ingredient1": "Calcium Phosphate", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45681/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Sacubitril, Aliskiren, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45612, "ingredient1": "Calcium Phosphate", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45682/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Celecoxib", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45613, "ingredient1": "Calcium Phosphate", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45683/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Celecoxib", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45614, "ingredient1": "Calcium Phosphate", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45684/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Celecoxib", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45615, "ingredient1": "Ginger", "ingredient2": "Nitisinone", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.", "source": "DDInter", "management_text": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45685/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[60] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[66] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45616, "ingredient1": "Calcium Phosphate", "ingredient2": "Norfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45686/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45617, "ingredient1": "Calcium Phosphate", "ingredient2": "Ofloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45687/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Fluconazole, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Rifamycin, Kanamycin, More", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45618, "ingredient1": "Calcium Phosphate", "ingredient2": "Omadacycline", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45688/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Ascorbic acid", "alternatives_b": "Tigecycline, Eravacycline", "updated_at": 1767369485}, {"id": 45619, "ingredient1": "Ginger", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors. Dosage adjustments may be required based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is coadministered with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45689/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc, Lebanon, NJ.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Ketoconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45620, "ingredient1": "Folic acid", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45690/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45621, "ingredient1": "Calcium Phosphate", "ingredient2": "Oxytetracycline", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45691/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Tigecycline, Eravacycline, Rifamycin, Kanamycin, Ampicillin, Azithromycin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45622, "ingredient1": "Folic acid", "ingredient2": "Pancrelipase", "severity": "Moderate", "effect": "Exogenous pancreatic enzymes may interfere with the gastrointestinal absorption of folic acid and iron. The exact mechanism of interaction is unknown.", "source": "DDInter", "management_text": "Patients receiving therapeutic iron or folate therapy should be monitored for potentially reduced hematologic response if pancreatic enzymes are administered concomitantly. Separating the times of administration may be helpful.", "mechanism_text": "Absorption", "recommendation": "Patients receiving therapeutic iron or folate therapy should be monitored for potentially reduced hematologic response if pancreatic enzymes are administered concomitantly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45692/", "reference_text": "[1] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[2] \"Product Information. Cotazym (pancrelipase).\" Organon, West Orange, NJ.[3] Dietze F, Bruschke G \"Inhibition of iron absorption by pancreatic extracts.\" Lancet 1 (1970): 424[4] Zempsky WT, Rosenstein BJ, Carroll JA, Oski FA \"Effect of pancreatic enzyme supplements on iron absorption.\" Am J Dis Child 143 (1989): 969-72", "alternatives_a": "Glutamic acid, Citric acid", "alternatives_b": "Iron sucrose, Cyanocobalamin, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Tolbutamide, Inulin, Hexaminolevulinate, Secretin human, Galactose, More", "updated_at": 1767369485}, {"id": 45623, "ingredient1": "Calcium Phosphate", "ingredient2": "Patiromer", "severity": "Moderate", "effect": "INTERVAL: Simultaneous administration of cation-donating preparations may reduce the potassium exchange capability of cation-exchange resins due to binding of the cation to the resin.", "source": "DDInter", "management_text": "Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.g., mineral supplements; antacids; products containing antacids such as didanosine buffered tablets or pediatric oral solution) by several hours if possible.", "mechanism_text": "Others", "recommendation": "Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45693/", "reference_text": "[1] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[2] \"Product Information. Resonium Calcium (calcium polystyrene sulfonate).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[3] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45624, "ingredient1": "Calcium Phosphate", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45694/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45625, "ingredient1": "Calcium Phosphate", "ingredient2": "Penicillamine", "severity": "Moderate", "effect": "INTERVAL: Oral administration of aluminum, copper, iron, zinc, magnesium, and possibly other minerals such as calcium may decrease the gastrointestinal absorption of penicillamine, and vice versa. The proposed mechanism involves chelation of penicillamine to polyvalent cations, which leads to formation of a nonabsorbable complex.", "source": "DDInter", "management_text": "Mineral supplements or other products containing polyvalent cations (e.g., antacids or preparations containing antacids such as didanosine buffered tablets or pediatric oral solution) should be administered at least two hours before or two hours after the penicillamine dose. In addition, pharmacologic response to penicillamine should be monitored more closely whenever these products are added to or withdrawn from therapy, and the penicillamine dosage adjusted as necessary.", "mechanism_text": "Absorption", "recommendation": "Mineral supplements or other products containing polyvalent cations (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45695/", "reference_text": "[1] Lyle WH \"Penicillamine and iron.\" Lancet 2 (1976): 420[2] \"Product Information. Cuprimine (penicillamine).\" Merck & Co, Inc, West Point, PA.[3] Netter P, Bannwarth B, Pere P, Nicolas A \"Clinical pharmacokinetics of D-penicillamine.\" Clin Pharmacokinet 13 (1987): 317-33[4] Haagsma CJ \"Clinically important drug interactions with disease-modifying antirheumatic drugs.\" Drugs Aging 13 (1998): 281-9[5] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[6] Joyce DA \"D-penicillamine pharmacokinetics and pharmacodynamics in man.\" Pharmacol Ther 42 (1989): 405-27[7] Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG \"Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate.\" Clin Pharmacol Ther 33 (1983): 465-70[8] Harkness JA, Blake DR \"Penicillamine nephropathy and iron.\" Lancet 2 (1982): 1368-9[9] Osman MA, Patel RB, Schuna A, Sundstrom WR, Welling PG \"Reduction in oral penicillamine absorption by food, antacid and ferrous sulfate.\" Clin Pharmacol Ther 33 (1983): 465-70[10] \"Product Information. Cuprimine (penicillamine).\" Merck & Co, Inc, West Point, PA.[11] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67", "alternatives_a": "Auranofin, Aurothioglucose, Sodium aurothiomalate", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45626, "ingredient1": "Pyridoxine", "ingredient2": "Pentobarbital", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45696/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 45627, "ingredient1": "Folic acid", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45697/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45628, "ingredient1": "Folic acid", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45698/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45629, "ingredient1": "Calcium Phosphate", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45699/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45630, "ingredient1": "Calcium Phosphate", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45700/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45631, "ingredient1": "Ginger", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of pralsetinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors. Monitor closely for adverse effects whenever a CYP450 3A4 inhibitor is added to therapy. Alternative treatments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pralsetinib is used with CYP450 3A inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45701/", "reference_text": "[1] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation, Cambridge, MA.", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45632, "ingredient1": "Ginger", "ingredient2": "Prasugrel", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45702/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45633, "ingredient1": "Folic acid", "ingredient2": "Primidone", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45703/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, More", "alternatives_b": "Suvorexant, Methohexital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, Ramelteon, More", "updated_at": 1767369485}, {"id": 45634, "ingredient1": "Calcium Phosphate", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45704/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Esmolol", "alternatives_b": "Calcium glucoheptonate", "updated_at": 1767369485}, {"id": 45635, "ingredient1": "Folic acid", "ingredient2": "Pyrimethamine", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45705/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil", "updated_at": 1767369485}, {"id": 45636, "ingredient1": "Ginger", "ingredient2": "Reteplase", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45706/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45637, "ingredient1": "Ginger", "ingredient2": "Rilpivirine", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of rilpivirine, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring may be advisable if CYP450 3A4 inhibitors are coadministered with rilpivirine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45707/", "reference_text": "[1] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[2] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Edurant (rilpivirine).\" Tibotec Pharmaceuticals, Titusville, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45638, "ingredient1": "Ginger", "ingredient2": "Ripretinib", "severity": "Moderate", "effect": "Coadministration of CYP450 3A4 inhibitors with ripretinib may increase the plasma concentrations and the risk of adverse effects (e.g., palmar-plantar erythrodysesthesia, hypertension, cardiac dysfunction, arthralgia/myalgia) of ripretinib and its active metabolite (DP-5439). The proposed mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of ripretinib and DP-5439.", "source": "DDInter", "management_text": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor. Clinical and laboratory monitoring should be considered whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when ripretinib is used concomitantly with a CYP450 3A4 inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45708/", "reference_text": "[1] Cerner Multum, Inc. \"Australian Product Information.\" O 0[2] \"Product Information. Qinlock (ripretinib).\" Deciphera Pharmaceuticals, Waltham, MA.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[5] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[12] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[13] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[14] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[15] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[17] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[18] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[19] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[20] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[21] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[22] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[23] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[29] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[30] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[31] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[32] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[33] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[34] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45639, "ingredient1": "Ginger", "ingredient2": "Rivaroxaban", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45709/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45640, "ingredient1": "Folic acid", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair folate absorption and increase the metabolism of circulating folate. Coadministration with folate therapy may reduce the anticonvulsant effects of phenytoin, phenobarbital, primidone, and succinimides. The exact mechanism of interaction is unknown. Available data pertain primarily to phenytoin.", "source": "DDInter", "management_text": "Caution is advised when folate therapy is coadministered with anticonvulsants. Close monitoring for clinical and laboratory evidence of diminished therapeutic response to both treatments is recommended. Patients should be advised to notify their physician if they experience loss of seizure control.", "mechanism_text": "Antagonism", "recommendation": "Caution is advised when folate therapy is coadministered with anticonvulsants.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45710/", "reference_text": "[1] Furlanut M, Benetello P, Avogaro A, Dainese R \"Effects of folic acid on phenytoin kinetics in healthy subjects.\" Clin Pharmacol Ther 24 (1978): 294-7[2] Katz M \"Potential danger of self-medication with folic acid.\" N Engl J Med 289 (1973): 1095[3] Berg MJ, Fischer LJ, Rivey MP, Vern BA, Lantz RK, Schottelius DD \"Phenytoin and folic acid interaction: a preliminary report.\" Ther Drug Monit 5 (1983): 389-94[4] Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M \"Phenytoin-folic acid interaction: A lesson to be learned.\" Clin Neuropharmacol 22 (1999): 268-72[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Ch'ien LT, Krumdieck CL, Scott CW Jr, Butterworth CE Jr \"Harmful effect of megadoses of vitamins: electroencephalogram abnormalities and seizures induced by intravenous folate in drug- treated epileptics.\" Am J Clin Nutr 28 (1975): 51-8[7] MacCosbe PE, Toomey K \"Interaction of phenytoin and folic acid.\" Clin Pharm 2 (1983): 362-9[8] Yuen GJ \"Interaction of phenytoin and folic acid: an alternative explanation.\" Clin Pharm 3 (1984): 116,119[9] \"Product Information. Levoleucovorin (levoleucovorin).\" Spectrum Chemical, Gardena, CA.[10] \"Product Information. L-Methylfolate Calcium (l-methylfolate).\" Virtus Pharmaceuticals LLC, Tampa, FL.[11] Carl GF, Smith ML \"Phenytoin-folate interactions: differing effects of the sodium salt and the free acid of phenytoin.\" Epilepsia 33 (1992): 372-5[12] Steinweg DL, Bentley ML \"Seizures following reduction in phenytoin level after orally administered folic acid.\" Neurology 64 (2005): 1982[13] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[14] \"Product Information. Wellcovorin (leucovorin).\" Glaxo Wellcome, Research Triangle Park, NC.[15] Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ \"Phenytoin-folic acid interaction.\" Ann Pharmacother 29 (1995): 726-35[16] Berg MJ, Fincham RW, Ebert BE, Schottelius DD \"Phenytoin pharmacokinetics: before and after folic acid administration.\" Epilepsia 33 (1992): 712-20[17] Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD \"Phenytoin and folic acid: individualized drug-drug interaction.\" Ther Drug Monit 5 (1983): 395-9[18] Veldhorst-Janssen NM, Boersma HH, de Krom MC, van Rijswijk RE \"Oral tegafur/folinic acid chemotherapy decreases phenytoin efficacy.\" Br J Cancer 90 (2004): 745[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[22] Berg MJ, Stumbo PJ, Chenard CA, Fincham RW, Schneider PJ, Schottelius D \"Folic acid improves phenytoin pharmacokinetics.\" J Am Diet Assoc 95 (1995): 352-6[23] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[24] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[25] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[26] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tiagabine, Brivaracetam, Cannabidiol, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Ganaxolone, Phenacemide, Trimethadione, More", "updated_at": 1767369485}, {"id": 45641, "ingredient1": "Calcium Phosphate", "ingredient2": "Sarecycline", "severity": "Moderate", "effect": "INTERVAL: Administration of a tetracycline with aluminum, calcium, or magnesium salts significantly decreases tetracycline serum concentrations. The proposed mechanism is chelation of tetracycline by the cation, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract. The interaction has also been reported with parenteral doxycycline and oral antacids.", "source": "DDInter", "management_text": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "mechanism_text": "Absorption", "recommendation": "The administration of tetracyclines and preparations containing aluminum, magnesium, or calcium should be separated by two to four hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45711/", "reference_text": "[1] Nguyen VX, Nix DE, Gillikin S, Schentag JJ \"Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline.\" Antimicrob Agents Chemother 33 (1989): 434-6[2] Gotz VP, Ryerson GG \"Evaluation of tetracycline on theophylline disposition in patients with chronic obstructive airways disease.\" Drug Intell Clin Pharm 20 (1986): 694-6[3] Upton RA \"Pharmacokinetic interactions between theophylline and other medication (Part I).\" Clin Pharmacokinet 20 (1991): 66-80[4] \"Product Information. Nuzyra (omadacycline).\" Paratek Pharmaceuticals, Inc., Boston, MA.[5] \"Product Information. Seysara (sarecycline).\" Allergan Inc, Irvine, CA.[6] McCormack JP, Reid SE, Lawson LM \"Theophylline toxicity induced by tetracycline.\" Clin Pharm 9 (1990): 546-9[7] Neuvonen PJ \"Interactions with the absorption of tetracyclines.\" Drugs 11 (1976): 45-54[8] D'Arcy PF, McElnay JC \"Drug-antacid interactions: assessment of clinical importance.\" Drug Intell Clin Pharm 21 (1987): 607-17[9] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.[10] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[11] Garty M, Hurwitz A \"Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline.\" Clin Pharmacol Ther 28 (1980): 203-7[12] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[13] Covington TR, Lawson LC, Young LL, eds. \"Handbook of Nonprescription Drugs. 10th ed.\" Washington, DC: American Pharmaceutical Association (1993):[14] \"Product Information. Achromycin (tetracycline).\" Lederle Laboratories, Wayne, NJ.[15] \"Product Information. Declomycin (demeclocycline).\" Lederle Laboratories, Wayne, NJ.", "alternatives_a": "Ascorbic acid", "alternatives_b": "Tigecycline, Eravacycline", "updated_at": 1767369485}, {"id": 45642, "ingredient1": "Secobarbital", "ingredient2": "Pyridoxine", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45712/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Suvorexant, Triazolam, Flurazepam, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Chloral hydrate, Quazepam, Paraldehyde, More", "updated_at": 1767369485}, {"id": 45643, "ingredient1": "Ginger", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of selpercatinib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with CYP450 3A4 inhibitors. Patients should be closely monitored for development of serious adverse effects such as QT interval prolongation, liver transaminase and bilirubin elevations, hypertension, hemorrhage, edema and hypersensitivity reactions (e.g., fever, rash, arthralgias/myalgias with concurrent decreased platelets or transaminitis), and the dosing of selpercatinib adjusted or withheld as necessary in accordance with the product labeling.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with CYP450 3A4 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45713/", "reference_text": "[1] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company, Indianapolis, IN.[3] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Entrectinib, Imatinib, Dabrafenib, Dacomitinib, Pexidartinib, Fedratinib, Larotrectinib, Bosutinib, Vemurafenib, Lapatinib, Selumetinib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45644, "ingredient1": "Calcium Phosphate", "ingredient2": "Tolevamer", "severity": "Moderate", "effect": "INTERVAL: Simultaneous administration of cation-donating preparations may reduce the potassium exchange capability of cation-exchange resins due to binding of the cation to the resin.", "source": "DDInter", "management_text": "Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.g., mineral supplements; antacids; products containing antacids such as didanosine buffered tablets or pediatric oral solution) by several hours if possible.", "mechanism_text": "Others", "recommendation": "Patients should consider separating the times of administration of the cation-exchange resin and any cation-donating preparation (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45714/", "reference_text": "[1] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[2] \"Product Information. Resonium Calcium (calcium polystyrene sulfonate).\" Sanofi-Synthelabo Canada Inc, Markham, ON.[3] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45645, "ingredient1": "Calcium Phosphate", "ingredient2": "Sotalol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45715/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol, Acetylsalicylic acid, Ivabradine", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45646, "ingredient1": "Calcium Phosphate", "ingredient2": "Sparfloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45716/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45647, "ingredient1": "Ginger", "ingredient2": "Streptokinase", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45717/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa, Hemin, Voxelotor, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45648, "ingredient1": "Calcium Phosphate", "ingredient2": "Strontium chloride Sr-89", "severity": "Moderate", "effect": "INTERVAL: Saturation of bone-binding sites by calcium may reduce uptake of strontium-89 chloride.", "source": "DDInter", "management_text": "Calcium-containing preparations should be withheld for 2 weeks before until 2 weeks after administration of strontium-89 chloride.", "mechanism_text": "Distribution", "recommendation": "Calcium-containing preparations should be withheld for 2 weeks before until 2 weeks after administration of strontium-89 chloride.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45718/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[5] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Samarium (153Sm) lexidronam", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45649, "ingredient1": "Folic acid", "ingredient2": "Sulfadiazine", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45719/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 45650, "ingredient1": "Folic acid", "ingredient2": "Sulfadoxine", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45720/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Tinidazole, Ascorbic acid, More", "updated_at": 1767369485}, {"id": 45651, "ingredient1": "Folic acid", "ingredient2": "Sulfamethizole", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45721/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Sorbitol, Sodium citrate, Magnesium citrate, Sodium chloride, Neomycin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, More", "updated_at": 1767369485}, {"id": 45652, "ingredient1": "Folic acid", "ingredient2": "Sulfamethoxazole", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45722/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, More", "alternatives_b": "Capreomycin, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid, More", "updated_at": 1767369485}, {"id": 45653, "ingredient1": "Folic acid", "ingredient2": "Sulfasalazine", "severity": "Minor", "effect": "Sulfasalazine may impair the intestinal absorption and/or metabolism of folic acid to its physiologically useful form. Folate deficiency, sometimes manifested as megaloblastic or macrocytic anemia, has been reported in patients treated chronically with sulfasalazine. However, those patients generally had inflammatory bowel disease or other risk factors for folate deficiency such as celiac disease, rheumatoid arthritis, or nutritional deficiencies. In any case, clinicians should be mindful of the potential interaction with sulfasalazine in patients receiving folic acid supplementation. Those not responding to folic acid may require folinic acid, whose action is not inhibited by sulfasalazine.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism, Absorption", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45723/", "reference_text": "[1] Logan EC, Williamson LM, Ryrie DR \"Sulphasalazine associated pancytopenia may be caused by acute folate deficiency.\" Gut 27 (1986): 868-72[2] Elsborg L, Larsen L \"Folate deficiency in chronic inflammatory bowel diseases.\" Scand J Gastroenterol 14 (1979): 1019-24[3] Swinson C, Perry J, Lumb M, Levi AJ \"Role of sulphasalazine in the aetiology of folate deficiency in ulcerative colitis.\" Gut 22 (1981): 456-61[4] Darcy-Vrillon B, Selhub J, Rosenberg IH \"Analysis of sequential events in intestinal absorption of folylpolyglutamate.\" Am J Physiol 255 (1988): g361-6[5] Hopkinson ND, Garcia FS, Gumpel JM \"Haematological side-effects pf sulphasalazine in inflammatory arthritis.\" Br J Rheumatol 28 (1989): 414-7[6] Spinel E \"Sulfasalazine and folate deficiency.\" JAMA 250 (1983): 900[7] Zimmerman J \"Drug intractions in intestinal transport of folic acid and methotrexate.\" Biochem Pharmacol 44 (1992): 1839-42[8] \"Sulfasalazine inhibits folate absorption.\" Nutr Rev 46 (1988): 320-3[9] Robenberg IH \"Drugs and folic acid absorption.\" Gastroenterology 63 (1972): 353-7[10] Franklin J, Rosenberg HH \"Impaired folic acid absorption in inflammatory bowel disease: effects of salicylazosulfapyridine (Azulfidine).\" Gastroenterology 64 (1973): 517-25[11] Longstreth G, Green R \"Folate status in patients receiving maintenance doses of sulfasalazine.\" Arch Intern Med 143 (1983): 902-4[12] Baum CL, Selhub J, Rosenberg Ihl \"Antifolate actions of sulfasalazine on intact lymphocytes.\" J Lab Clin Med 97 (1981): 779-84[13] Goldberg J \"Sulfasalazine and folate deficiency.\" JAMA 249 (1983): 729[14] Selhub J, Dhar GJ, Rosenberg IH \"Inhibition of folate enzymes by sulfasalazine.\" J Clin Invest 61 (1978): 221-4[15] Halsted CH, Gandhi G, Tamura T \"Sulfasalazine inhibits the absorption of folates in ulcerative colitis.\" N Engl J Med 305 (1981): 1513-7", "alternatives_a": "Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 45654, "ingredient1": "Ginger", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45724/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Lesinurad, Febuxostat, Pegloticase, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45655, "ingredient1": "Folic acid", "ingredient2": "Sulfisoxazole", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45725/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, Darunavir, Ketoconazole, More", "updated_at": 1767369485}, {"id": 45656, "ingredient1": "Ginger", "ingredient2": "Tenecteplase", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45726/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45657, "ingredient1": "Thiopental", "ingredient2": "Pyridoxine", "severity": "Minor", "effect": "One small study has suggested that pyridoxine may decrease serum levels of phenobarbital. The mechanism is unknown. Phenobarbital is the only barbiturate specifically implicated in this interaction. However, other barbiturates may behave in a similar fashion. Close observation for altered barbiturate effects is indicated if these drugs must be used together.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45727/", "reference_text": "[1] Hansson O, Sillanpaa M \"Pyridoxine and serum concentration of phenytoin and phenobarbitone.\" Lancet 1 (1976): 256", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Trimethoprim, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Halothane, Alfentanil, Remifentanil, Sodium oxybate, Isoflurane, Nitrous oxide, Fentanyl, Desflurane, Sufentanil, Propofol, Enflurane, More", "updated_at": 1767369485}, {"id": 45658, "ingredient1": "Calcium Phosphate", "ingredient2": "Thyroid, porcine", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration of calcium-containing products may decrease the oral bioavailability of levothyroxine by one-third in some patients. Pharmacologic effects of levothyroxine may be reduced. The exact mechanism of interaction is unknown but may involve nonspecific adsorption of levothyroxine to calcium at acidic pH levels, resulting in an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours. Monitoring of serum TSH levels is recommended. Patients with gastrointestinal or malabsorption disorders may be at a greater risk of developing clinical or subclinical hypothyroidism due to this interaction.", "mechanism_text": "Absorption", "recommendation": "Some experts recommend separating the times of administration of levothyroxine and calcium-containing preparations by at least 4 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45728/", "reference_text": "[1] Csako G, McGriff NJ, Rotman-Pikielny P, Sarlis NJ, Pucino F \"Exaggerated levothyroxine malabsorption due to calcium carbonate supplementation in gastrointestinal disorders.\" Ann Pharmacother 35 (2001): 1578-83[2] Singh N, Singh PN, Hershman JM \"Effect of calcium carbonate on the absorption of levothyroxine.\" JAMA 283 (2000): 2822-5[3] Neafsey PJ \"Levothyroxine and calcium interaction: timing is everything.\" Home Healthc Nurse 22 (2004): 338-9[4] Schneyer CR \"Calcium carbonate and reduction of levothyroxine efficacy.\" JAMA 279 (1998): 750[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[6] \"Product Information. Armour thyroid (thyroid desiccated).\" Forest Pharmaceuticals, St. Louis, MO.[7] \"Product Information. Synthroid (levothyroxine).\" Abbott Pharmaceutical, Abbott Park, IL.[8] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[9] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[10] Cerner Multum, Inc. \"Australian Product Information.\" O 0[11] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[12] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[13] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45659, "ingredient1": "Ginger", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45729/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45660, "ingredient1": "Ginger", "ingredient2": "Ticlopidine", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45730/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45661, "ingredient1": "Calcium Phosphate", "ingredient2": "Tiludronic acid", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 2 hours before or 2 hours after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45731/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45662, "ingredient1": "Calcium Phosphate", "ingredient2": "Timolol", "severity": "Moderate", "effect": "INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.", "source": "DDInter", "management_text": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.", "mechanism_text": "Absorption", "recommendation": "It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45732/", "reference_text": "[1] Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E \"Interaction of atenolol with furosemide and calcium and aluminum salts.\" Clin Pharmacol Ther 30 (1981): 429-35[2] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub[7] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"", "alternatives_a": "Esmolol, Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45663, "ingredient1": "Ginger", "ingredient2": "Tinzaparin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45733/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45664, "ingredient1": "Ginger", "ingredient2": "Tirofiban", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45734/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45665, "ingredient1": "Folic acid", "ingredient2": "Triamterene", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45735/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Eplerenone, Amiloride, Finerenone", "updated_at": 1767369485}, {"id": 45666, "ingredient1": "Calcium Phosphate", "ingredient2": "Trichlormethiazide", "severity": "Moderate", "effect": "Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.", "source": "DDInter", "management_text": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.", "mechanism_text": "Synergism", "recommendation": "Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45736/", "reference_text": "[1] Drinka PJ, Nolten WE \"Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics.\" J Am Geriatr Soc 32 (1984): 405-7[2] Santos F, Smith MJ, Chan JC \"Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D3). Action of hydrochlorothiazide.\" Am J Dis Child 140 (1986): 139-42[3] Duarte CG, Winnacker JL, Becker KL, Pace A \"Thiazide-induced hypercalcemia.\" N Engl J Med 284 (1971): 828-30[4] Franciosa JA, Pierpont G \"Cardiovascular clinical pharmacology of impedance reducing agents.\" J Chronic Dis 34 (1981): 341-52[5] Parfitt AM \"The interactions of thiazide diuretics with parathyroid hormone and vitamin D. Studies in patients with hypoparathyroidism.\" J Clin Invest 51 (1972): 1879-88[6] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[7] Gora ML, Seth SK, Bay WH, Visconti JA \"Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate.\" Clin Pharm 8 (1989): 227-9[8] Ljunghall S, Backman U, Danielson BG, Fellstrom B, Johansson G, Wikstrom B \"Calcium and magnesium metabolism during long-term treatment with thiazides.\" Scand J Urol Nephrol 15 (1981): 257-62[9] Alon U, Costanzo LS, Chan JC \"Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.\" Miner Electrolyte Metab 10 (1984): 379-86[10] Middler S, Pak CY, Murad F, Bartter FC \"Thiazide diuretics and calcium metabolism.\" Metabolism 22 (1973): 139-46[11] Popovtzer MM, Subryan VL, Alfrey AC, Reeve EB, Schrier RW \"The acute effect of chlorothiazide on serum-ionized calcium. Evidence for a parathyroid hormone-dependent mechanism.\" J Clin Invest 55 (1975): 1295-302[12] Riis B, Christiansen C \"Actions of thiazide on vitamin D metabolism: a controlled therapeutic trial in normal women early in the postmenopause.\" Metabolism 34 (1985): 421-4[13] Parfitt AM \"Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism.\" N Engl J Med 281 (1969): 55-9[14] Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R \"Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy.\" Can Med Assoc J 121 (1979): 591-4[15] Parfitt AM \"Thiazide-induced hypercalcemia in vitamin D-treated hypoparathyroidism.\" Ann Intern Med 77 (1972): 557-63", "alternatives_a": "Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45667, "ingredient1": "Calcium Phosphate", "ingredient2": "Triethylenetetramine", "severity": "Moderate", "effect": "Concurrent oral administration of mineral supplements or mineral-containing products may block the absorption of trientine, and vice versa. The mechanism is trientine chelation of polyvalent metal ions resulting in a nonabsorbable complex.", "source": "DDInter", "management_text": "In general, mineral supplements or mineral-containing products (e.g., antacids) should not be used in patients treated with trientine.", "mechanism_text": "Absorption", "recommendation": "In general, mineral supplements or mineral-containing products (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45737/", "reference_text": "[1] \"Product Information. Syprine (trientine).\" Aton Pharma, Lawrenceville, NJ.[2] \"Product Information. Syprine (trientine).\" Aton Pharma, Lawrenceville, NJ.", "alternatives_a": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Sapropterin, Zinc acetate, Phenylbutyric acid, More", "alternatives_b": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "updated_at": 1767369485}, {"id": 45668, "ingredient1": "Folic acid", "ingredient2": "Trimethoprim", "severity": "Moderate", "effect": "Folate antagonists such as sulfonamides, triamterene, trimethoprim, or pyrimethamine may decrease folic acid serum concentration. The mechanism may be related to inhibition of the enzyme dihydrofolate reductase by the folate antagonists, which converts folic acid into its active tetrahydrofolate form. In addition, it should be noted that folic acid doses greater than 2.5 mg may lead to treatment failure of antifolate antimalarials such as pyrimethamine.", "source": "DDInter", "management_text": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended. This may be especially important for pregnant women taking folic acid to reduce their risk of neural tube defects and in patients with megaloblastic anemia. Folic acid doses greater than 2.5 mg should be avoided in patients receiving pyrimethamine. Patients receiving antifolate antimalarials with folic acid should be monitored for possible treatment failure.", "mechanism_text": "Antagonism", "recommendation": "Monitoring of patient response to folic acid supplementation if they are also taking folate antagonists is recommended.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45738/", "reference_text": "[1] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Mulenga M, Malunga P, Bennett S. et.al \"Folic acid treatment of Zambian children with moderate to severe malaria anemia.\" Am J Trop Med Hyg 74 (2006): 986-90[4] Mbaye A, Richardson K, Balajo B, et.al \"Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.\" Am J Trop Med Hyg 74 (2006): 760-4[5] Nzila A, Okombo J, Molloy AM \"Impact of folate supplementation on the efficacy of sulfadoxine/pyrimethamine in preventing malaria in pregnancy: the potential of 5-methyl-tetrahydrofolate.\" J Antimicrob Chemother 69 (2014): 323-30[6] Carter JY, Loolpapit MP, Lema OE, Tome JL, Nagelkerke NJK, Watkins WM \"Reduction of the efficacy of antifolate antimalarial therapy by folic acid supplementation.\" Am J Trop Med Hyg 73 (2005): 166-70[7] van Eijk AM, Ouma PO, Williamson J, et al. \"Plasma Folate Level and High-Dose Folate Supplementation Predict Sulfadoxine-Pyrimethamine Treatment Failure in Pregnant Women in Western Kenya Who Have Uncomplicated Malaria.\" J Infect Dis 198 (2008): 1550-3[8] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[9] Ouma P, Parise ME, Hamel MJ, et.al \"A randomized controlled trial of folate supplementation when treating malaria in pregnancy with sulfadoxine-pyrimethamine.\" PLoS Clin Trials 1 (2006): e28[10] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[11] Van Hensbroek MB, Morris-Jones S, Meisner S, et.al \"Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria.\" Trans R Soc Trop Med Hyg 89 (1995): 672-6[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Cerner Multum, Inc. \"Australian Product Information.\" O 0[14] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[15] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[16] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[17] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[18] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[19] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[20] Cerner Multum, Inc. \"Australian Product Information.\" O 0[21] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[22] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cyanocobalamin, Iron protein succinylate, Iron, Ferrous gluconate, Ferric maltol, Iron sucrose, Ferrous fumarate, Sorbitol, Caffeine, Edrophonium, Indocyanine green, More", "alternatives_b": "Capreomycin, Rifamycin, Bedaquiline, Rifapentine, Streptomycin, Cycloserine, Rifabutin, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 45669, "ingredient1": "Calcium Phosphate", "ingredient2": "Trovafloxacin", "severity": "Moderate", "effect": "INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics. Absorption may also be reduced by sucralfate, which contains aluminum, as well as other polyvalent cations such as iron and zinc. The mechanism is chelation of quinolones by polyvalent cations, forming a complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "mechanism_text": "Absorption", "recommendation": "When coadministration cannot be avoided, quinolone antibiotics should be dosed either 2 to 4 hours before or 4 to 6 hours after polyvalent cation-containing products to minimize the potential for interaction.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45739/", "reference_text": "[1] Teng R, Dogolo LC, Willavize SA, Friedman HL, Vincent J \"Effect of Maalox and omeprazole on the bioavailability of trovafloxacin.\" J Antimicrob Chemother 39 Suppl B (1997): 93-7[2] Noyes M, Polk RE \"Norfloxacin and absorption of magnesium-aluminum.\" Ann Intern Med 109 (1988): 168-9[3] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A \"Inhibition of norfloxacin absorption by antacids.\" Antimicrob Agents Chemother 34 (1990): 432-5[4] \"Product Information. Zagam (sparfloxacin).\" Rhone-Poulenc Rorer, Collegeville, PA.[5] \"Product Information. Factive (gemifloxacin).\" GeneSoft Inc, San Francisco, CA.[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories, Braintree, MA.[7] Johnson RD, Dorr MB, Talbot GH, Caille G \"Effect of Maalox on the oral absorption of sparfloxacin.\" Clin Ther 20 (1998): 1149-58[8] Zix JA, Geerdes-Fenge HF, Rau M, Vockler J, Borner K, Koeppe P, Lode H \"Pharmacokinetics of sparfloxacin and interaction with cisapride and sucralfate.\" Antimicrob Agents Chemother 41 (1997): 1668-72[9] Shimada J, Shiba K, Oguma T, et al \"Effect of antacid on absorption of the quinolone lomefloxacin.\" Antimicrob Agents Chemother 36 (1992): 1219-24[10] Wadworth AN, Goa KL \"Lomefloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use.\" Drugs 42 (1991): 1018-60[11] Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P \"Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.\" Antimicrob Agents Chemother 33 (1989): 1901-7[12] \"Product Information. Raxar (grepafloxacin).\" Glaxo Wellcome, Research Triangle Park, NC.[13] Yuk JH \"Ciprofloxacin levels when receiving sucralfate.\" J Am Geriatr Soc 262 (1989): 901[14] Nix DE, Watson WA, Lener ME, et al \"Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.\" Clin Pharmacol Ther 46 (1989): 700-5[15] Spivey JM, Cummings DM, Pierson NR \"Failure of prostatitis treatment secondary to probable ciprofloxacin-sucralfate drug interaction.\" Pharmacotherapy 16 (1996): 314-6[16] Honig PK, Gillespie BK \"Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs.\" Clin Pharmacokinet 35 (1998): 167-71[17] Allen A, Vousden M, Porter A, Lewis A \"Effect of Maalox((R)) on the bioavailability of oral gemifloxacin in healthy volunteers.\" Chemotherapy 45 (1999): 504-11[18] Garrelts JC, Godley PJ, Peterie JD, Gerlach EH, Yakshe CC \"Sucralfate significantly reduces ciprofloxacin concentrations in serum.\" Antimicrob Agents Chemother 34 (1990): 931-3[19] Lehto P, Kivisto KT \"Different effects of products containing metal ions on the absorption of lomefloxacin.\" Clin Pharmacol Ther 56 (1994): 477-82[20] Lehto P, Kivisto KT \"Effect of sucralfate on absorption of norfloxacin and ofloxacin.\" Antimicrob Agents Chemother 38 (1994): 248-51[21] Akerele JO, Okhamafe AO \"Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.\" J Antimicrob Chemother 28 (1991): 87-94[22] Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW \"Norfloxacin interaction with antacids and minerals.\" Br J Clin Pharmacol 33 (1992): 115-6[23] \"Product Information. Levaquin (levofloxacin).\" Ortho Pharmaceutical Corporation, Raritan, NJ.[24] Grasela TH Jr, Schentag JJ, Sedman AJ, et al \"Inhibition of enoxacin absorption by antacids or ranitidine.\" Antimicrob Agents Chemother 33 (1989): 615-7[25] Sahai J, Healy DP, Stotka J, Polk RE \"The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin.\" Br J Clin Pharmacol 35 (1993): 302-4[26] Parpia SH, Nix DE, Hejmanowski LG, Goldstein HR, Wilton JH, Schentag JJ \"Sucralfate reduces the gastrointestinal absorption of norfloxacin.\" Antimicrob Agents Chemother 33 (1989): 99-102[27] Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT \"Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.\" Antimicrob Agents Chemother 36 (1992): 830-2[28] Polk RE, Helay DP, Sahai J, Drwal L, Racht E \"Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers.\" Antimicrob Agents Chemother 33 (1989): 1841-4[29] \"Product Information. Baxdela (delafloxacin).\" Melinta Therapeutics, Lincolnshire, IL.[30] Kamberi M, Nakashima H, Ogawa K, Oda N, Nakano S \"The effect of staggered dosing of sucralfate on oral bioavailability of sparfloxacin.\" Br J Clin Pharmacol 49 (2000): 98-103[31] Lober S, Ziege S, Rau M, Schreiber G, Mignot A, Koeppe P, Lode H \"Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium.\" Antimicrob Agents Chemother 43 (1999): 1067-71[32] \"Product Information. Trovan (trovafloxacin).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Calcium glucoheptonate, Calcium chloride, Ascorbic acid, Calcium chloride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45670, "ingredient1": "Ginger", "ingredient2": "Urokinase", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45740/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45671, "ingredient1": "Calcium Phosphate", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium. Calcium chloride has been used to manage acute severe verapamil toxicity.", "source": "DDInter", "management_text": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "mechanism_text": "Antagonism", "recommendation": "Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45741/", "reference_text": "[1] Lipman J, Jardine I, Roos C, Dreosti L \"Intravenous calcium chloride as an antidote to verapamil-induced hypotension.\" Intensive Care Med 8 (1982): 55-7[2] Oszko MA, Klutman NE \"Use of calcium salts during cardiopulmonary resuscitation for reversing verapamil-associated hypotension.\" Clin Pharm 6 (1987): 448-9[3] Woie L, Storstein L \"Successful treatment of suicidal verapamil poisoning with calcium gluconate.\" Eur Heart J 2 (1981): 239-42[4] Henry M, Kay MM, Viccellio P \"Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride.\" Am J Emerg Med 3 (1985): 334-6[5] Moller IW \"Cardiac arrest following intravenous verapamil combined with halothane anaesthesia.\" Br J Anaesth 59 (1987): 522-6[6] Moroni F, Mannaioni PF, Dolara A, Ciaccheri M \"Calcium gluconate and hypertonic sodium chloride in a case of massive verapamil poisoning.\" Clin Toxicol 17 (1980): 395-400[7] Schoen MD, Parker RB, Hoon TJ, et al \"Evaluation of the pharmacokinetics and electrocardiographic effects of intravenous verapamil with intravenous calcium chloride pretreatment in normal subjects.\" Am J Cardiol 67 (1991): 300-4[8] Guadagnino V, Greengart A, Hollander G, Solar M, Shani J, Lichstein E \"Treatment of severe left ventricular dysfunction with calcium chloride in patients receiving verapamil.\" J Clin Pharmacol 27 (1987): 407-9[9] Luscher TF, Noll G, Sturmer T, Huser B, Wenk M \"Calcium gluconate in severe verapamil intoxication.\" N Engl J Med 330 (1994): 718-20[10] McMillan R \"Management of acute severe verapamil intoxication.\" J Emerg Med 6 (1988): 193-6[11] Bar-Or D, Gasiel Y \"Calcium and calciferol antagonise effect of verapamil in atrial fibrillation.\" Br Med J (Clin Res Ed) 282 (1981): 1585-6[12] Morris DL, Goldschlager N \"Calcium infusion for reversal of adverse effects of intravenous verapamil.\" JAMA 249 (1983): 3212-3[13] Perkins CM \"Serious verapamil poisoning: treatment with intravenous calcium gluconate.\" Br Med J 2 (1978): 1127[14] O'Quinn SV, Wohns DH, Clarke S, Koch G, Patterson JH, Adams KF \"Influence of calcium on the hemodynamic and anti-ischemic effects of nifedipine observed during treadmill exercise testing.\" Pharmacotherapy 10 (1990): 247[15] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[16] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[17] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[18] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[19] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[20] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[21] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[22] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[23] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[24] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[25] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[27] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[28] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[29] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[30] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[31] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[32] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[33] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[34] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[35] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[36] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[37] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[38] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[39] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[40] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[41] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[42] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[43] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[44] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[45] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8", "alternatives_a": "Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril", "alternatives_b": "Ascorbic acid", "updated_at": 1767369485}, {"id": 45672, "ingredient1": "Ginger", "ingredient2": "Verteporfin", "severity": "Moderate", "effect": "Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.", "source": "DDInter", "management_text": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.", "mechanism_text": "Antagonism", "recommendation": "If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45742/", "reference_text": "[1] \"Product Information. Visudyne (verteporfin)\" Valeant Pharmaceuticals, Costa Mesa, CA.[2] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc, Markham, ON.", "alternatives_a": "Aflibercept, Bevacizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45673, "ingredient1": "Ginger", "ingredient2": "Vorapaxar", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45743/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45674, "ingredient1": "Ginger", "ingredient2": "Warfarin", "severity": "Moderate", "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45744/", "reference_text": "[1] Heck AM, DeWitt BA, Lukes AL \"Potential interactions between alternative therapies and warfarin.\" Am J Health Syst Pharm 57 (2000): 1221-7; quiz 1228-30[2] Kruth P, Brosi E, Fux R, Morike K, Gleiter CH \"Ginger-associated overanticoagulation by phenprocoumon.\" Ann Pharmacother 38 (2004): 257-60[3] Vaes LP, Chyka PA \"Interactions of warfarin with garlic, ginger, or ginseng: nature of evidence.\" Ann Pharmacother 34 (2000): 1478-82[4] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998): 2200-11[5] Jiang X, Williams KM, Liauw WS, et al. \"Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.\" Br J Clin Pharmacol 59 (2005): 425-32[6] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Folic Acid (folic acid).\" Method Pharmaceuticals, LLC, Arlington, TX.[9] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[10] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[11] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[12] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[13] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[14] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[15] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[16] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[17] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[18] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[19] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[20] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[21] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[22] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[23] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[24] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[25] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[26] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[27] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[28] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[29] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[30] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[31] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[32] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[33] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[34] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[35] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[36] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[37] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[38] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[39] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[40] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[41] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[42] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[43] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[44] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[45] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[46] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[47] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5[48] Davies NT \"Anti-nutrient factors affecting mineral utilization.\" Proc Nutr Soc 38 (1979): 121-8[49] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[50] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[51] Cerner Multum, Inc. \"Australian Product Information.\" O 0[52] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[53] Mangels AR \"Bone nutrients for vegetarians.\" Am J Clin Nutr 100 (2014): epub", "alternatives_a": "Cilostazol, Iloprost, Treprostinil, Desirudin, Protein C, Acenocoumarol, Selexipag, Epoprostenol, Drotrecogin alfa", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45675, "ingredient1": "Ibandronate", "ingredient2": "Aluminum hydroxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45745/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45676, "ingredient1": "Ibandronate", "ingredient2": "Amikacin (liposome)", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45746/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Levofloxacin, More", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45677, "ingredient1": "Ibandronate", "ingredient2": "Amphotericin B (cholesteryl sulfate)", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45747/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45678, "ingredient1": "Ibandronate", "ingredient2": "Amphotericin B (liposomal)", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45748/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45679, "ingredient1": "Ibandronate", "ingredient2": "Attapulgite", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45749/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 45680, "ingredient1": "Ibandronate", "ingredient2": "Human botulinum neurotoxin A/B immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45750/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45681, "ingredient1": "Ibandronate", "ingredient2": "Bromfenac", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45751/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Fluocinolone acetonide, Cortisone, Hydrocortisone, Betamethasone, Fluorometholone", "updated_at": 1767369485}, {"id": 45682, "ingredient1": "Ibandronate", "ingredient2": "Bumetanide", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and loop diuretics may potentiate the risk of hypocalcemia. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. These effects may be additive with those of loop diuretics, which tend to increase the urinary excretion of calcium.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are coadministered with loop diuretics. Renal function as well as serum calcium levels should be monitored during and after treatment, since the effects of bisphosphonates can continue for many weeks after discontinuation. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasm, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are coadministered with loop diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45752/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Romosozumab, Cholecalciferol, Denosumab, Burosumab", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 45683, "ingredient1": "Ibandronate", "ingredient2": "Calcium acetate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45753/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "updated_at": 1767369485}, {"id": 45684, "ingredient1": "Ibandronate", "ingredient2": "Calcium carbonate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45754/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45685, "ingredient1": "Ibandronate", "ingredient2": "Calcium citrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45755/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Ascorbic acid", "updated_at": 1767369485}, {"id": 45686, "ingredient1": "Ibandronate", "ingredient2": "Calcium glubionate anhydrous", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45756/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate", "updated_at": 1767369485}, {"id": 45687, "ingredient1": "Ibandronate", "ingredient2": "Calcium gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45757/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate, Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More", "updated_at": 1767369485}, {"id": 45688, "ingredient1": "Ibandronate", "ingredient2": "Calcium glycerophosphate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45758/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45689, "ingredient1": "Ibandronate", "ingredient2": "Calcium lactate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45759/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Calcium glucoheptonate", "updated_at": 1767369485}, {"id": 45690, "ingredient1": "Ibandronate", "ingredient2": "Capreomycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45760/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45691, "ingredient1": "Iron", "ingredient2": "Ibandronate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45761/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45692, "ingredient1": "Ibandronate", "ingredient2": "Choline salicylate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45762/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 45693, "ingredient1": "Ibandronate", "ingredient2": "Chromium picolinate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45763/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45694, "ingredient1": "Ibandronate", "ingredient2": "Cidofovir", "severity": "Major", "effect": "Coadministration of cidofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Dose-related nephrotoxicity is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as one or two doses of cidofovir.", "source": "DDInter", "management_text": "Concomitant use of cidofovir with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) is considered contraindicated.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cidofovir with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45764/", "reference_text": "[1] \"Product Information. Vistide (cidofovir).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45695, "ingredient1": "Ibandronate", "ingredient2": "Cisplatin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45765/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45696, "ingredient1": "Ibandronate", "ingredient2": "Clofarabine", "severity": "Moderate", "effect": "Coadministration of clofarabine with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Moreover, renal impairment secondary to the use of these agents may reduce the clearance of clofarabine, which is primarily eliminated by renal excretion. This may increase the risk of other adverse effects such as nausea, vomiting, stomatitis, hypertension, hypotension, myelosuppression, hemorrhage, and hepatotoxicity.", "source": "DDInter", "management_text": "Drugs that are potentially nephrotoxic (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, carboplatin, cisplatin, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) should be avoided during the 5 days of clofarabine administration if possible. Renal function should be evaluated prior to and during therapy, and administration discontinued immediately if substantial increases (e.g., grade 3 or higher) in creatinine are noted.", "mechanism_text": "Excretion", "recommendation": "Drugs that are potentially nephrotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45766/", "reference_text": "[1] \"Product Information. Clolar (clofarabine).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Fluorouracil, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45697, "ingredient1": "Ibandronate", "ingredient2": "Colistimethate", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45767/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45698, "ingredient1": "Ibandronate", "ingredient2": "Copper gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45768/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45699, "ingredient1": "Ibandronate", "ingredient2": "Cyclosporine", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45769/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45700, "ingredient1": "Ibandronate", "ingredient2": "Human cytomegalovirus immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45770/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 45701, "ingredient1": "Ibandronate", "ingredient2": "Deferasirox", "severity": "Major", "effect": "Coadministration with oral bisphosphonates may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Fatal gastrointestinal hemorrhages have been reported during deferasirox therapy, especially in elderly patients with advanced hematologic malignancies and/or low platelet counts. Non-fatal upper gastrointestinal irritation, ulceration, and hemorrhage have also been reported, including in children and adolescents. Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents, including intravenous bisphosphonates.", "source": "DDInter", "management_text": "Caution is advised if deferasirox is used in combination with drugs that have known ulcerogenic potential, including oral bisphosphonates. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, vomiting blood, anorexia, and/or black, tarry stools. Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents, including intravenous bisphosphonates. Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections. Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations. A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy. Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if deferasirox is used in combination with drugs that have known ulcerogenic potential, including oral bisphosphonates.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45771/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Rafat C, Fakhouri F, Ribeil JA, Delarue R, Le Quintrec M \"Fanconi Syndrome Due to Deferasirox.\" Am J Kidney Dis (2009):[3] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45702, "ingredient1": "Ibandronate", "ingredient2": "Denosumab", "severity": "Moderate", "effect": "Osteonecrosis of the jaw (ONJ) has been reported with the use of angiogenesis inhibitors including denosumab, bevacizumab, and sunitinib. Concomitant exposure with other risk factors such as bisphosphonates (potency, route of administration, and cumulative dose), cancer, chemotherapy, corticosteroids, radiotherapy to the head and neck, dental disease, invasive dental procedures, or poor oral hygiene may increase the risk. Most reported cases with bevacizumab have occurred in patients who received prior or concomitant treatment with intravenous bisphosphonates or had a history of dental disease requiring invasive dental procedures.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used simultaneously or sequentially with denosumab or bevacizumab. Prior to initiating treatment, a thorough dental examination and appropriate preventive dentistry should be considered. If possible, invasive dental procedures should be avoided in patients who have previously received or are receiving intravenous bisphosphonates. Good oral hygiene practices should be maintained during treatment. Patients should be advised to seek medical attention if they experience signs and symptoms of osteonecrosis in the jaw, such as: pain in the mouth, teeth, or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, loosening of a tooth, or exposure of bone in the jaw. Temporary interruption of treatment should be considered if clinically appropriate, until the condition resolves.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used simultaneously or sequentially with denosumab or bevacizumab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45772/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Prolia (denosumab).\" Amgen USA, Thousand Oaks, CA.[5] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cholecalciferol, Vosoritide, Denosumab, Burosumab", "alternatives_b": "Tiludronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab", "updated_at": 1767369485}, {"id": 45703, "ingredient1": "Ibandronate", "ingredient2": "Diatrizoate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45773/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45704, "ingredient1": "Ibandronate", "ingredient2": "Diclofenac", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45774/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Betamethasone, Fluorometholone, Fluocinolone acetonide, Cortisone, Hydrocortisone, Betamethasone, Fluorometholone, Misoprostol, More", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45705, "ingredient1": "Ibandronate", "ingredient2": "Didanosine", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45775/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 45706, "ingredient1": "Ibandronate", "ingredient2": "Diflunisal", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45776/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 45707, "ingredient1": "Ibandronate", "ingredient2": "Entecavir", "severity": "Moderate", "effect": "Because entecavir is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of entecavir and/or the coadministered drug. In patients with renal impairment, the apparent oral clearance of entecavir has been shown to decrease as the creatinine clearance decreases.", "source": "DDInter", "management_text": "Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during therapy with entecavir.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45777/", "reference_text": "[1] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.[2] \"Product Information. Baraclude (entecavir).\" Bristol-Myers Squibb, Princeton, NJ.", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "alternatives_b": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45708, "ingredient1": "Ibandronate", "ingredient2": "Etelcalcetide", "severity": "Major", "effect": "Concomitant use of etelcalcetide with other medicines known to lower serum calcium may increase the risk of hypocalcemia. The proposed mechanism is additive reduction in serum calcium levels. Significant decreases in serum calcium may cause paraesthesias, myalgias, muscle spasms, seizures, QT interval prolongation, and ventricular arrhythmia. Etelcalcetide given alone may lead to severe hypocalcemia requiring concomitant treatment with therapies to increase serum calcium levels.", "source": "DDInter", "management_text": "Close monitoring of corrected serum calcium levels is recommended if etelcalcetide is used in combination with other medications known to lower serum calcium, such as denosumab, calcitonin, foscarnet, bisphosphonates, or loop diuretics. It is recommended that the patient's corrected serum calcium level should be measured within one week of initiation or dose adjustment of etelcalcetide and monitored approximately every 4 weeks. In addition, the manufacturer product labeling should be consulted for management guidelines in the event of a reduction in corrected serum calcium levels below the lower limit of the normal range and/or symptoms of hypocalcemia. Patients should also be advised to contact their health care professional if they experience symptoms of hypocalcemia, such as numbness or tingling in the fingers, toes, or around the mouth, muscle spasms, twitches or cramps, seizures, confusion, and irregular heartbeats.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of corrected serum calcium levels is recommended if etelcalcetide is used in combination with other medications known to lower serum calcium, such as denosumab, calcitonin, foscarnet, bisphosphonates, or loop diuretics.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45778/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Cholecalciferol, Vosoritide", "alternatives_b": "Cinacalcet, Doxercalciferol, Salmon calcitonin, Calcifediol, Paricalcitol", "updated_at": 1767369485}, {"id": 45709, "ingredient1": "Ibandronate", "ingredient2": "Etacrynic acid", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and loop diuretics may potentiate the risk of hypocalcemia. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. These effects may be additive with those of loop diuretics, which tend to increase the urinary excretion of calcium.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are coadministered with loop diuretics. Renal function as well as serum calcium levels should be monitored during and after treatment, since the effects of bisphosphonates can continue for many weeks after discontinuation. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasm, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are coadministered with loop diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45779/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Romosozumab, Cholecalciferol, Denosumab, Burosumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45710, "ingredient1": "Ibandronate", "ingredient2": "Etodolac", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45780/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "updated_at": 1767369485}, {"id": 45711, "ingredient1": "Ibandronate", "ingredient2": "Exenatide", "severity": "Moderate", "effect": "Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide. The mechanism of interaction is unknown. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45781/", "reference_text": "[1] \"Product Information. Byetta (exenatide).\" Amylin Pharmaceuticals Inc, San Diego, CA.[2] \"Product Information. Byetta (exenatide).\" Amylin Pharmaceuticals Inc, San Diego, CA.", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Empagliflozin, Dulaglutide, Tolbutamide, Miglitol, Glimepiride, More", "updated_at": 1767369485}, {"id": 45712, "ingredient1": "Ibandronate", "ingredient2": "Fenoprofen", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45782/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45713, "ingredient1": "Ibandronate", "ingredient2": "Tetraferric tricitrate decahydrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45783/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45714, "ingredient1": "Ibandronate", "ingredient2": "Ferrous fumarate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45784/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45715, "ingredient1": "Ibandronate", "ingredient2": "Ferrous gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45785/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45716, "ingredient1": "Ibandronate", "ingredient2": "Ferrous sulfate anhydrous", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45786/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45717, "ingredient1": "Ibandronate", "ingredient2": "Flucytosine", "severity": "Moderate", "effect": "Drugs that impair glomerular filtration may prolong the half-life of flucytosine and lead to accumulation.", "source": "DDInter", "management_text": "Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).", "mechanism_text": "Excretion", "recommendation": "Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45787/", "reference_text": "[1] \"Product Information. Ancobon (flucytosine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Fluconazole, Micafungin, Caspofungin, Itraconazole, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Anidulafungin, Voriconazole, Fluconazole, More", "updated_at": 1767369485}, {"id": 45718, "ingredient1": "Ibandronate", "ingredient2": "Flurbiprofen", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45788/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Chlorhexidine, Povidone-iodine, Fluocinolone acetonide, Cortisone, Hydrocortisone, More", "updated_at": 1767369485}, {"id": 45719, "ingredient1": "Ibandronate", "ingredient2": "Gentamicin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45789/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 45720, "ingredient1": "Ibandronate", "ingredient2": "Givosiran", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45790/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Phenylbutyric acid, More", "updated_at": 1767369485}, {"id": 45721, "ingredient1": "Ibandronate", "ingredient2": "Human immunoglobulin G (intravenous and subcutaneous)", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45791/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45722, "ingredient1": "Indomethacin", "ingredient2": "Ibandronate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45792/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Fludrocortisone, Fluocinolone acetonide, Hydrocortisone, Betamethasone, Fluorometholone, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Fluocinolone acetonide, Cortisone, More", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45723, "ingredient1": "Inotersen", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Coadministration of inotersen with other nephrotoxic agents may increase the risk of renal impairment due to additive adverse effects on the kidney. Inotersen can cause glomerulonephritis that may result in dialysis-dependent renal failure.", "source": "DDInter", "management_text": "Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) . Serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and a urinalysis should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should generally not be initiated in patients with a UPCR of 1000 mg/g or higher, or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of glomerulonephritis and to seek medical attention if they occur, including edema, shortness of breath, coughing, hematuria, and decreased urination.", "mechanism_text": "Excretion", "recommendation": "Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45793/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Tegsedi (inotersen).\" Akcea Therapeutics, Cambridge, MA.", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis", "updated_at": 1767369485}, {"id": 45724, "ingredient1": "Iobenguane (I-131)", "ingredient2": "Ibandronate", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45794/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45725, "ingredient1": "Iodipamide", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45795/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45726, "ingredient1": "Iodixanol", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45796/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45727, "ingredient1": "Iohexol", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45797/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45728, "ingredient1": "Iopamidol", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45798/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45729, "ingredient1": "Iopromide", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45799/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45730, "ingredient1": "Iothalamic acid", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45800/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45731, "ingredient1": "Ioversol", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45801/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45732, "ingredient1": "Ioxilan", "ingredient2": "Ibandronate", "severity": "Major", "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.", "source": "DDInter", "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.", "mechanism_text": "Synergism", "recommendation": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45802/", "reference_text": "[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH \"Risk factors for nephrotoxicity onset associated with polymyxin B therapy.\" J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J \"Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies.\" Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R \"Acute renal failure.\" BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ \"Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients.\" Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK \"Acute renal insufficiency during telavancin therapy in clinical practice.\" J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F \"Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview.\" ([2016, Jan 18]):[7] Bennett WM, Porter GA \"Nephrotoxicity of common drugs used by urologists.\" Urol Clin North Am 17 (1990): 145-56", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid", "updated_at": 1767369485}, {"id": 45733, "ingredient1": "Iron protein succinylate", "ingredient2": "Ibandronate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45803/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45734, "ingredient1": "Ibandronate", "ingredient2": "Kanamycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45804/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 45735, "ingredient1": "Ibandronate", "ingredient2": "Kaolin", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45805/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Pectin, Activated charcoal", "updated_at": 1767369485}, {"id": 45736, "ingredient1": "Ibandronate", "ingredient2": "Ketoprofen", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45806/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45737, "ingredient1": "Ibandronate", "ingredient2": "Lenvatinib", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45807/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 45738, "ingredient1": "Ibandronate", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45808/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45739, "ingredient1": "Ibandronate", "ingredient2": "Lutetium Lu 177 dotatate", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45809/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45740, "ingredient1": "Ibandronate", "ingredient2": "Magaldrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45810/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45741, "ingredient1": "Ibandronate", "ingredient2": "Magnesium carbonate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45811/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45742, "ingredient1": "Ibandronate", "ingredient2": "Magnesium chloride", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45812/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sodium chloride, Sodium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, Sodium bicarbonate, Sodium chloride, Potassium acetate, Ammonium chloride", "updated_at": 1767369485}, {"id": 45743, "ingredient1": "Ibandronate", "ingredient2": "Magnesium citrate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45813/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sorbitol, Sulfamethizole, Sodium citrate, Mannitol, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, More", "updated_at": 1767369485}, {"id": 45744, "ingredient1": "Ibandronate", "ingredient2": "Magnesium gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45814/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sodium chloride, Sodium sulfate", "updated_at": 1767369485}, {"id": 45745, "ingredient1": "Ibandronate", "ingredient2": "Magnesium glycinate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45815/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45746, "ingredient1": "Ibandronate", "ingredient2": "Magnesium hydroxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45816/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Apomorphine, Fesoterodine, Pentosan polysulfate, Phenazopyridine, Alprostadil, Trospium, Mirabegron, Acetohydroxamic acid, Yohimbine, Flavoxate, Darifenacin, More", "updated_at": 1767369485}, {"id": 45747, "ingredient1": "Ibandronate", "ingredient2": "Magnesium oxide", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45817/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Sodium chloride, Sodium sulfate, Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, More", "updated_at": 1767369485}, {"id": 45748, "ingredient1": "Ibandronate", "ingredient2": "Magnesium sulfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45818/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Alvimopan, Sorbitol, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Prucalopride, Sodium sulfate, More", "alternatives_b": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "updated_at": 1767369485}, {"id": 45749, "ingredient1": "Ibandronate", "ingredient2": "Meclofenamic acid", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45819/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45750, "ingredient1": "Ibandronate", "ingredient2": "Mefenamic acid", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45820/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "updated_at": 1767369485}, {"id": 45751, "ingredient1": "Ibandronate", "ingredient2": "Meloxicam", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45821/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Misoprostol, More", "updated_at": 1767369485}, {"id": 45752, "ingredient1": "Ibandronate", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45822/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45753, "ingredient1": "Ibandronate", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45823/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 45754, "ingredient1": "Ibandronate", "ingredient2": "Moxetumomab Pasudotox", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45824/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45755, "ingredient1": "Ibandronate", "ingredient2": "Nabumetone", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45825/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45756, "ingredient1": "Ibandronate", "ingredient2": "Naproxen", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45826/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "updated_at": 1767369485}, {"id": 45757, "ingredient1": "Ibandronate", "ingredient2": "Neomycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45827/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Rifamycin, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, Rifamycin, More", "updated_at": 1767369485}, {"id": 45758, "ingredient1": "Ibandronate", "ingredient2": "Netilmicin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45828/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Levofloxacin, More", "updated_at": 1767369485}, {"id": 45759, "ingredient1": "Ibandronate", "ingredient2": "Olsalazine", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45829/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Hydrocortisone, Betamethasone, Beclomethasone dipropionate, Cromoglicic acid", "updated_at": 1767369485}, {"id": 45760, "ingredient1": "Ibandronate", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Theoretically, coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of oxaliplatin, which is primarily eliminated unchanged by the kidney.", "source": "DDInter", "management_text": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of oxaliplatin such as peripheral sensory neuropathies and neutropenia should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45830/", "reference_text": "[1] \"Product Information. Eloxatin (oxaliplatin).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45761, "ingredient1": "Ibandronate", "ingredient2": "Oxaprozin", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45831/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "updated_at": 1767369485}, {"id": 45762, "ingredient1": "Ibandronate", "ingredient2": "Pemetrexed", "severity": "Moderate", "effect": "Coadministration with drugs that are nephrotoxic may delay and/or decrease the clearance of pemetrexed, which is primarily eliminated unchanged by the kidney via glomerular filtration and active tubular secretion.", "source": "DDInter", "management_text": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if pemetrexed is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45832/", "reference_text": "[1] \"Product Information. Alimta (pemetrexed).\" Lilly, Eli and Company, Indianapolis, IN.", "alternatives_a": "Fluorouracil, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, Decitabine, Azacitidine, Tioguanine", "alternatives_b": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "updated_at": 1767369485}, {"id": 45763, "ingredient1": "Ibandronate", "ingredient2": "Pentamidine", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45833/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Miltefosine, Fexinidazole, Nifurtimox, Benznidazole", "updated_at": 1767369485}, {"id": 45764, "ingredient1": "Ibandronate", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45834/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "updated_at": 1767369485}, {"id": 45765, "ingredient1": "Ibandronate", "ingredient2": "Piroxicam", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45835/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Cortisone, Hydrocortisone, Betamethasone, Fluorometholone", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45766, "ingredient1": "Ibandronate", "ingredient2": "Plazomicin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45836/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45767, "ingredient1": "Ibandronate", "ingredient2": "Polymyxin B", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45837/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Tetracycline, Rifamycin, Miconazole, Chloramphenicol, Chlorhexidine, Tetracycline, Chloramphenicol, Chlorhexidine, Tinidazole, Linezolid, Oritavancin, More", "updated_at": 1767369485}, {"id": 45768, "ingredient1": "Ibandronate", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "INTERVAL: Administration of quinapril with some oral medications may significantly decrease their absorption and may result in subtherapeutic serum concentrations. The proposed mechanism is chelation of the drug by the magnesium hydroxide excipient in quinapril tablets.", "source": "DDInter", "management_text": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "mechanism_text": "Absorption", "recommendation": "The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45838/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Multum Information Services, Inc. Expert Review Panel\"[3] Ray K, Dorman S, Watson R \"Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction.\" J Hum Hypertens 13 (1999): 717-20[4] Good CB, McDermott L \"Diet and serum potassium in patients on ACE inhibitors.\" JAMA 274 (1995): 538[5] \"Product Information. Vasotec (enalapril).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Tequin (gatifloxacin)\" Bristol-Myers Squibb, Princeton, NJ.[7] Wallace AW, Victory JM, Amsden GW \"Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers.\" J Clin Pharmacol 43 (2003): 92-6", "alternatives_a": "Romosozumab, Cholecalciferol, Denosumab, Burosumab", "alternatives_b": "Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril, Moexipril, Perindopril, Bisoprolol, Benazepril, Trandolapril, Fosinopril, Indapamide", "updated_at": 1767369485}, {"id": 45769, "ingredient1": "Ibandronate", "ingredient2": "Remdesivir", "severity": "Moderate", "effect": "Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient, sulfobutylether-beta-cyclodextrin sodium (SBECD). Both GS-441524 and SBECD are primarily eliminated by the kidneys, thus renal impairment secondary to the use of nephrotoxic agents may reduce their clearance and increase the risk of accumulation.", "source": "DDInter", "management_text": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function. Caution is advised if remdesivir is used in patients who have recently received potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function (estimated glomerular filtration rate, or eGFR, for adult and pediatric patients older than 28 days; serum creatinine for full-term neonates at least 7 days up to 28 days old) should be evaluated prior to starting remdesivir and monitored daily during treatment or as clinically appropriate.", "mechanism_text": "Excretion", "recommendation": "Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45839/", "reference_text": "[1] Gilead Sciences, Inc \"About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir.\" ([2020]):[2] European Medicines Agency \"Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf.\" ([2020 Apr 03]):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] US Food and Drug Administration \"Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download.\" ([2020, May 1]]):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 45770, "ingredient1": "Ibandronate", "ingredient2": "Human Rho(D) immune globulin", "severity": "Major", "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.", "source": "DDInter", "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.", "mechanism_text": "Synergism", "recommendation": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45840/", "reference_text": "[1] MMWR Morb Mortal Wkly Rep \"Renal insufficiency and failure associated with immune globulin intravenous therapy -- United States, 1985-1998. Available from: URL: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4824a3.htm.\" ([1999 Jun 25]):[2] \"Product Information. BabyBIG (botulism immune globulin).\" FFF Enterprises, Temecula, CA.[3] Guo X, Nzerue C \"How to prevent, recognize, and treat drug-induced nephrotoxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2002 Apr]):[4] Moses S \"Nephrotoxic drugs, drug-induced nephrotoxicity. Available from: URL: http://www.fpnotebook.com/Renal/Pharm/NphrtxcDrgs.htm.\" ([2011 Nov 25]):[5] Perazella MA \"Renal vulnerability to drug toxicity. Available from: URL: http://www.ccjm.org/content/69/4/289.full.pdf.\" ([2009]):[6] Levy JB, Pusey EY \"Nephrotoxicity of intravenous immunoglobulin. Available from: URL: http://qjmed.oxfordjournals.org/content/93/11/751.full.pdf+html.\" ([2000]):[7] \"Product Information. Respigam (respiratory syncytial virus immune globulin).\" Medimmune Inc, Gaithersburg, MD.[8] \"Product Information. Bivigam (immune globulin intravenous).\" Biotest Pharmaceuticals Corporation, Boca Raton, FL.[9] \"Product Information. Cytogam (cytomegalovirus immune globulin).\" CSL Behring, King of Prussia, PA.[10] Naughton CA \"Drug-induced nephrotoxicity. Available from: URL: http://www.aafp.org/afp/2008/0915/p743.html.\" ([2008]):[11] KDIGO. Kidney Disease Improving Global Outcomes \"KDIGO clinical practice guideline for acute kidney injury. Available from: URL: http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-AKI-Suppl-Appendices-A-F_March2012.pdf.\" ([2012 Mar]):", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Bezlotoxumab, Palivizumab", "updated_at": 1767369485}, {"id": 45771, "ingredient1": "Ibandronate", "ingredient2": "Rofecoxib", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45841/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45772, "ingredient1": "Ibandronate", "ingredient2": "Romosozumab", "severity": "Moderate", "effect": "Coadministration of romosozumab with bisphosphonates, denosumab, angiogenesis inhibitors, or corticosteroids may increase the risk of developing osteonecrosis of the jaw (ONJ). The condition can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Other risk factors for ONJ include cancer, chemotherapy, radiotherapy to the head and neck, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy.", "source": "DDInter", "management_text": "Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw. A routine oral examination should be performed by the prescriber prior to initiation of romosozumab treatment. For patients requiring invasive dental procedures, clinical judgment and risk-benefit assessment should guide the management plan of each patient based on their clinical circumstances. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45842/", "reference_text": "[1] \"Product Information. Evenity (romosozumab).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Romosozumab, Cholecalciferol, Vosoritide, Burosumab", "alternatives_b": "Tiludronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab", "updated_at": 1767369485}, {"id": 45773, "ingredient1": "Ibandronate", "ingredient2": "Salsalate", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45843/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Ziconotide", "updated_at": 1767369485}, {"id": 45774, "ingredient1": "Ibandronate", "ingredient2": "Selenium", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45844/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45775, "ingredient1": "Ibandronate", "ingredient2": "Sirolimus", "severity": "Major", "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.", "source": "DDInter", "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45845/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Sheiner PA, Mor E, Chodoff L, Glabman S, Emre S, Schwartz ME, Miller CM \"Acute renal, failure associated with the use of ibuprofen in two liver transplant recipients on FK506.\" Transplantation 57 (1994): 1132-3[4] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, More", "updated_at": 1767369485}, {"id": 45776, "ingredient1": "Ibandronate", "ingredient2": "Salicylic acid (sodium)", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45846/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45777, "ingredient1": "Ibandronate", "ingredient2": "Streptomycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45847/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, Isoniazid, Ethambutol, More", "updated_at": 1767369485}, {"id": 45778, "ingredient1": "Ibandronate", "ingredient2": "Sucralfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45848/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Levofloxacin, Tetracycline, Dexlansoprazole, Misoprostol, Bismuth subcitrate potassium, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, Vonoprazan, Amoxicillin", "alternatives_b": "Romosozumab, Vosoritide, Denosumab, Burosumab", "updated_at": 1767369485}, {"id": 45779, "ingredient1": "Iron sucrose", "ingredient2": "Ibandronate", "severity": "Moderate", "effect": "INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of bisphosphonates to the ferric ion component of sucroferric oxyhydroxide, forming an insoluble complex that is poorly absorbed from the gastrointestinal tract.", "source": "DDInter", "management_text": "Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide. No dosing recommendations are available for use with other bisphosphonates. Patients may follow the manufacturers' suggestion provided in the individual bisphosphonate label regarding use with mineral supplements and other polyvalent cation-containing products (i.e., administer sucroferric oxyhydroxide at least 30 minutes after risedronate, 1 hour after ibandronate, and at least 2 hours before or 2 hours after clodronate, etidronate, or tiludronate).", "mechanism_text": "Absorption", "recommendation": "Alendronate should be administered at least 1 hour before sucroferric oxyhydroxide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45849/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[4] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[5] \"Product Information. Velphoro (sucroferric oxyhydroxide).\" Fresenius Medical Care North America, Lexington, MA.[6] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Vosoritide, Denosumab, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, More", "updated_at": 1767369485}, {"id": 45780, "ingredient1": "Ibandronate", "ingredient2": "Sulfasalazine", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45850/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "updated_at": 1767369485}, {"id": 45781, "ingredient1": "Ibandronate", "ingredient2": "Sulindac", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45851/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45782, "ingredient1": "Ibandronate", "ingredient2": "Sunitinib", "severity": "Moderate", "effect": "Osteonecrosis of the jaw (ONJ) has been reported with the use of angiogenesis inhibitors including denosumab, bevacizumab, and sunitinib. Concomitant exposure with other risk factors such as bisphosphonates (potency, route of administration, and cumulative dose), cancer, chemotherapy, corticosteroids, radiotherapy to the head and neck, dental disease, invasive dental procedures, or poor oral hygiene may increase the risk. Most reported cases with bevacizumab have occurred in patients who received prior or concomitant treatment with intravenous bisphosphonates or had a history of dental disease requiring invasive dental procedures.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used simultaneously or sequentially with denosumab or bevacizumab. Prior to initiating treatment, a thorough dental examination and appropriate preventive dentistry should be considered. If possible, invasive dental procedures should be avoided in patients who have previously received or are receiving intravenous bisphosphonates. Good oral hygiene practices should be maintained during treatment. Patients should be advised to seek medical attention if they experience signs and symptoms of osteonecrosis in the jaw, such as: pain in the mouth, teeth, or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, loosening of a tooth, or exposure of bone in the jaw. Temporary interruption of treatment should be considered if clinically appropriate, until the condition resolves.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used simultaneously or sequentially with denosumab or bevacizumab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45852/", "reference_text": "[1] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] \"Product Information. Prolia (denosumab).\" Amgen USA, Thousand Oaks, CA.[5] \"Product Information. Sutent (sunitinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.", "alternatives_a": "Cholecalciferol, Vosoritide, Denosumab, Burosumab", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 45783, "ingredient1": "Ibandronate", "ingredient2": "Tacrolimus", "severity": "Major", "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.", "source": "DDInter", "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45853/", "reference_text": "[1] \"Product Information. Prograf (tacrolimus).\" Fujisawa, Deerfield, IL.[2] \"Product Information. Rapamune (sirolimus)\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Sheiner PA, Mor E, Chodoff L, Glabman S, Emre S, Schwartz ME, Miller CM \"Acute renal, failure associated with the use of ibuprofen in two liver transplant recipients on FK506.\" Transplantation 57 (1994): 1132-3[4] \"Product Information. Afinitor (everolimus).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab", "alternatives_b": "Minoxidil, Deoxycholic acid, Pimecrolimus, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, Tralokinumab, More", "updated_at": 1767369485}, {"id": 45784, "ingredient1": "Ibandronate", "ingredient2": "Telavancin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45854/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 45785, "ingredient1": "Ibandronate", "ingredient2": "Telbivudine", "severity": "Moderate", "effect": "Because telbivudine is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of telbivudine and/or the coadministered drug.", "source": "DDInter", "management_text": "Caution is advised if telbivudine is prescribed in combination with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during therapy with telbivudine.", "mechanism_text": "Excretion", "recommendation": "Caution is advised if telbivudine is prescribed in combination with potentially nephrotoxic drugs (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45855/", "reference_text": "[1] \"Product Information. Tyzeka (telbivudine).\" IDEC Pharmaceuticals Corporation, San Diego, CA.", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab", "alternatives_b": "Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More", "updated_at": 1767369485}, {"id": 45786, "ingredient1": "Ibandronate", "ingredient2": "Temsirolimus", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45856/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tiludronic acid, Alendronic acid, Vosoritide, Cholecalciferol, Burosumab, Risedronic acid", "alternatives_b": "Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More", "updated_at": 1767369485}, {"id": 45787, "ingredient1": "Ibandronate", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "In multiple myeloma patients, the risk of renal dysfunction may be increased when intravenous bisphosphonates are used in combination with thalidomide. The mechanism of interaction has not been described.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in multiple myeloma patients who are receiving treatment with thalidomide. Renal function and serum electrolytes should be monitored. Product labelings for pamidronate and zoledronic acid recommend that single doses not exceed 90 mg and 4 mg, respectively, and the duration of infusion not less than 2 hours and 15 minutes, respectively. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration. In those treated for bone metastases, treatment should not be resumed until renal function returns to baseline.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in multiple myeloma patients who are receiving treatment with thalidomide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45857/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Tiludronic acid, Cholecalciferol, Vosoritide, Burosumab", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 45788, "ingredient1": "Ibandronate", "ingredient2": "Tobramycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and aminoglycosides may potentiate the risks of hypocalcemia and nephrotoxicity, particularly when the bisphosphonate is administered intravenously. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium, while aminoglycosides can induce renal tubular damage resulting in renal loss of calcium and magnesium. Hypomagnesemia, in turn, may also lead to peripheral parathyroid hormone resistance and impaired parathyroid hormone secretion, thus compromising the normal homeostatic response to hypocalcemia.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides. Renal function as well as serum calcium and magnesium levels should be monitored during and after treatment, since renal loss of calcium and magnesium can continue for many weeks after cessation of aminoglycosides, as can the effect of bisphosphonates. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasms, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are used in patients who have recently received or are receiving treatment with aminoglycosides.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45858/", "reference_text": "[1] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[4] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[5] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[6] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[10] Pedersen-Bjergaard U, Myhre J \"Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.\" Br Med J 302 (1991): 295[11] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Gatifloxacin, Rifamycin, Lomefloxacin, Ampicillin, Azithromycin, Famciclovir, Cefuroxime, Trifluridine, Benzylpenicillin, Erythromycin, Levofloxacin, More", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45789, "ingredient1": "Ibandronate", "ingredient2": "Tolmetin", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45859/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45790, "ingredient1": "Ibandronate", "ingredient2": "Torasemide", "severity": "Moderate", "effect": "Coadministration of bisphosphonates and loop diuretics may potentiate the risk of hypocalcemia. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. These effects may be additive with those of loop diuretics, which tend to increase the urinary excretion of calcium.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are coadministered with loop diuretics. Renal function as well as serum calcium levels should be monitored during and after treatment, since the effects of bisphosphonates can continue for many weeks after discontinuation. Patients and clinicians should be alert to signs and symptoms of clinical hypocalcemia such as muscle spasm, carpopedal spasm, laryngeal spasm, tetany, convulsions, mental changes (irritability, depression, psychosis), increased intracranial pressure, papilledema, QT interval prolongation, and cardiac arrhythmias.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are coadministered with loop diuretics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45860/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More", "alternatives_b": "Romosozumab, Cholecalciferol, Denosumab, Burosumab", "updated_at": 1767369485}, {"id": 45791, "ingredient1": "Ibandronate", "ingredient2": "Valdecoxib", "severity": "Moderate", "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.", "source": "DDInter", "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45861/", "reference_text": "[1] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Didronel I.V. Infusion (etidronate).\" MGI Pharma Inc, Minnetonka, MN.[4] Graham, Malaty \"Alendronate and naproxen are synergistic for development of gastric ulcers (Vol 161, pg 107, 1921).\" Arch Intern Med 161 (2001): 1862[5] Graham DY, Malaty HM \"Alendronate and naproxen are synergistic for development of gastric ulcers.\" Arch Intern Med 161 (2001): 107-10[6] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[7] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[8] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[11] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[12] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.", "alternatives_a": "Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine", "alternatives_b": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45792, "ingredient1": "Ibandronate", "ingredient2": "Vancomycin", "severity": "Moderate", "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.", "source": "DDInter", "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45862/", "reference_text": "[1] \"Product Information. Zometa (zoledronic acid).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Kanis JA, Preston CJ, Yates AJ, Percival RC, Mundy KI, Russell RG \"Effects of intravenous diphosphonates on renal function.\" Lancet 1 (1983): 1328[3] Chang JT, Green L, Beitz J \"Renal failure with the use of zoledronic acid.\" N Engl J Med 349 (2003): 1676-9; discussion 1676-9[4] \"Product Information. Aredia (pamidronate).\" Novartis Pharmaceuticals, East Hanover, NJ.[5] Lockridge L, Papac RJ, Perazella MA \"Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.\" Am J Kidney Dis 40 (2002): E2[6] Osullivan TL, Akbari A, Cadnapaphornchai P \"Acute renal failure associated with the administration of parenteral etidronate.\" Ren Fail 16 (1994): 767-73[7] Zazgornik J, Grafinger P, Biesenbach G, Hubmann R, Fridrik M \"Acute renal failure and alendronate.\" Nephrol Dial Transplant 12 (1997): 2797-8[8] Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D \"Short-term, high-dose pamidronate-induced acute tubular necrosis: The postulated mechanisms of bisphosphonate nephrotoxicity.\" Am J Kidney Dis 41 (2003): E18[9] Markowitz GS, Fine PL, Stack JI, et al. \"Toxic acute tubular necrosis following treatment with zoledronate (Zometa).\" Kidney Int 64 (2003): 281-289[10] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[11] \"Product Information. Ostac (clodronate).\" Hoffmann-La Roche Limited, Mississauga, IA.[12] Janssen Van Doorn K, Neyns B, Van Der Niepen P, Verbeelen D \"Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.\" Nephron 89 (2001): 467-8[13] \"Product Information. Didronel Tablets (etidronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Tinidazole, Linezolid, Oritavancin, Daptomycin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin, Rifamycin, More", "alternatives_b": "Tiludronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45793, "ingredient1": "Ibandronate", "ingredient2": "Zinc acetate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45863/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Teduglutide, Lonafarnib, Fosdenopterin, More", "updated_at": 1767369485}, {"id": 45794, "ingredient1": "Ibandronate", "ingredient2": "Zinc gluconate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45864/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Sodium chloride, Sodium sulfate", "updated_at": 1767369485}, {"id": 45795, "ingredient1": "Ibandronate", "ingredient2": "Zinc sulfate", "severity": "Moderate", "effect": "INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to interfere with the gastrointestinal absorption of oral bisphosphonates.", "source": "DDInter", "management_text": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "mechanism_text": "Absorption", "recommendation": "Antacids or other oral medications containing aluminum, calcium, magnesium and other polyvalent cations should be administered at least 30 minutes after the bisphosphonate dose.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45865/", "reference_text": "[1] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[2] \"Product Information. Bonefos (clodronate).\" Rhone-Poulenc Rorer Canada Inc, Laval, QC.[3] \"Product Information. Skelid (tilundronate).\" Sanofi Winthrop Pharmaceuticals, New York, NY.[4] Darcy PF \"Nutrient-drug interactions.\" Adverse Drug React Toxicol Rev 14 (1995): 233-54[5] \"Product Information. Fosamax (alendronate).\" Merck & Co, Inc, West Point, PA.[6] \"Product Information. Actonel (risedronate).\" Procter and Gamble Pharmaceuticals, Cincinnati, OH.[7] \"Product Information. Boniva (ibandronate).\" Roche Laboratories, Nutley, NJ.[8] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vosoritide, Denosumab, Cholecalciferol, Burosumab, Romosozumab, Zoledronic acid, Pamidronic acid", "alternatives_b": "Tetracaine, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Sodium chloride, Sodium sulfate, Sodium acetate, More", "updated_at": 1767369485}, {"id": 45796, "ingredient1": "Bortezomib", "ingredient2": "Acetohexamide", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45866/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45797, "ingredient1": "Human adenovirus e serotype 4 strain cl-68578 antigen", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "There are no data regarding the use of live, unattenuated Adenovirus Type 4 and Type 7 vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies. Caution is advised.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, unattenuated Adenovirus Type 4 and Type 7 vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45867/", "reference_text": "[1] \"Product Information. Adenovirus Vaccine Type 4 and Type 7 (adenovirus vaccine, live).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45798, "ingredient1": "Aminoglutethimide", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45868/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 45799, "ingredient1": "Amprenavir", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45869/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45800, "ingredient1": "Bortezomib", "ingredient2": "Aurothioglucose", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45870/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 45801, "ingredient1": "Bortezomib", "ingredient2": "Bacillus calmette-guerin substrain tice live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45871/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45802, "ingredient1": "Bortezomib", "ingredient2": "Bedaquiline", "severity": "Moderate", "effect": "Coadministration of bedaquiline with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; other antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; ketolide and macrolide antibiotics; interferons; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), especially in patients with diminished hepatic reserve. Patients treated with bedaquiline should have serum ALT, AST, alkaline phosphatase, and bilirubin monitored at baseline and monthly during treatment, or as often as needed. An increase of serum aminotransferases to greater than 3 times ULN should be followed by repeat testing within 48 hours. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Discontinue bedaquiline if aminotransferase elevations are accompanied by total bilirubin elevation greater than 2 times ULN, aminotransferase elevations are greater than 8 times ULN, or aminotransferase elevations persist beyond 2 weeks.", "mechanism_text": "Synergism", "recommendation": "The use of bedaquiline with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45872/", "reference_text": "[1] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[2] \"Product Information. Sirturo (bedaquiline).\" Janssen Pharmaceuticals, Titusville, NJ.[3] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Enasidenib, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 45803, "ingredient1": "Bortezomib", "ingredient2": "Benznidazole", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45873/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More", "alternatives_b": "Miltefosine, Pentamidine, Nifurtimox", "updated_at": 1767369485}, {"id": 45804, "ingredient1": "Bortezomib", "ingredient2": "Bifidobacterium longum infantis", "severity": "Moderate", "effect": "Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms contained in probiotic products. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy. It may be advisable to avoid using probiotics, particularly products containing saccharomyces boulardii, in patients who are significantly immunosuppressed.", "mechanism_text": "Others", "recommendation": "Caution is advised when probiotics are used during immunosuppressant or intense antineoplastic therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45874/", "reference_text": "[1] Borriello SP, Hammes WP, Holzapfel W, et.al \"Safety of probiotics that contain lactobacilli or bifidobacteria.\" Clin Infect Dis 36 (2003): 775-80[2] Salminen MK, Tynkkynen S, Rautelin H, et al. \"Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland.\" Clin Infect Dis 35 (2002): 1155-60[3] Schlegel L, Lemerle S, Geslin P \"Lactobacillus species as opportunistic pathogens in immunocompromised patients.\" Eur J Clin Microbiol Infect Dis 17 (1998): 887-8[4] Salminen MK, Rautelin H, Tynkkynen S, et al. \"Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG.\" Clin Infect Dis 38 (2004): 62-9[5] Husni RN, Gordon SM, Washington JA, Longworth DL \"Lactobacillus bacteremia and endocarditis: review of 45 cases.\" Clin Infect Dis 25 (1997): 1048-55[6] Boyle RJ, Robins-Browne RM, Tang ML \"Probiotic use in clinical practice: what are the risks?\" Am J Clin Nutr 83 (2006): 1256-64[7] Lolis N, Veldekis D, Moraitou H, et.al \"Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin.\" Crit Care 12 (2008): epub[8] Rautio M, Jousimies-Somer H, Kauma H, et al. \"Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG.\" Clin Infect Dis 28 (1999): 1159-60[9] Saxelin M, Chuang NH, Chassy B, et.al \"Lactobacilli and bacteremia in southern Finland, 1989-1992\" Clin Infect Dis 22 (1996): 564-6[10] Oggioni MR, Pozzi G, Valensin PE, Galieni P, Bigazzi C \"Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis.\" J Clin Microbiol 36 (1998): 325-6[11] Mackay AD, Taylor MB, Kibbler CC, Hamilton-Miller JM \"Lactobacillus endocarditis caused by a probiotic organism.\" Clin Microbiol Infect 5 (1999): 290-2", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45805, "ingredient1": "Bortezomib", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45875/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45806, "ingredient1": "Bortezomib", "ingredient2": "Bosentan", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45876/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Porfimer sodium, Niraparib, Selinexor, Aflibercept, More", "alternatives_b": "Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, Darunavir, Probenecid, More", "updated_at": 1767369485}, {"id": 45807, "ingredient1": "Brentuximab vedotin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Brentuximab vedotin can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. The peripheral neuropathy associated with brentuximab vedotin treatment is cumulative and primarily sensory, but cases of peripheral motor neuropathy have also been reported. Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin.", "source": "DDInter", "management_text": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects. Patients should be closely monitored for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent neuropathy or hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The potential for increased risk and/or severity of peripheral neuropathy and hepatotoxicity should be considered when brentuximab vedotin is used with other drugs that are also associated with these adverse effects.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45877/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc, Bothell, WA.[2] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Mitotane, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45808, "ingredient1": "Brigatinib", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45878/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45809, "ingredient1": "Brivaracetam", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inhibitors of CYP450 2C19 may increase the plasma concentrations of brivaracetam, which is partially metabolized by the isoenzyme. The risk of a clinically relevant CYP450 2C19-mediated interaction is considered to be low according to the manufacturer.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45879/", "reference_text": "[1] \"Product Information. Briviact (brivaracetam).\" UCB Pharma Inc, Smyrna, GA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Ticlid (ticlopidine).\" Syntex Laboratories Inc, Palo Alto, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45810, "ingredient1": "Butabarbital", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45880/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Ethchlorvynol, Midazolam, More", "updated_at": 1767369485}, {"id": 45811, "ingredient1": "Butalbital", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45881/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Ethchlorvynol, Midazolam, More", "updated_at": 1767369485}, {"id": 45812, "ingredient1": "Cabazitaxel", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45882/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Irinotecan", "updated_at": 1767369485}, {"id": 45813, "ingredient1": "Calaspargase pegol", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45883/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45814, "ingredient1": "Canagliflozin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45884/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45815, "ingredient1": "Canakinumab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45885/", "reference_text": "[1] \"Product Information. Kineret (anakinra).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc, Tarrytown, NY.[3] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45816, "ingredient1": "Candida albicans", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45886/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45817, "ingredient1": "Cannabidiol", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration of cannabidiol with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cannabidiol causes dose-related elevations of liver transaminases, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST).", "source": "DDInter", "management_text": "Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa. Serum transaminases and total bilirubin levels should be obtained prior to initiating cannabidiol, and patients with elevated baseline transaminase levels above 3 times the ULN accompanied by elevations in bilirubin above 2 times the ULN should be evaluated. Patients who develop clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, jaundice, dark urine) should have serum transaminases and total bilirubin measured promptly, and cannabidiol treatment interrupted or discontinued as appropriate. Cannabidiol should be discontinued in patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Also consider dosage adjustment or discontinuation of any coadministered medication that is known to affect the liver.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45887/", "reference_text": "[1] \"Product Information. Epidiolex (cannabidiol).\" Greenwich Biosciences Inc, Carlsbad, CA.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Epidiolex (cannabidiol).\" Greenwich Biosciences Inc, Carlsbad, CA.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45818, "ingredient1": "Carbamazepine", "ingredient2": "Bortezomib", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45888/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[3] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[6] Phuphanich S, Supko JG, Carson KA, et.al \"Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.\" J Neurooncol 100 (2010): 95-103[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Mitotane, Aflibercept, Trastuzumab, Talimogene laherparepvec, Estramustine, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45819, "ingredient1": "Carboplatin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45889/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45820, "ingredient1": "Carfilzomib", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45890/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45821, "ingredient1": "Carisoprodol", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45891/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Orphenadrine, Chlorzoxazone, Tizanidine, Baclofen, Methocarbamol, Chlormezanone", "updated_at": 1767369485}, {"id": 45822, "ingredient1": "Cenobamate", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45892/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45823, "ingredient1": "Ceritinib", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45893/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45824, "ingredient1": "Cerivastatin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45894/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 45825, "ingredient1": "Certolizumab pegol", "ingredient2": "Bortezomib", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45895/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45826, "ingredient1": "Chloramphenicol", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45896/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Ivosidenib, Talimogene laherparepvec, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More", "alternatives_b": "Tetracycline, Mupirocin, Rifamycin, Oxytetracycline, Bacitracin, Demeclocycline, Rifaximin, Gentamicin, Amikacin, Neomycin, Tetracycline, More", "updated_at": 1767369485}, {"id": 45827, "ingredient1": "Chloroquine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45897/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 45828, "ingredient1": "Chlorpropamide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45898/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Tisagenlecleucel, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45829, "ingredient1": "Bortezomib", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45899/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45830, "ingredient1": "Bortezomib", "ingredient2": "Vibrio cholerae CVD 103-HgR strain live antigen (live)", "severity": "Moderate", "effect": "There are no data regarding the use of live, attenuated cholera vaccine during treatment with immunosuppressive therapies, including alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. It is not known whether immunosuppressed patients may have an increased risk of adverse reactions or a decreased or suboptimal immunologic response to the vaccine.", "source": "DDInter", "management_text": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "mechanism_text": "Others", "recommendation": "The safety and efficacy of live, attenuated cholera vaccine have not been established in patients receiving immunosuppressive therapies.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45900/", "reference_text": "[1] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[3] \"Product Information. Vaxchora (cholera vaccine, live).\" PaxVax, Miami, FL.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45831, "ingredient1": "Cilostazol", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active metabolites, which are substrates of these isoenzymes. The possibility of prolonged and/or increased pharmacologic effects of cilostazol should be considered.", "source": "DDInter", "management_text": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience adverse effects of cilostazol such as dizziness, nausea, diarrhea, bleeding, or irregular heartbeat.", "mechanism_text": "Metabolism", "recommendation": "Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 and/or 2C19 inhibitor is added to or withdrawn from cilostazol therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45901/", "reference_text": "[1] Suri A, Bramer SL \"Effect of omeprazole on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 53-9[2] Herrlin K, Segerdahl M, Gustafsson LL, Kalso E \"Methadone, ciprofloxacin, and adverse drug reactions.\" Lancet 356 (2000): 2069-70[3] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.[4] Suri A, Forbes WP, Bramer SL \"Effects of CYP3A inhibition on the metabolism of cilostazol.\" Clin Pharmacokinet 37 (1999): 61-8[5] Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M \"Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers.\" Biopharm Drug Dispos 32 (2011): 168-74[6] Shahzadi A, Javed I, Aslam B, et al. \"Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers.\" Pak J Pharm Sci 24 (2011): 63-8[7] Sawant RD \"Rhabdomyolysis due to an uncommon interaction of ciprofloxacin with simvastatin.\" Can J Clin Pharmacol 16 (2009): e78-9[8] Hedaya MA, El-Afify DR, El-Maghraby GM \"The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers.\" Biopharm Drug Dispos 27 (2006): 103-10[9] McLellan RA, Drobitch RK, Monshouwer M, Renton KW \"Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human.\" Drug Metab Dispos 24 (1996): 1134-8[10] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.[11] \"Product Information. Pletal (cilostazol).\" Otsuka American Pharmaceuticals, Rockville, MD.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 45832, "ingredient1": "Cinacalcet", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with cinacalcet may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by cinacalcet, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is advised if cinacalcet must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range (e.g., class IC antiarrhythmic agents, phenothiazines, certain beta blockers, and most tricyclic antidepressants). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cinacalcet is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cinacalcet must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45902/", "reference_text": "[1] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp.\" ([2006]):[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Sensipar (cinacalcet).\" Amgen USA, Thousand Oaks, CA.[4] \"Product Information. Sensipar (cinacalcet).\" Amgen USA, Thousand Oaks, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol, Paricalcitol", "updated_at": 1767369485}, {"id": 45833, "ingredient1": "Cisplatin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45903/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45834, "ingredient1": "Citalopram", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45904/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 45835, "ingredient1": "Cladribine", "ingredient2": "Bortezomib", "severity": "Major", "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45905/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[3] \"Product Information. Leustatin (cladribine).\" Ortho Biotech Inc, Raritan, NJ.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Vismodegib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45836, "ingredient1": "Clarithromycin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45906/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Vonoprazan, Levofloxacin, Dirithromycin, Lincomycin, Clindamycin", "updated_at": 1767369485}, {"id": 45837, "ingredient1": "Clobazam", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45907/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Meprobamate, Hydroxyzine, Chlordiazepoxide, Halazepam, Buspirone, Clorazepic acid", "updated_at": 1767369485}, {"id": 45838, "ingredient1": "Clofarabine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The liver is a known target organ for clofarabine toxicity, and concomitant use of other potentially hepatotoxic agents may increase the risk of liver injury. Severe and fatal hepatotoxicity has occurred with the use of clofarabine alone.", "source": "DDInter", "management_text": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Hepatic function should be monitored during clofarabine administration, and therapy discontinued if grade 3 to 4 liver enzyme or bilirubin elevations occur. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of clofarabine with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45908/", "reference_text": "[1] \"Product Information. Clolar (clofarabine).\" sanofi-aventis, Bridgewater, NJ.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "Fluorouracil, Mercaptopurine, Trifluridine, Floxuridine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 45839, "ingredient1": "Clopidogrel", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with inhibitors of CYP450 2C19 may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation by the isoenzyme to a pharmacologically active metabolite.", "source": "DDInter", "management_text": "Based on existing data, it may be advisable to closely monitor the therapeutic efficacy of clopidogrel during concomitant treatment with CYP450 2C19 inhibitors.", "mechanism_text": "Metabolism", "recommendation": "Based on existing data, it may be advisable to closely monitor the therapeutic efficacy of clopidogrel during concomitant treatment with CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45909/", "reference_text": "[1] Moayyedi P, Sadowski DC \"Proton pump inhibitors and clopidogrel -- hazardous drug interaction or hazardous interpretation of data?\" Can J Gastroenterol 23 (2009): 251-2[2] Pezalla E, Day D, Pulliadath I \"Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.\" J Am Coll Cardiol 52 (2008): 1038-9[3] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb, Princeton, NJ.[4] Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J \"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.\" J Thromb Haemost 4 (2006): 2508-9[5] Lau WC, Gurbel PA \"The drug-drug interaction between proton pump inhibitors and clopidogrel.\" CMAJ 180 (2009): 699-700[6] \"Product Information. Cordarone (amiodarone).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[7] Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B \"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.\" Am Heart J 157 (2009): 148.e1-5[8] Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T \"Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactions.\" Br J Clin Pharmacol 49 (2000): 244-53[9] \"Product Information. Kapidex (dexlansoprazole).\" Takeda Pharmaceuticals America, Lincolnshire, IL.[10] Frere C, Cuisset T, Morange PE, et al. \"Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome.\" Am J Cardiol 101 (2008): 1088-1093[11] Mega JL, Close SL, Wiviott SD, et al. \"Cytochrome p-450 polymorphisms and response to clopidogrel.\" N Engl J Med 360 (2009): 354-62[12] Gilard M, Arnaud B, Cornily JC, et al \"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.\" J Am Coll Cardiol 51 (2008): 256-60[13] Li XQ, Andersson TB, Ahlstrom M, Weidolf L \"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.\" Drug Metab Dispos 32 (2004): 821-7[14] Juurlink DN, Gomes T, Ko DT, et al \"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.\" CMAJ 180 (2009): 713-8[15] Simon T, Verstuyft C, Mary-Krause M, et al \"Genetic determinants of response to clopidogrel and cardiovascular events.\" N Engl J Med 360 (2009): 363-75[16] Varenhorst C, Janes S, Erlinge D, et al \"Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.\" Eur Heart J 30 (2009): 1744-52[17] Small DS, Farid NA, Payne CD, et al. \"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.\" J Clin Pharmacol 48 (2008): 475-84[18] Hulot JS, Bura A, Villard E, et al. \"Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.\" Blood (2006):[19] Collet JP, Hulot JS, Pena A, et al. \"Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.\" Lancet 373 (2009): 309-17[20] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[21] \"Product Information. VFEND (voriconazole).\" Pfizer U.S. Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Ticagrelor, Betrixaban, Apixaban, Rivaroxaban, Iloprost, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More", "updated_at": 1767369485}, {"id": 45840, "ingredient1": "Clotrimazole", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45910/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin, Tetracycline, Minocycline, More", "updated_at": 1767369485}, {"id": 45841, "ingredient1": "Clozapine", "ingredient2": "Bortezomib", "severity": "Major", "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.", "source": "DDInter", "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45911/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] Canadian Pharmacists Association \"e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink.\"[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Talimogene laherparepvec, Sonidegib, Estramustine, Aminolevulinic acid", "alternatives_b": "Fluphenazine, Haloperidol, Thiothixene, Amisulpride, Promazine, Thioridazine, Lumateperone, Pimozide, Trifluoperazine, Cariprazine, Paliperidone, More", "updated_at": 1767369485}, {"id": 45842, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45912/", "reference_text": "[1] \"Product Information. Spherulin (coccidioidin skin test).\" ALK Laboratories Inc, Wallingford, CT.[2] \"Product Information. Tuberculin PPD (Mantoux) (tuberculin purified protein derivative).\" Connaught Laboratories Ltd, Toronto, ON.[3] \"Product Information. Candin (candida albicans extract).\" Nielsen Biosciences Inc, San Diego, CA.[4] \"Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen).\" Aventis Pharmaceuticals, Swiftwater, PA.[5] \"Product Information. Multitest CMI (skin test antigens, multiple).\" Aventis Pharmaceuticals, Swiftwater, PA.[6] \"Product Information. Histolyn-Cyl (histoplasmin).\" ALK Laboratories Inc, Wallingford, CT.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45843, "ingredient1": "Colchicine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45913/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, Niraparib, More", "alternatives_b": "Pegloticase, Febuxostat, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 45844, "ingredient1": "Conivaptan", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.", "source": "DDInter", "management_text": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45914/", "reference_text": "[1] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc, Nashville, TN.[2] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc, Nashville, TN.[3] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[6] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[21] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[35] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T \"Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol.\" Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[36] Weber A, Jager R, Borner A, et al. \"Can grapefruit juice influence ethinyl estradiol bioavailability?\" Contraception 53 (1996): 41-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Mitotane, More", "alternatives_b": "Tolvaptan", "updated_at": 1767369485}, {"id": 45845, "ingredient1": "Dabrafenib", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45915/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45846, "ingredient1": "Dapagliflozin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45916/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45847, "ingredient1": "Dapsone", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45917/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Minocycline, Clindamycin, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine", "updated_at": 1767369485}, {"id": 45848, "ingredient1": "Deferasirox", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45918/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Belzutifan, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 45849, "ingredient1": "Deferiprone", "ingredient2": "Bortezomib", "severity": "Major", "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.", "source": "DDInter", "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45919/", "reference_text": "[1] \"Product Information. Ferriprox (deferiprone).\" ApoPharma USA Inc, Rockville, MD.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid.\"[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, Talimogene laherparepvec, More", "alternatives_b": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More", "updated_at": 1767369485}, {"id": 45850, "ingredient1": "Delavirdine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45920/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45851, "ingredient1": "Denosumab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.", "source": "DDInter", "management_text": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45921/", "reference_text": "[1] \"Product Information. Prolia (denosumab).\" Amgen USA, Thousand Oaks, CA.[2] \"Product Information. Lonsurf (tipiracil-trifluridine).\" Taiho Oncology, Inc., Princeton, NJ.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Tiludronic acid, Vosoritide, Etidronic acid, Ibandronate, Cholecalciferol, Burosumab, Romosozumab", "updated_at": 1767369485}, {"id": 45852, "ingredient1": "Diazepam", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45922/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More", "alternatives_b": "Meprobamate, Hydroxyzine, Chlordiazepoxide, Halazepam, Buspirone, Clorazepic acid", "updated_at": 1767369485}, {"id": 45853, "ingredient1": "Didanosine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45923/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45854, "ingredient1": "Dimethyl fumarate", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45924/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Ivosidenib, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Aminolevulinic acid, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45855, "ingredient1": "Dinutuximab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45925/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45856, "ingredient1": "Diroximel fumarate", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45926/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Ivosidenib, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Aminolevulinic acid, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45857, "ingredient1": "Disulfiram", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45927/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Lindane, Diamorphine, Acamprosate, Lofexidine, Methadone, Levacetylmethadol, Nalmefene, Nicotine, Buprenorphine", "updated_at": 1767369485}, {"id": 45858, "ingredient1": "Bortezomib", "ingredient2": "Valproic acid", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45928/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45859, "ingredient1": "Docetaxel", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45929/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Irinotecan", "updated_at": 1767369485}, {"id": 45860, "ingredient1": "Dulaglutide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45930/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45861, "ingredient1": "Duvelisib", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45931/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc., Needham, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Selinexor, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45862, "ingredient1": "Echinacea", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45932/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45863, "ingredient1": "Efalizumab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45933/", "reference_text": "[1] \"Product Information. Raptiva (efalizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "updated_at": 1767369485}, {"id": 45864, "ingredient1": "Efavirenz", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45934/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Enasidenib, Mitotane, Niraparib, Selinexor, Aflibercept, Trastuzumab, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45865, "ingredient1": "Elagolix", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45935/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "alternatives_b": "Norethisterone, Nafarelin, Cetrorelix, Pasireotide, Ganirelix, Relugolix, Lanreotide, Gonadorelin", "updated_at": 1767369485}, {"id": 45866, "ingredient1": "Elotuzumab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45936/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45867, "ingredient1": "Empagliflozin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45937/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Belzutifan, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45868, "ingredient1": "Enfortumab vedotin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45938/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45869, "ingredient1": "Enzalutamide", "ingredient2": "Bortezomib", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45939/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[3] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[6] Phuphanich S, Supko JG, Carson KA, et.al \"Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.\" J Neurooncol 100 (2010): 95-103[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "updated_at": 1767369485}, {"id": 45870, "ingredient1": "Epirubicin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.", "source": "DDInter", "management_text": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "mechanism_text": "Synergism", "recommendation": "Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45940/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ellence (epirubicin)\" Pharmacia and Upjohn, Kalamazoo, MI.[4] \"Product Information. Hivid (zalcitabine).\" Roche Laboratories, Nutley, NJ.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, Selinexor, Aflibercept, Venetoclax, More", "alternatives_b": "Idarubicin, Valrubicin, Plicamycin, Mitomycin, Daunorubicin, Dactinomycin", "updated_at": 1767369485}, {"id": 45871, "ingredient1": "Eribulin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45941/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45872, "ingredient1": "Ertugliflozin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45942/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45873, "ingredient1": "Erythromycin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45943/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Dirithromycin, Lincomycin, Clindamycin, Minocycline, Clindamycin, Isotretinoin, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Rifamycin, More", "updated_at": 1767369485}, {"id": 45874, "ingredient1": "Escitalopram", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45944/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 45875, "ingredient1": "Eslicarbazepine", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45945/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45876, "ingredient1": "Esomeprazole", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45946/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Vonoprazan, Levofloxacin, Fenoprofen, Ketorolac, Indomethacin, Glucosamine, Chondroitin sulfate, More", "updated_at": 1767369485}, {"id": 45877, "ingredient1": "Etanercept", "ingredient2": "Bortezomib", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45947/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "updated_at": 1767369485}, {"id": 45878, "ingredient1": "Ethambutol", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45948/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 45879, "ingredient1": "Ethionamide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45949/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 45880, "ingredient1": "Etoposide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45950/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Anagrelide, More", "alternatives_b": "Irinotecan", "updated_at": 1767369485}, {"id": 45881, "ingredient1": "Etravirine", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45951/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Niraparib, Aflibercept, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45882, "ingredient1": "Exenatide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45952/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45883, "ingredient1": "Fedratinib", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended with the concomitant use of fedratinib and CYP450 2C19 inhibitors. Patients should be monitored for adverse effects including anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended with the concomitant use of fedratinib and CYP450 2C19 inhibitors.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45953/", "reference_text": "[1] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation, Summit, NJ.[2] \"Product Information. Nexium (esomeprazole)\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[4] Gunston GD, Mehta U \"Potentially serious drug interactions with grapefruit juice.\" S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD \"Grapefruit juice and drugs - how significant is the interaction.\" Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients.\" Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD \"Grapefruit juice-drug interactions.\" Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. \"Dramatic inhibition of amiodarone metabolism induced by grapefruit juice.\" Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR \"Grapefruit juice felodipine interaction: Effect of naringin and 6',7'-dihydroxybergamottin in humans.\" Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW \"The influence of caffeine on the steady-state pharmacokinetics of theophylline.\" Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A \"Interaction between grapefruit juice and diazepam in humans.\" Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.\" Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD \"Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.\" Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A \"Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation.\" Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ \"Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components.\" Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K \"Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.\" Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC \"Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers.\" J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E \"Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers.\" Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG \"Drug-food interactions in clinical practice.\" J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC \"The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study.\" Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ \"Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors.\" Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK \"Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy.\" Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. \"Grapefruit juice increases oral nimodipine bioavailability.\" Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K \"Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects.\" Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al \"Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance.\" Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ \"Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid.\" Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG \"Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.\" Clin Pharmacokinet 38 (2000): 41-57[28] \"Grapefruit juice interactions with drugs.\" Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. \"Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.\" Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS \"Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice.\" Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD \"Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics.\" Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J \"Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers.\" Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A \"Effect of grapefruit juice on cyclosporine pharmacokinetics.\" Pediatr Nephrol 10 (1996): 395[34] Flanagan D \"Understanding the grapefruit-drug interaction.\" Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ \"Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.\" Clin Pharmacol Ther 58 (1995): 127-31", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45884, "ingredient1": "Felbamate", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45954/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45885, "ingredient1": "Filgrastim", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45955/", "reference_text": "[1] \"Product Information. Leukine (sargramostim).\" Immunex Corporation, Seattle, WA.[2] \"Product Information. Granix (tbo-filgrastim).\" Teva Pharmaceuticals USA, North Wales, PA.[3] \"Product Information. Stemgen (ancestim)\" Amgen, Thousand Oaks, CA.[4] \"Product Information. Neupogen (filgrastim).\" Amgen, Thousand Oaks, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Aflibercept, Anagrelide, More", "updated_at": 1767369485}, {"id": 45886, "ingredient1": "Fingolimod", "ingredient2": "Bortezomib", "severity": "Major", "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.", "source": "DDInter", "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45956/", "reference_text": "[1] \"Product Information. Gilenya (fingolimod).\" Novartis Pharmaceuticals, East Hanover, NJ.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45887, "ingredient1": "Flibanserin", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45957/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, More", "alternatives_b": "Ritodrine, Bremelanotide, Bromocriptine, Cabergoline", "updated_at": 1767369485}, {"id": 45888, "ingredient1": "Fludarabine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45958/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Fluorouracil, Mercaptopurine, Trifluridine, Floxuridine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 45889, "ingredient1": "Fluvastatin", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45959/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Belzutifan, Mitotane, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 45890, "ingredient1": "Glimepiride", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45960/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, Niraparib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45891, "ingredient1": "Glipizide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45961/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, Niraparib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45892, "ingredient1": "Glyburide", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45962/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Belzutifan, Mitotane, Niraparib, Selinexor, Aflibercept, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45893, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates. The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45963/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 45894, "ingredient1": "Bortezomib", "ingredient2": "Sodium aurothiomalate", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45964/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "Penicillamine", "updated_at": 1767369485}, {"id": 45895, "ingredient1": "Golimumab", "ingredient2": "Bortezomib", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45965/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45896, "ingredient1": "Griseofulvin", "ingredient2": "Bortezomib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45966/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Salicylic acid, Selenium Sulfide, Thiabendazole, Miconazole, Ciclopirox, Econazole, Flucytosine, Tioconazole, Chlorphenesin", "updated_at": 1767369485}, {"id": 45897, "ingredient1": "Hepatitis A Vaccine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45967/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45898, "ingredient1": "Hepatitis B Vaccine (Recombinant)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45968/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45899, "ingredient1": "Human papillomavirus type 11 L1 capsid protein antigen", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45969/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45900, "ingredient1": "Hydralazine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45970/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More", "alternatives_b": "Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine", "updated_at": 1767369485}, {"id": 45901, "ingredient1": "Hydroxychloroquine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45971/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, More", "alternatives_b": "Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine", "updated_at": 1767369485}, {"id": 45902, "ingredient1": "Idelalisib", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. The risk and/or severity of diarrhea may be increased when idelalisib is used with other agents that cause diarrhea.", "source": "DDInter", "management_text": "The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible. Patients treated with idelalisib should be monitored for development of severe diarrhea or colitis and have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction and/or life-threatening diarrhea or intestinal perforation. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Patients should also contact their physician immediately if the number of bowel movements per day increases by six or more, or if they have new or worsening abdominal pain, chills, fever, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "The use of idelalisib with other agents that can induce hepatotoxicity and/or diarrhea should be avoided whenever possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45972/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences, Foster City, CA.", "alternatives_a": "Hydroxyurea, Cisplatin, Porfimer sodium, Estramustine, Aminolevulinic acid, Procarbazine, Altretamine, Anagrelide", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45903, "ingredient1": "Indinavir", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45973/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45904, "ingredient1": "Infliximab", "ingredient2": "Bortezomib", "severity": "Major", "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).", "source": "DDInter", "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.", "mechanism_text": "Synergism", "recommendation": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45974/", "reference_text": "[1] FDA. U.S. Food and Drug Administration \"FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. Available from: URL: http://www.fda.gov/Drugs/DrugSafety/ucm270849.htm.\" ([2011 Sept 7]):[2] \"Product Information. Cimzia (certolizumab).\" UCB Pharma Inc, Smyrna, GA.[3] \"Product Information. Simponi (golimumab).\" Centocor Inc, Malvern, PA.[4] \"Product Information. Enbrel (etanercept).\" Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] \"Product Information. Remicade (infliximab).\" Centocor Inc, Malvern, PA.[6] \"Product Information. Humira (adalimumab).\" Abbott Pharmaceutical, Abbott Park, IL.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "updated_at": 1767369485}, {"id": 45905, "ingredient1": "Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45975/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45906, "ingredient1": "Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45976/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45907, "ingredient1": "Insulin human", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45977/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45908, "ingredient1": "Insulin aspart (aspart)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45978/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45909, "ingredient1": "Insulin aspart (aspart protamine)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45979/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45910, "ingredient1": "Insulin degludec", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45980/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45911, "ingredient1": "Insulin detemir", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45981/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45912, "ingredient1": "Insulin glargine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45982/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45913, "ingredient1": "Insulin glulisine", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45983/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45914, "ingredient1": "Insulin human (inhalation, rapid acting)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45984/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45915, "ingredient1": "Insulin human (isophane)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45985/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45916, "ingredient1": "Insulin lispro", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45986/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45917, "ingredient1": "Insulin lispro (protamine)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45987/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45918, "ingredient1": "Insulin human (regular)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45988/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45919, "ingredient1": "Insulin human (zinc)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45989/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45920, "ingredient1": "Insulin human (zinc extended)", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45990/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45921, "ingredient1": "Interferon alfa-2a, Recombinant", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45991/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45922, "ingredient1": "Interferon alfa-2b", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45992/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45923, "ingredient1": "Interferon alfa-n1", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45993/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45924, "ingredient1": "Interferon alfacon-1", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45994/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45925, "ingredient1": "Interferon beta-1a", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45995/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45926, "ingredient1": "Interferon beta-1b", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45996/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Sotorasib, Enasidenib, Belzutifan, More", "updated_at": 1767369485}, {"id": 45927, "ingredient1": "Diiodohydroxyquinoline", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45997/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More", "alternatives_b": "Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Clindamycin, Trichlormethiazide, Ciclopirox, Darunavir, Probenecid, More", "updated_at": 1767369485}, {"id": 45928, "ingredient1": "Ipilimumab", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45998/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45929, "ingredient1": "Isoniazid", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/45999/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Mitotane, Niraparib, More", "alternatives_b": "Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Pyridoxine, Pretomanid, Aminosalicylic acid", "updated_at": 1767369485}, {"id": 45930, "ingredient1": "Itraconazole", "ingredient2": "Bortezomib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46000/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More", "alternatives_b": "Micafungin, Caspofungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin", "updated_at": 1767369485}, {"id": 45931, "ingredient1": "Bortezomib", "ingredient2": "Ivosidenib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46001/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, Niraparib, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45932, "ingredient1": "Bortezomib", "ingredient2": "Ixabepilone", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46002/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Anagrelide, More", "alternatives_b": "Idarubicin, Valrubicin, Plicamycin, Mitomycin, Daunorubicin, Dactinomycin", "updated_at": 1767369485}, {"id": 45933, "ingredient1": "Bortezomib", "ingredient2": "Ixazomib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46003/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, Aflibercept, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45934, "ingredient1": "Bortezomib", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor. When oral midazolam was administered concomitantly with and at 2 or 4 hours after administration of lefamulin tablets, mean midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by approximately 100% and 200%, respectively.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever oral lefamulin is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used with drugs that undergo metabolism via CYP450 3A4, particularly sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46004/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[3] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc., King of Prussia, PA.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, Niraparib, More", "alternatives_b": "Bacitracin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 45935, "ingredient1": "Bortezomib", "ingredient2": "Leflunomide", "severity": "Major", "effect": "The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. The recent, concomitant, or sequential use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.", "source": "DDInter", "management_text": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa. Due to the prolonged elimination half-life of leflunomide's active metabolite, an interaction may occur even when these agents are initiated after the discontinuation of treatment with leflunomide or teriflunomide. Liver enzymes, bilirubin, platelet, white blood cell count, and hemoglobin or hematocrit should be evaluated at baseline and regularly during therapy.", "mechanism_text": "Synergism", "recommendation": "Close monitoring is recommended if leflunomide or teriflunomide is used in patients who are currently receiving or have recently received other immunosuppressive and hepatotoxic agents, and vice versa.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46005/", "reference_text": "[1] \"Product Information. Arava (leflunomide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.", "alternatives_a": "Pertuzumab, Vismodegib, Enasidenib, Belzutifan, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Aminolevulinic acid, Tazemetostat, Vorinostat, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45936, "ingredient1": "Bortezomib", "ingredient2": "Lemborexant", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46006/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Niraparib, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Ethchlorvynol, Midazolam, More", "updated_at": 1767369485}, {"id": 45937, "ingredient1": "Bortezomib", "ingredient2": "Lesinurad", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46007/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Pegloticase, Febuxostat, Rasburicase, Probenecid", "updated_at": 1767369485}, {"id": 45938, "ingredient1": "Bortezomib", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46008/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More", "alternatives_b": "Apomorphine, Ropinirole, Opicapone, Cabergoline, Amantadine, Rasagiline, Entacapone, Selegiline, Tolcapone, Rotigotine, Bromocriptine, More", "updated_at": 1767369485}, {"id": 45939, "ingredient1": "Bortezomib", "ingredient2": "Linagliptin", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46009/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Ixazomib, Enasidenib, Porfimer sodium, Niraparib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45940, "ingredient1": "Bortezomib", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46010/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Bacitracin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 45941, "ingredient1": "Bortezomib", "ingredient2": "Liraglutide", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46011/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45942, "ingredient1": "Bortezomib", "ingredient2": "Lixisenatide", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46012/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45943, "ingredient1": "Bortezomib", "ingredient2": "Lomitapide", "severity": "Major", "effect": "Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.", "source": "DDInter", "management_text": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46013/", "reference_text": "[1] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.[2] \"Product Information. Juxtapid (lomitapide).\" Aegerion Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Enasidenib, Mitotane, Niraparib, Porfimer sodium, Selinexor, Aflibercept, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 45944, "ingredient1": "Bortezomib", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46014/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 45945, "ingredient1": "Bortezomib", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration with lorlatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C9 isoenzyme. The proposed mechanism involves decreased metabolic clearance due to induction of CYP450 2C9 by lorlatinib.", "source": "DDInter", "management_text": "Caution is advised when lorlatinib is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lorlatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lorlatinib is used concurrently with drugs that are known CYP450 2C9 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46015/", "reference_text": "[1] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] \"Product Information. Lorbrena (lorlatinib).\" Pfizer U.S. Pharmaceuticals Group, New York, NY.[6] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Selinexor, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45946, "ingredient1": "Bortezomib", "ingredient2": "Lovastatin", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46016/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Mitotane, Niraparib, Porfimer sodium, Aflibercept, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, More", "updated_at": 1767369485}, {"id": 45947, "ingredient1": "Bortezomib", "ingredient2": "Lyme disease vaccine (recombinant OspA)", "severity": "Moderate", "effect": "The administration of Lyme disease vaccine to immunosuppressed patients may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy. Vaccines may generally be administered to patients receiving corticosteroids as replacement therapy (e.g., for Addison's disease).", "mechanism_text": "Others", "recommendation": "The manufacturer suggests considering deferral of vaccination against Lyme disease until 3 months after discontinuation of immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46017/", "reference_text": "[1] \"Product Information. Lymerix (Lyme disease vaccine).\" SmithKline Beecham, Philadelphia, PA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45948, "ingredient1": "Bortezomib", "ingredient2": "Measles virus vaccine live attenuated", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46018/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45949, "ingredient1": "Bortezomib", "ingredient2": "Melphalan", "severity": "Minor", "effect": "Coadministration of melphalan plus prednisone has been shown to increase bortezomib systemic exposure. However, the interaction is unlikely to be clinically relevant.", "source": "DDInter", "management_text": "-", "mechanism_text": "Others", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46019/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Thiotepa, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Uracil mustard", "updated_at": 1767369485}, {"id": 45950, "ingredient1": "Bortezomib", "ingredient2": "Meningococcal polysaccharide vaccine group C", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46020/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45951, "ingredient1": "Bortezomib", "ingredient2": "Mephenytoin", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46021/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45952, "ingredient1": "Bortezomib", "ingredient2": "Methylphenobarbital", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46022/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45953, "ingredient1": "Bortezomib", "ingredient2": "Methotrexate", "severity": "Moderate", "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46023/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Methotrexate (methotrexate).\" Lederle Laboratories, Wayne, NJ.[3] Nesher G, Mates M, Zevin S \"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis.\" Arthritis Rheum 48 (2003): 571-572", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Tazemetostat, Altretamine, Tagraxofusp, Belzutifan, Mitotane, Selinexor, Aflibercept, Trastuzumab, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45954, "ingredient1": "Bortezomib", "ingredient2": "Metreleptin", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46024/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "alternatives_b": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "updated_at": 1767369485}, {"id": 45955, "ingredient1": "Bortezomib", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.", "source": "DDInter", "management_text": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46025/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] He K, Woolf TF, Hollenberg PF \"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).\" J Pharmacol Exp Ther 288 (1999): 791-7[3] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[6] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[8] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] \"Product Information. Korlym (mifepristone).\" Corcept Therapeutics Incorporated, Menlo Park, CA.[10] \"Product Information. Mifeprex (mifepristone)\" Danco Laboratories, New York, NY.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Mitotane, Niraparib, More", "alternatives_b": "Ulipristal, Danazol, Ospemifene, Bazedoxifene, Prasterone", "updated_at": 1767369485}, {"id": 45956, "ingredient1": "Bortezomib", "ingredient2": "Miglitol", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46026/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45957, "ingredient1": "Bortezomib", "ingredient2": "Mipomersen", "severity": "Major", "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.", "source": "DDInter", "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46027/", "reference_text": "[1] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.[2] \"Product Information. Kynamro (mipomersen).\" Genzyme Corporation, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 45958, "ingredient1": "Bortezomib", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46028/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[3] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[6] Phuphanich S, Supko JG, Carson KA, et.al \"Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.\" J Neurooncol 100 (2010): 95-103[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45959, "ingredient1": "Bortezomib", "ingredient2": "Modafinil", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46029/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Niraparib, Selinexor, More", "alternatives_b": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Dexmethylphenidate, Dextroamphetamine, Citicoline", "updated_at": 1767369485}, {"id": 45960, "ingredient1": "Bortezomib", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.", "source": "DDInter", "management_text": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46030/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Alkermes, Inc, Cambridge, MA.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Ivosidenib, Sonidegib, Mitotane, Porfimer sodium, Estramustine, Aminolevulinic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45961, "ingredient1": "Bortezomib", "ingredient2": "Mumps virus strain B level jeryl lynn live antigen", "severity": "Major", "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.", "source": "DDInter", "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.", "mechanism_text": "Others", "recommendation": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46031/", "reference_text": "[1] Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. \"Harrison's Principles of Internal Medicine. 14th ed.\" New York, NY: McGraw-Hill Health Professionals Division (1998):[2] \"Product Information. YF-Vax (yellow fever vaccine).\" sanofi pasteur, Swiftwater, PA.[3] \"Product Information. Attenuvax (measles virus vaccine, live, attenuated).\" Merck & Co, Inc, West Point, PA.[4] Kriner P, Lopez K, Leung J, Harpaz R, Bialek SR \"Notes from the field: varicella-associated death of a vaccinated child with leukemia - California, 2012.\" MMWR Morb Mortal Wkly Rep 63 (2014): 161[5] \"Product Information. M-M-R II (measles/mumps/rubella virus vaccine).\" Merck & Company Inc, West Point, PA.[6] Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK \"Acute retinal necrosis after herpes zoster vaccination.\" Arch Ophthalmol 129 (2011): 1495-7[7] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[8] \"Product Information. Meruvax II (rubella virus vaccine, live).\" Merck & Co, Inc, West Point, PA.[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45962, "ingredient1": "Bortezomib", "ingredient2": "Nafcillin", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46032/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, More", "alternatives_b": "Sulbactam, Oxacillin, Dicloxacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, Benzylpenicillin, More", "updated_at": 1767369485}, {"id": 45963, "ingredient1": "Bortezomib", "ingredient2": "Naltrexone", "severity": "Moderate", "effect": "Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.", "source": "DDInter", "management_text": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.", "mechanism_text": "Synergism", "recommendation": "The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46033/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Dextropropoxyphene, Methadone, Pentazocine, More", "updated_at": 1767369485}, {"id": 45964, "ingredient1": "Bortezomib", "ingredient2": "Natalizumab", "severity": "Major", "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.", "source": "DDInter", "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.", "mechanism_text": "Synergism", "recommendation": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46034/", "reference_text": "[1] \"Product Information. Tysabri (natalizumab).\" Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA.", "alternatives_a": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "updated_at": 1767369485}, {"id": 45965, "ingredient1": "Bortezomib", "ingredient2": "Nateglinide", "severity": "Moderate", "effect": "Bortezomib may interfere with the therapeutic effects of insulin and other antidiabetic agents.", "source": "DDInter", "management_text": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents. Patients should learn to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypo- or hyperglycemia occur during bortezomib therapy, patients should initiate appropriate remedial therapy immediately and contact their physician.", "mechanism_text": "Others", "recommendation": "Blood glucose should be closely monitored when bortezomib is prescribed to patients receiving insulin or other antidiabetic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46035/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Skillman TG, Feldman JM \"The pharmacology of sulfonylureas.\" Am J Med 70 (1981): 361-72[3] Jerntorp P, Almer LO \"Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes.\" Acta Med Scand 656 (1981): 33-6[4] \"Product Information. Glucotrol (glipizide).\" Pfizer US Pharmaceuticals, New York, NY.[5] \"Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association.\" Diabetes Care 25(Suppl 1) (2002): S50-S60[6] \"Product Information. Diabeta (glyburide).\" Hoechst Marion-Roussel Inc, Kansas City, MO.[7] Jerntorp P, Almer LO, Holin H, et al \"Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush.\" Eur J Clin Pharmacol 24 (1983): 237-42[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A \"Interaction of ethanol and glipizide in humans.\" Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al \"Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy.\" Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[11] \"Product Information. Diabinese (chlorpropamide).\" Pfizer US Pharmaceuticals, New York, NY.", "alternatives_a": "Pertuzumab, Olaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Guar gum", "updated_at": 1767369485}, {"id": 45966, "ingredient1": "Bortezomib", "ingredient2": "Naxitamab", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46036/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45967, "ingredient1": "Bortezomib", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46037/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Niraparib, More", "alternatives_b": "Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Fluvoxamine, More", "updated_at": 1767369485}, {"id": 45968, "ingredient1": "Bortezomib", "ingredient2": "Nelarabine", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46038/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Fluorouracil, Mercaptopurine, Trifluridine, Floxuridine, Pralatrexate, Decitabine, Azacitidine, Capecitabine", "updated_at": 1767369485}, {"id": 45969, "ingredient1": "Bortezomib", "ingredient2": "Nelfinavir", "severity": "Moderate", "effect": "Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme.", "source": "DDInter", "management_text": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be monitored for the development of potential bortezomib toxicities such as peripheral neuropathy, orthostatic hypotension, thrombocytopenia, and neutropenia.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to bortezomib should be monitored more closely whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46039/", "reference_text": "[1] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[2] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[3] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Enasidenib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45970, "ingredient1": "Bortezomib", "ingredient2": "Nevirapine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46040/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Mitotane, Niraparib, Porfimer sodium, More", "alternatives_b": "Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Rilpivirine, Dolutegravir, More", "updated_at": 1767369485}, {"id": 45971, "ingredient1": "Bortezomib", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46041/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[2] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Porfimer sodium, Selinexor, Aflibercept, Trastuzumab, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45972, "ingredient1": "Bortezomib", "ingredient2": "Niraparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib.", "source": "DDInter", "management_text": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if niraparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46042/", "reference_text": "[1] \"Product Information. Zejula (niraparib).\" Tesaro Inc., Waltham, MA.", "alternatives_a": "Pertuzumab, Panobinostat, Vismodegib, Sotorasib, Ivosidenib, Belzutifan, Sonidegib, Mitotane, Niraparib, Porfimer sodium, Estramustine, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45973, "ingredient1": "Bortezomib", "ingredient2": "Nitrofurantoin", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46043/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, More", "alternatives_b": "Bacitracin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 45974, "ingredient1": "Bortezomib", "ingredient2": "Ocrelizumab", "severity": "Moderate", "effect": "The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections.", "source": "DDInter", "management_text": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.", "mechanism_text": "Synergism", "recommendation": "The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46044/", "reference_text": "[1] \"Product Information. Ocrevus (ocrelizumab).\" Genentech, South San Francisco, CA.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45975, "ingredient1": "Bortezomib", "ingredient2": "Olaparib", "severity": "Moderate", "effect": "Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with olaparib.", "source": "DDInter", "management_text": "Caution is advised if olaparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed at baseline and monthly thereafter. Do not start olaparib until patients have recovered from hematologic toxicity caused by previous chemotherapy.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if olaparib is prescribed with other myelosuppressive agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46045/", "reference_text": "[1] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] \"Product Information. Lynparza (olaparib).\" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Panobinostat, Vismodegib, Olaparib, Enasidenib, Sonidegib, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Vorinostat, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45976, "ingredient1": "Bortezomib", "ingredient2": "Omacetaxine mepesuccinate", "severity": "Moderate", "effect": "The use of omacetaxine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Omacetaxine alone may cause severe myelosuppression, neutropenia, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other hematotoxic therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms such as fever, chills, shortness of breath, fatigue, and any unusual bleeding or bruising.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if omacetaxine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46046/", "reference_text": "[1] \"Product Information. Synribo (omacetaxine).\" Teva Pharmaceuticals USA, North Wales, PA.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Enasidenib, Belzutifan, Ivosidenib, Sonidegib, Mitotane, Porfimer sodium, Aminolevulinic acid, Omacetaxine mepesuccinate, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45977, "ingredient1": "Bortezomib", "ingredient2": "Omeprazole", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46047/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 45978, "ingredient1": "Bortezomib", "ingredient2": "Oritavancin", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46048/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Bacitracin, Polymyxin B, Daptomycin, Telavancin, Methenamine, Spectinomycin, Fosfomycin, Tedizolid, Dalbavancin", "updated_at": 1767369485}, {"id": 45979, "ingredient1": "Bortezomib", "ingredient2": "Osimertinib", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46049/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Porfimer sodium, Selinexor, Aflibercept, Trastuzumab, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45980, "ingredient1": "Bortezomib", "ingredient2": "Oxaliplatin", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46050/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "updated_at": 1767369485}, {"id": 45981, "ingredient1": "Bortezomib", "ingredient2": "Oxcarbazepine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46051/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Mitotane, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45982, "ingredient1": "Bortezomib", "ingredient2": "Ozanimod", "severity": "Major", "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.", "source": "DDInter", "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46052/", "reference_text": "[1] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation, Summit, NJ.", "alternatives_a": "Pertuzumab, Vismodegib, Sotorasib, Belzutifan, Mitotane, Porfimer sodium, Estramustine, Celecoxib, Aminolevulinic acid, Tazemetostat, Vorinostat, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45983, "ingredient1": "Bortezomib", "ingredient2": "Paclitaxel (protein-bound)", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46053/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Aflibercept, Anagrelide, Panobinostat, Venetoclax, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45984, "ingredient1": "Bortezomib", "ingredient2": "Palifermin", "severity": "Moderate", "effect": "INTERVAL: In a clinical trial, administration of palifermin within 24 hours of chemotherapy resulted in increased severity and duration of oral mucositis, presumably due to increased sensitivity of the rapidly dividing epithelial cells in the immediate post-chemotherapy period.", "source": "DDInter", "management_text": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "mechanism_text": "Others", "recommendation": "Palifermin should not be administered within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46054/", "reference_text": "[1] \"Product Information. Kepivance (palifermin).\" Shire US Inc, Florence, KY.", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45985, "ingredient1": "Bortezomib", "ingredient2": "Pantoprazole", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46055/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Tetracycline, Dexlansoprazole, Bismuth subcitrate potassium, Cimetidine, Vonoprazan, Levofloxacin", "updated_at": 1767369485}, {"id": 45986, "ingredient1": "Bortezomib", "ingredient2": "Pegaspargase", "severity": "Moderate", "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.", "source": "DDInter", "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46056/", "reference_text": "[1] \"Product Information. Oncaspar (pegaspargase).\" Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S \"Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase.\" Digestion 74 (2006): epub[4] Cerner Multum, Inc \"ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp.\" O 0 (2015):[5] \"Product Information. Elspar (asparaginase).\" Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW \"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.\" J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG \"Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine\" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E \"Severe hepatotoxicity from Escherichia coli L-asparaginase.\" J Natl Med Assoc 79 (1987): 775-9[9] \"Product Information. Asparlas (calaspargase pegol).\" Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al \"High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles.\" Blood 122 (2013): 2671[11] \"Product Information. Erwinaze (asparaginase Erwinia chrysanthemi).\" EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al \"Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors.\" Leuk Lymphoma 55 (2014): 1670-4", "alternatives_a": "Pertuzumab, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "updated_at": 1767369485}, {"id": 45987, "ingredient1": "Bortezomib", "ingredient2": "Pegfilgrastim", "severity": "Moderate", "effect": "INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.", "source": "DDInter", "management_text": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "mechanism_text": "Antagonism", "recommendation": "Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46057/", "reference_text": "[1] \"Product Information. Neulasta (pegfilgrastim).\" Amgen, Thousand Oaks, CA.[2] \"Product Information. Brukinsa (zanubrutinib).\" BeiGene USA, Inc, San Mateo, CA.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Aflibercept, Anagrelide, More", "updated_at": 1767369485}, {"id": 45988, "ingredient1": "Bortezomib", "ingredient2": "Peginterferon alfa-2a", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46058/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45989, "ingredient1": "Bortezomib", "ingredient2": "Peginterferon alfa-2b", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46059/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "alternatives_b": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, More", "updated_at": 1767369485}, {"id": 45990, "ingredient1": "Bortezomib", "ingredient2": "Peginterferon beta-1a", "severity": "Moderate", "effect": "Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46060/", "reference_text": "[1] \"Product Information. Plegridy (peginterferon beta-1a).\" Biogen Idec Inc, Cambridge, MA.[2] \"Product Information. Betaseron (interferon beta-1b).\" Berlex, Richmond, CA.[3] \"Product Information. Rebif (interferon beta-1a).\" Serono Laboratories Inc, Norwell, MA.[4] \"Product Information. Avonex (interferon beta-1a).\" Biogen, Cambridge, MA.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Enasidenib, Belzutifan, Mitotane, More", "alternatives_b": "Oprelvekin, Elapegademase, Histamine, Aldesleukin, Pegademase, Glatiramer", "updated_at": 1767369485}, {"id": 45991, "ingredient1": "Bortezomib", "ingredient2": "Pentobarbital", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46061/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tagraxofusp, Pegaspargase, Enasidenib, Belzutifan, Porfimer sodium, More", "alternatives_b": "Suvorexant, Flurazepam, Methohexital, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Ethchlorvynol, Midazolam, More", "updated_at": 1767369485}, {"id": 45992, "ingredient1": "Bortezomib", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.", "source": "DDInter", "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.", "mechanism_text": "Synergism", "recommendation": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46062/", "reference_text": "[1] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.[2] \"Product Information. Turalio (pexidartinib).\" Daiichi Sankyo, Inc., Parsippany, NJ.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Enasidenib, Porfimer sodium, Niraparib, Selinexor, Aflibercept, Trastuzumab, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}, {"id": 45993, "ingredient1": "Bortezomib", "ingredient2": "Phenylbutazone", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46063/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[5] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7", "alternatives_a": "Pertuzumab, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Selinexor, More", "alternatives_b": "Fenoprofen, Ketorolac, Indomethacin, Glucosamine, Chondroitin sulfate, Oxaprozin, Nabumetone, Flurbiprofen, Tolmetin, Meclofenamic acid, Mefenamic acid, More", "updated_at": 1767369485}, {"id": 45994, "ingredient1": "Bortezomib", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily metabolized by the isoenzyme with secondary contribution from CYP450 2C19.", "source": "DDInter", "management_text": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "mechanism_text": "Metabolism", "recommendation": "Given the potential for diminished pharmacologic effects of bortezomib in the presence of potent CYP450 3A4 inducers, concomitant use is not recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46064/", "reference_text": "[1] Uttamsingh V, Lu C, Miwa GT, Gan LS \"Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4 to the hepatic metabolism of teh protosome inhibitor bortezomib.\" Drug Metab Dispos 33 (2005): 1723-8[2] Pekol T, Daniels JS, Labutti J, et al \"Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.\" Drug Metab Dispos 33 (2005): 771-7[3] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Hellmann A, Rule S, Walewski J, et al. \"Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or Non-Hodgkin's lymphoma.\" Clin Pharmacokinet 50 (2011): 781-91[6] Phuphanich S, Supko JG, Carson KA, et.al \"Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.\" J Neurooncol 100 (2010): 95-103[7] \"Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[8] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[9] \"Product Information. Orkambi (ivacaftor-lumacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.[10] \"Product Information. Symdeko 4-Week (ivacaftor-tezacaftor).\" Vertex Pharmaceuticals, Cambridge, MA.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Enasidenib, Belzutifan, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Tiagabine, Ethotoin, Topiramate, Ezogabine, Paramethadione, Perampanel, Methsuximide, Zonisamide, Lamotrigine, Ganaxolone, Fenfluramine, More", "updated_at": 1767369485}, {"id": 45995, "ingredient1": "Bortezomib", "ingredient2": "Pirfenidone", "severity": "Minor", "effect": "Coadministration with bortezomib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The clinical significance is unknown, as bortezomib is considered a weak inhibitor of CYP450 2C19 in vitro.", "source": "DDInter", "management_text": "-", "mechanism_text": "Metabolism", "recommendation": "-", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46065/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR \"Elevated international normalized ratio with the consumption of grapefruit and use of warfarin.\" SAGE Open Med Case Rep 0 (2013): 1-3[3] Guo LQ, Yamazoe Y \"Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines.\" Acta Pharmacol Sin 25 (2004): 129-36[4] Kempin SJ \"Warfarin resistance caused by broccoli.\" N Engl J Med 308 (1983): 1229-30[5] Lee M, Schwartz RN, Sharifi R \"Warfarin resistance and vitamin K.\" Ann Intern Med 94 (1981): 140-1[6] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G \"Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy.\" Eur J Clin Pharmacol 63 (2007): 565-70[7] Sullivan DM, Ford MA, Boyden TW \"Grapefruit juice and the response to warfarin.\" Am J Health Syst Pharm 55 (1998): 1581-3[8] Harrell CC, Kline SS \"Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin.\" Jama J Am Med Assn 282 (1999): 1133-4[9] Grant P \"Warfarin and cranberry juice: an interaction?\" J Heart Valve Dis 13 (2004): 25-6[10] Kazmier FJ, Spittell JA Jr \"Coumarin drug interactions.\" Mayo Clin Proc 45 (1970): 249-55[11] Ge B, Zhang Z, Zuo Z \"Updates on the clinical evidenced herb-warfarin interactions.\" Evid Based Complement Alternat Med 2014 (2014): 957362[12] Kuykendall JR, Houle MD, Rhodes RS \"Possible warfarin failure due to interaction with smokeless tobacco.\" Ann Pharmacother 38 (2004): 595-7[13] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT \"Recommendations for the use of medications with continuous enteral nutrition.\" Am J Health Syst Pharm 66 (2009): 1438-67[14] Zallman JA, Lee DP, Jeffrey PL \"Liquid nutrition as a cause of warfarin resistance.\" Am J Hosp Pharm 38 (1981): 1174[15] Watson AJ, Pegg M, Green JR \"Enteral feeds may antagonise warfarin.\" Br Med J 288 (1984): 557[16] Monterrey-Rodriguez J \"Interaction between warfarin and mango fruit.\" Ann Pharmacother 36 (2002): 940-1[17] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines \"Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm.\" ([2003 Sept]):[18] Karlson B, Leijd B, Hellstrom K \"On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment.\" Acta Med Scand 220 (1986): 347-50[19] Griffiths AP, Beddall A, Pegler S \"Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.\" J R Soc Health 128 (2008): 324-6[20] Roberts D, Flanagan P \"Case report: Cranberry juice and warfarin.\" Home Healthc Nurse 29 (2011): 92-7[21] O'Reilly RA, Rytand DA \"\"Resistance\" to warfarin due to unrecognized vitamin K supplementation.\" N Engl J Med 303 (1980): 160-1[22] Parr MD, Record KE, Griffith GL, et al \"Effect of enteral nutrition on warfarin therapy.\" Clin Pharm 1 (1982): 274-6[23] Andersen P, Godal HC \"Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K.\" Acta Med Scand 198 (1975): 269-70[24] Cambria-Kiely JA \"Effect of soy milk on warfarin efficacy.\" Ann Pharmacother 36 (2002): 1893-6[25] Howard PA, Hannaman KN \"Warfarin resistance linked to enteral nutrition products.\" J Am Diet Assoc 85 (1985): 713-5[26] Rindone JP, Murphy TW \"Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding.\" Am J Ther 13 (2006): 283-4[27] Suvarna R, Pirmohamed M, Henderson L \"Possible interaction between warfarin and cranberry juice.\" BMJ 327 (2003): 1454[28] Beckey NP, Korman LB, Parra D \"Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.\" Pharmacotherapy 19 (1999): 1075-9[29] Westfall LK \"An unrecognized cause of warfarin resistance.\" Drug Intell Clin Pharm 15 (1981): 131[30] Walker FB \"Myocardial infarction after diet-induced warfarin resistance.\" Arch Intern Med 144 (1984): 2089-90[31] Pedersen FM, Hamberg O, Hess K, Ovesen L \"The effect of dietary vitamin K on warfarin-induced anticoagulation.\" J Intern Med 229 (1991): 517-20[32] Griffith LD, Olvey SE, Triplett WC \"Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus.\" Crit Care Med 10 (1982): 799-800[33] Wells PS, Holbrook AM, Crowther NR, Hirsh J \"Interactions of warfarin with drugs and food.\" Ann Intern Med 121 (1994): 676-83[34] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html.\" ([2018]):[35] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT \"Anticoagulation instability with life-threatening complication after dietary modification.\" Postgrad Med J 66 (1990): 855-7[36] Hamann GL, Campbell JD, George CM \"Warfarin-cranberry juice interaction.\" Ann Pharmacother 45 (2011): e17[37] MacLeod SM, Sellers EM \"Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants.\" Drugs 11 (1976): 461-70[38] Jarvis S, Li C, Bogle RG \"Possible interaction between pomegranate juice and warfarin.\" Emerg Med J 27 (2010): 74-5", "alternatives_a": "Pertuzumab, Oxaliplatin, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Ixazomib, Sotorasib, Enasidenib, Belzutifan, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 45996, "ingredient1": "Bortezomib", "ingredient2": "Pitavastatin", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46066/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Sotorasib, Belzutifan, More", "alternatives_b": "Gemfibrozil, Fenofibric acid, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, Colesevelam, Alirocumab", "updated_at": 1767369485}, {"id": 45997, "ingredient1": "Bortezomib", "ingredient2": "Polatuzumab vedotin", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46067/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Sotorasib, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Anagrelide, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More", "updated_at": 1767369485}, {"id": 45998, "ingredient1": "Bortezomib", "ingredient2": "Poliovirus type 1 antigen (formaldehyde inactivated)", "severity": "Moderate", "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.", "source": "DDInter", "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.", "mechanism_text": "Antagonism", "recommendation": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46068/", "reference_text": "[1] \"Product Information. Imovax Rabies (rabies vaccine).\" sanofi pasteur, Swiftwater, PA.[2] Department of Health. National Health Service \"Immunisation Against Infectious Disease - \"The Green Book\". Chapter 6: Contraindications and special considerations. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chap\" ([2017 Aug]):[3] CDC. Centers for Disease Control and Prevention/ \"Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence.\" MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18[4] \"Product Information. Havrix (hepatitis A vaccine).\" SmithKline Beecham, Philadelphia, PA.[5] \"Product Information. Fluzone Influenza Vaccine (influenza virus vaccine).\" Connaught, Swiftwater, PA.[6] CDC Centers for Disease Control and Prevention \"General Best Practice Guidelines for Immunization: Altered Immunocompetence. Available from: URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf.\" ([2017, Apr 17]):[7] \"Product Information. Biothrax (anthrax vaccine adsorbed).\" Emergent BioSolutions Inc., Lansing, MI.[8] \"Product Information. Omnihib (haemophilus b conjugate vaccine).\" SmithKline Beecham, Philadelphia, PA.[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0[10] \"Product Information. Influenza Virus Vaccine, H5N1, Inactivated (influenza virus vaccine, H5N1, inactivated).\" GlaxoSmithKline, Research Triangle Park, NC.", "alternatives_a": "Pertuzumab, Aminolevulinic acid, Tazemetostat, Tagraxofusp, Sotorasib, Enasidenib, Belzutifan, Mitotane, Porfimer sodium, Anagrelide, Ivosidenib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 45999, "ingredient1": "Bortezomib", "ingredient2": "Pomalidomide", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46069/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, More", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More", "updated_at": 1767369485}, {"id": 46000, "ingredient1": "Bortezomib", "ingredient2": "Ponatinib", "severity": "Moderate", "effect": "Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Bortezomib treatment causes a peripheral neuropathy that is predominantly sensory, although cases of mixed sensorimotor neuropathy have also been reported.", "source": "DDInter", "management_text": "Caution is advised if bortezomib is used with other neurotoxic agents. Patients should be closely monitored for symptoms of neuropathy such as visual disturbances or burning, tingling, pain, numbness, and/or weakness in the extremities. Patients experiencing new or worsening peripheral neuropathy may require an adjustment in the dosage and schedule of bortezomib in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if bortezomib is used with other neurotoxic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/46070/", "reference_text": "[1] \"Product Information. Velcade (bortezomib).\" Millennium Pharmaceuticals Inc, Cambridge, MA.[2] Argov Z, Mastaglia FL \"Drug-induced peripheral neuropathies.\" Br Med J 1 (1979): 663-6[3] Cavaletti G, Jakubowiak AJ \"Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.\" Leuk Lymphoma 51 (2010): 1178-87[4] \"Product Information. Accolate (zafirlukast).\" Zeneca Pharmaceuticals, Wilmington, DE.", "alternatives_a": "Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Enasidenib, Porfimer sodium, Aflibercept, Trastuzumab, Hydroxyurea, Estramustine, More", "alternatives_b": "Entrectinib, Imatinib, Asciminib, Acalabrutinib, Dacomitinib, Tepotinib, Avapritinib, Larotrectinib, Bosutinib, Lapatinib, Selumetinib, More", "updated_at": 1767369485}]